













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
 
Chemical Genetics in zebrafish: 
Modulation of cAMP and MAPK pathways in 
behaviour 
 
Pia Rengtved Lundegaard 
 
 
Presented for the Degree of  











ABSTRACT TO THESIS 
The prevalence of stress and anxiety disorders in modern society is increasing, but 
the development of new treatments decreasing due to high research costs and low 
success rates in clinical trials. The latest type of compounds introduced to treat 
anxiety and depression was the specific serotonin reuptake inhibitors (SSRI), which 
was introduced in 1987. Since then, no new class of compounds have been 
introduced, suggesting that the need to find alternative targets in treating mental 
disorders is needed.  
In this thesis I have used the zebrafish as a model organism to study the modulation 
of behaviours through intracellular signalling pathways, known to be involved in 
learning, memory and anxiety.  
First, using the pro-convulsant compound, pentylenetetrazole (PTZ), an automated 
tracking system was established to quantify and analyse swimming behaviour in 
larvae zebrafish. Pentylenetetrazole induces seizures in zebrafish at high 
concentrations, however this thesis identifies that the combination of a low level of 
PTZ and subjecting the fish to alternating cycles of light and dark induced a reversed 
response to light and dark. A group of compounds with known anti-seizure effects 
were subsequently screened, which found that a combinational treatment with 






Secondly, using the same automated analysis setup, the effect of cAMP modulators 
was studied on behaviour in zebrafish larvae. Our lab has previously established that 
Rolipram, a PDE4 inhibitor, causes anxiety thigmotaxis in zebrafish larvae. In this 
thesis we treated zebrafish larvae with Rolipram and other compounds modulating 
cAMP, which greatly increased the swimming activity, which was reversed by 
subsequently treating with PD0325901. To test if the pharmacological modulation of 
cAMP-levels through the inhibition of other PDEs would lead to increased locomotor 
activity, a small library of PDE inhibitors was screened, and 4 compounds were 
identified that caused an increase in locomotion – three of these compounds were 
PDE4-inhibitors. 
Finally, by using two behavioural assays, I found that in adult fish Rolipram cause 







The number of people suffering from mental disorders, like depression and stress, are 
increasing. However, the available treatments for these types of diseases are not very 
effective, and the development of new drugs is slow. New drugs introduced into the 
market are often variants of already existing drugs, and often have limited effect or 
unwanted effects. The development of new drugs for mental illness is a slow and 
often un-successful task. The lack of good animal models to be used in the initial 
drug development process is lacking, as the cost and ethical reasons in utilizing 
rodents in drug discovery screening approach is not feasible. In this thesis I have 
used the zebrafish as an alternative screening model, to attempt to identify alternative 
pathways that can be involved in the regulation and development of mental illness, 
like anxiety or stress. Previously our lab has shown that drugs known to target 
signalling pathways in the brain can have an anxiety-enhancing effect on zebrafish. 
Through behavioural studies in zebrafish I have found that drugs, that are primarily 
used to treat different types of cancer, can in low doses be beneficial in relieving 
anxiety-like symptoms in zebrafish, that has are caused by the activation of pathways 
involved in cell signalling. This indicates that the search for alternative pathways in 
the treatment of mental illness should be extended to include more general signalling 











I hereby declare that this thesis has been composed by me, this work has not been 
submitted for any other degree or professional qualification, the work is my own and 
contribution from others has been clearly indicated. 
 
 








The existence of this thesis would not have been possible without the support and help of so 
many people.  
Firstly, I would like to thank my supervisor, Liz Patton, for your support and guidance 
throughout this thesis. You have an amazing scientific drive, which is an inspiration. Thank 
you.   
Secondly, thank you to my second supervisor, Professor David Porteous. Thank you for your 
advice and suggestions through the years.  
To my industry supervisor, Dr. Lars Christian B. Rønn; Thank you so much for all your 
support and your help, both in the good times and the bad times. Thank you for you calm and 
rational approach to science and to life in general. It is an inspiration and a pleasure to work 
with you.  
 To Dr. Tino Dyhring, from NeuroSearch A/S; thank you for all your help.  
Thank you to everyone at the Patton  lab – past and present. To Karthika for excellent fish 
care and breeding. To Zhiqiang for genotyping the pde4d-fish. Thank you to Corina, Jenny, 
Judith, Juan and Sue for everything!  
To Professor Douglas Armstrong for allowing me to work with ActualTrack, and in helping 
me with the adult behavioural analysis. 
A big thank you also, to the people at the Ion Channel group at the University of 
Copenhagen. Especially Professor Søren-Peter Olesen, for allowing me to join your lab in a 
time of need. For your constant support and encouragement. To associate professor Nicole 
Schmitt; an amazing scientist, who have succeeded in providing a great work frame for 
doing great science. Thank you both very much, and I am looking forward to continuing 
working with you.  
Thank you to Anders-Peter Larsen for all your help with R and the Bootstrapping analysis.  
Thank you Karin De linde Lind. You have been my zebrafish-allied at NeuroSearch A/S 





Thank you to Associate professor Bo Hjort Bentzen, for being a great friend and support. To 
the people in the front-office at NeuroSearch; Jonas, Morten Grunnet, Morten Grupe and Bo 
Skaaning. Thank you for the company.  
Thank you to Peter Buhl and Tine Østergaard for great fish-work at NeuroSearch.  
To Tau – my office-man at the DARC side. Thank you for everything.   
To Tom Jepps – thank you for all your help and for teaching me how to do qPCR. Your help 
has been invaluable, and without you in the lab, this thesis would never have been 
completed.   
Most importantly I want to say a huge thank you to my amazing husband, Lars. Without you, 
this thesis would not have existed. Thank you for always believing in me, and for you 
constant support and encouragement throughout this PhD.  
To our three amazing children, Nicoline, Frida and Carl. Thank you for all the joy and 
happiness and for putting life in perspective.  
To my amazing mother, Bente for being such a cool mum, and for your constant and 
unyielding support through the good and the sad times.  
A big thank you to my parents-in laws – Gudrun and Henrik, for always being there for us.  
Also a big thank you to all our amazing neighbours at Svalin – our own little piece of 
environmentally sustainable haven. You have been a constant support for our entire family 











This thesis is dedicated to my father, Kurt, who sadly decided to leave us far too early.  







Table of contents  
1 Introduction .................................................................................................... 1 
1.1 Introduction ............................................................................................. 2 
1.1.1 The zebrafish embryo model.............................................................. 3 
1.1.1.1 The movement repertoire in zebrafish ......................................... 4 
1.1.2 Translational validity of zebrafish in anxiety research ........................ 6 
1.1.2.1.1 Behavioural assays in larvae zebrafish...................................... 7 
1.1.3 Understanding behaviour ................................................................... 8 
1.1.3.1 Symptoms of anxiety and depression .......................................... 9 
1.1.3.1.1 Anxiety ................................................................................... 9 
1.1.3.1.2 Depression ............................................................................ 10 
1.1.4 Modelling anxiety and depression in rodent models.......................... 10 
1.1.4.1 Current drug treatments for anxiety ........................................... 11 
1.1.4.1.1 Targeting the gamma-amino butyric acid receptor .................. 12 
1.1.4.1.2 Antidepressants used for the treatment of anxiety ................... 13 
1.1.4.2 The cAMP signalling pathway .................................................. 17 





1.1.4.4 Cyclic AMP in Stress and Anxiety ............................................ 23 
1.1.4.5 Phenotypic drug screening ........................................................ 24 
1.1.4.5.1 Setting up a phenotypic screen in zebrafish larvae .................. 25 
1.2 Aims of this thesis .................................................................................. 27 
2 Materials and Methods .................................................................................. 28 
2.1 Materials................................................................................................ 29 
2.1.1 General buffer recipes ..................................................................... 29 
2.2 Methods ................................................................................................. 33 
2.2.1 Fish husbandry ................................................................................ 33 
2.2.1.1 Setting up a zebrafish facility .................................................... 33 
2.2.1.2 Water quality parameters .......................................................... 34 
2.2.1.3 Filtration systems ..................................................................... 34 
2.2.1.3.1 Bio filters .............................................................................. 34 
2.2.1.4 Maintaining zebrafish ............................................................... 35 
2.2.2 Raising zebrafish larvae................................................................... 35 
2.2.3 Behavioural assays .......................................................................... 36 
2.2.3.1 Larvae behaviour assays ........................................................... 36 
2.2.3.1.1 Swimming activity ................................................................ 36 





2.2.3.1.2.1 Normalizing data ............................................................. 37 
2.2.3.1.2.2 Statistical analysis ........................................................... 38 
2.2.3.1.3 Visual Motor Response .......................................................... 38 
2.2.3.1.3.1 Visual Motor Response Protocol ...................................... 39 
2.2.3.1.4 Data analysis ......................................................................... 39 
2.2.3.2 Adult behavioural assays .......................................................... 40 
2.2.3.2.1 Shoaling assay ....................................................................... 40 
2.2.3.2.1.1 Drug treatment ................................................................ 40 
2.2.3.2.1.2 Video recordings ............................................................. 40 
2.2.3.2.1.3 Data analysis ................................................................... 41 
2.2.3.2.2 Novel Tank Test .................................................................... 41 
2.2.3.2.2.1 Drug treatments............................................................... 42 
2.2.3.2.2.2 Video Recordings ............................................................ 42 
2.2.3.2.2.3 Data analysis ................................................................... 42 
2.2.4 Drug treatments............................................................................... 43 
2.2.4.1 Rolipram .................................................................................. 43 
2.2.4.2 PD0325901 .............................................................................. 43 
2.2.4.3 IBMX ...................................................................................... 43 





2.2.5 Drug screens ................................................................................... 44 
2.2.5.1 PDE inhibitor screen ................................................................ 44 
2.2.5.2 PTZ screen ............................................................................... 44 
2.2.6 Protein analysis ............................................................................... 45 
2.2.6.1 Protein extraction ..................................................................... 45 
2.2.6.1.1 10 ml lysis buffer for protein extraction .................................. 45 
2.2.6.2 Protein determination ............................................................... 46 
2.2.6.3 Western Blotting ...................................................................... 47 
2.2.6.3.1 Buffers for Western Blotting .................................................. 47 
2.2.6.3.1.1 Running buffer ................................................................ 47 
2.2.6.3.1.2 Transfer buffer (Towbin) ................................................. 47 
2.2.6.3.2 Sample preparation ................................................................ 47 
2.2.6.3.3 SDS page .............................................................................. 48 
2.2.6.3.4 Protein Transfer ..................................................................... 48 
2.2.6.3.5 Protein detection .................................................................... 49 
2.2.7 Cortisol determination ..................................................................... 50 
2.2.7.1 Cortisol extraction .................................................................... 50 
2.2.7.2 Cortisol assay ........................................................................... 50 





2.2.8.1 Cyclic AMP extraction ............................................................. 51 
2.2.8.2 ELISA assay ............................................................................ 52 
2.2.8.3 Data analysis ............................................................................ 52 
2.2.9 Quantitative PCR ............................................................................ 52 
2.2.9.1 RNA Extraction and quantification ........................................... 53 
2.2.9.2 Reverse Transcription ............................................................... 53 
2.2.9.3 GeNorm reference kit ............................................................... 54 
2.2.9.4 Quantitative PCR ..................................................................... 56 
2.2.9.4.1 Analysis of qPCR data ........................................................... 57 
3 An alternative PTZ model in zebrafish larvae................................................. 58 
3.1 Introduction ........................................................................................... 59 
3.1.1 Automated analysis of zebrafish behaviour ...................................... 59 
3.1.1.1 Large scale small molecule screens in zebrafish larvae .............. 60 
3.1.2 Available commercial tracking software solutions ............................ 61 
3.1.3 Epilepsy models .............................................................................. 63 
3.1.3.1 Genetic models of epilepsy ....................................................... 63 
3.1.3.2 Pentylenetetrazole-induced model of epilepsy ........................... 64 
3.1.3.2.1 GABA signalling ................................................................... 65 





3.1.4 Aim of chapter ................................................................................ 67 
3.2 Results ................................................................................................... 68 
3.2.1 Sub-convulsive levels of PTZ induce a distinct change in the PTZ 
response  ....................................................................................................... 68 
3.2.2 Poor effect of compounds on the PTZ-induced phenotype ................ 70 
3.2.2.1 Effect of valproate and ethosuximide ........................................ 70 
3.2.3 Diazepam-rescue of PTZ-induced phenotype ................................... 74 
3.2.4 Neuroactive compounds protect against the 5mM PTZ induced 
locomotor phenotype..................................................................................... 76 
3.2.4.1 The sedative effect of diazepam can be suppressed by co-treatment 
with neurosteroids ..................................................................................... 79 
3.2.5 PTZ increase the expression of c-fos ................................................ 82 
3.3 Discussion ............................................................................................. 84 
3.3.1 Low concentration of PTZ leads to distinct behavioural phenotype in 
zebrafish larvae ............................................................................................. 85 
3.3.2 Poor effect of compounds with previously reported anti-epileptic 
function on the light/dark phenotype .............................................................. 86 
3.3.3 Neuroactive steroids are effective against PTZ-induced behavioural 
changes  ....................................................................................................... 89 
3.3.4 Co-treatment with a neurosteroid abolishes the sedative effect of 





3.3.5 Other behavioural effects of PTZ ..................................................... 91 
3.4 Conclusion ............................................................................................. 92 
4 Modulating behaviour through cAMP and MAPK.......................................... 94 
4.1 Introduction ........................................................................................... 95 
4.1.1 Measuring anxiety in zebrafish larvae .............................................. 97 
4.1.2 Modulation of cAMP in zebrafish larvae cause thigmotaxis .............. 99 
4.1.2.1 MAPK signalling regulate thigmotaxis in zebrafish larvae ....... 101 
4.1.2.1.1 The MAPK pathway ............................................................ 102 
4.1.2.1.2 Regulation of PDE4 isoforms by PKA and MAPK signalling 105 
4.2 Aim of chapter ..................................................................................... 107 
4.3 Results ................................................................................................. 107 
4.3.1 Rolipram increase the swimming activity of zebrafish larvae .......... 107 
4.3.2 Long-term effect of Rolipram treatment on swimming activity ....... 109 
4.3.3 PDE inhibitors cause an increase in locomotor activity ................... 112 
4.3.4 Inhibition of MEK impedes hyperactivity in PDE4 treated larvae ... 117 
4.3.5 Increased cAMP levels in vivo following treatment with Rolipram . 119 
4.3.5.1 MEK inhibition only cause decreased cAMP levels in forskolin 
treated larvae, but not in Rolipram-treated larvae ...................................... 121 
4.3.6 Rolipram activates MAPK signalling ............................................. 122 





4.4.1 Rolipram increases cAMP in zebrafish larvae ................................ 124 
4.4.2 PDE4 inhibition causes hyperactivity in zebrafish larvae ................ 125 
4.4.3 Cyclic AMP and MAPK cross talk in zebrafish behaviour .............. 127 
4.4.4 Concluding remarks ...................................................................... 129 
5 Modulation of behaviour in adult zebrafish through PDE4 inhibition ............ 131 
5.1 Introduction ......................................................................................... 132 
5.1.1 The shoaling assay ........................................................................ 132 
5.1.2 The novel tank assay ..................................................................... 133 
5.2 Aim of chapter ..................................................................................... 135 
5.3 Results ................................................................................................. 135 
5.3.1 Setting up the novel tank assay ...................................................... 135 
5.3.1.1 Buspirone causes an anxiolytic effect on zebrafish .................. 136 
5.3.2 Rolipram and its effect on the behaviour of adult zebrafish ............. 139 
5.3.2.1 Anxiogenic effect of Rolipram in the novel tank diving test ..... 139 
5.3.3 Inhibiting MEK activity does not cause anxiolytic behaviour in adult 
fish  ..................................................................................................... 141 
5.3.3.1 Rolipram causes bottom dwelling in groups of adult fish ......... 143 
5.3.4 Increased whole-body cortisol levels in adult zebrafish in response to 
Rolipram treatment ..................................................................................... 146 





5.3.5.1 Pde4d-loss of function cause an decrease in shoaling behaviour 149 
5.3.5.2 A specific pde4d-inhibitor partly recapitulates the phenotype of the 
pde4d-mutants ......................................................................................... 151 
5.4 Discussion ........................................................................................... 152 
5.4.1 Validation of the novel tank assay using a known anxiolytic compound 
  ..................................................................................................... 152 
5.4.1.1 Challenges when using automated behavioural analysis ........... 153 
5.4.2 Rolipram increase bottom dwelling and erratic behaviours in the novel 
tank test  ..................................................................................................... 155 
5.4.2.1 Rolipram cause bottom dwelling in the shoaling assay, but has no 
effect on shoal cohesion ........................................................................... 156 
5.4.2.2 MEK inhibition reverse the Rolipram-induced phenotype ........ 157 
5.4.2.3 Genetic disruption of Pde4d-activity cause disruption in shoal 
cohesion and less bottom dwelling in zebrafish ......................................... 158 
5.4.3 Concluding remarks ...................................................................... 160 
6 Future directions and concluding remarks .................................................... 162 
6.1 Final comments .................................................................................... 163 
6.2 Further directions ................................................................................. 167 
6.2.1 Identify specific site of MAPK activation in zebrafish brains .......... 167 





7 References .................................................................................................. 170 
8 APPENDIX – Supplementary data .............................................................. 191 
8.1 Chemical structures and synthesis methods of for the PDE inhibitors from 







LIST OF FIGURES 
FIGURE 1.1.1: DEVELOPMENTAL TIMELINE OF LARVAL BEHAVIOUR. ....................................................... 5 
FIGURE 1.1.2: SCHEMATIC DRAWING OF THE INTRACELLULAR SIGNALLING PATHWAYS INVOLVED IN 
REGULATING NEUROTRANSMITTER SIGNALLING. ........................................................................... 16 
FIGURE 1.1.3: SCHEMATIC OF THE ACTIVATION OF THE ADENYLATE CYCLASE THROUGH A G PROTEIN 
COUPLED RECEPTOR. ...................................................................................................................... 18 
FIGURE 1.1.4: STRUCTURAL ORGANISATION OF THE PDE4 FAMILY. ...................................................... 21 
FIGURE 3.1.1: THE TWO COMMERCIALLY AVAILABLE TRACKING SYSTEMS. .......................................... 62 
FIGURE 3.2.1 A: PENTYLENETETRAZOLE (PTZ) INDUCES A BEHAVIOURAL PHENOTYPE IN LARVAL 
ZEBRAFISH. ..................................................................................................................................... 69 
FIGURE 3.2.2: ETHOSUXIMIDE CAUSE PARTIAL RESCUE OF PTZ PHENOTYPE. ........................................ 72 
FIGURE 3.2.3: TRACKING PLOTS OF VALPROATE DOSE CURVE WITH 5MM PTZ. .................................... 73 
FIGURE 3.2.4: THE CLASSIC BENZODIAZEPINE, DIAZEPAM, CAN PARTIALLY REVERSE THE LIGHT/DARK 
SWITCHING IN PHENOTYPE, INDUCED BY 5MM OF PTZ TREATMENT. ............................................ 75 
FIGURE 3.2.5: ALFAXALONE EFFICIENTLY REVERSE THE PTZ-INDUCED PHENOTYPE. ........................... 77 
FIGURE 3.2.6: THE NEUROSTEROID, ALLOPREGNANOLONE REVERSES THE PTZ-INDUCED PHENOTYPE . 78 
FIGURE 3.2.7: COMBINATIONAL TREATMENT WITH ALFAXALONE ABOLISHES SEDATIVE EFFECT OF 
DIAZEPAM....................................................................................................................................... 80 
FIGURE 3.2.8: PRELIMINARY QUANTITATIVE PCR ANALYSIS OF CFOS EXPRESSION IN ZEBRAFISH 
LARVAE. ......................................................................................................................................... 83 
FIGURE 4.1.1: CYCLIC AMP MODULATORS CAUSE THIGMOTAXIS IN ZEBRAFISH LARVAE. .................. 100 
FIGURE 4.1.2: MEK INHIBITION COUNTERACTS THIGMOTAXIS INDUCED BY CAMP-MODULATION IN 
ZEBRAFISH LARVAE. ..................................................................................................................... 102 
FIGURE 4.1.3: THE RAF-MEK-ERK SIGNALLING CASCADE. ............................................................... 104 
FIGURE 4.1.4: SCHEMATIC ILLUSTRATION OF THE CROSS TALK BETWEEN CAMP AND RAF-MEK-ERK 





FIGURE 4.3.1: COMPOUNDS MODULATING CAMP LEVELS CAUSE AN INCREASE IN LOCOMOTOR 
ACTIVITY. ..................................................................................................................................... 109 
FIGURE 4.3.2: LONG TERM EFFECT OF ROLIPRAM ON SWIMMING ACTIVITY ON 5 DPF OLD LARVAE ..... 111 
FIGURE 4.3.3: GRAPH 1 OF 2: CONCENTRATION RESPONSE OF PHOSPHODIESTERASE INHIBITORS. ....... 113 
FIGURE 4.3.4: GRAPH 2 OF 2: CONCENTRATION RESPONSE OF PHOSPHODIESTERASE INHIBITORS ........ 114 
FIGURE 4.3.5: SUMMARY OF PDE INHIBITORS AND THEIR EFFECT OF SWIMMING ACTIVITY IN 5 DPF 
LARVAE ........................................................................................................................................ 115 
FIGURE 4.3.6: ROLIPRAM INDUCED HYPERACTIVITY CAN BE REVERSED THROUGH MEK-INHIBITION . 118 
FIGURE 4.3.7: INCREASED CAMP LEVELS IN WHOLE LARVAE TREATED WITH ROLIPRAM AND 
FORSKOLIN. .................................................................................................................................. 120 
FIGURE 4.3.8: ELISA ASSAY DETERMINING CAMP LEVELS FOLLOWING COMBINATION TREATMENT. 121 
FIGURE 4.3.9: ROLIPRAM TREATMENT INCREASES PERK IN WHOLE EMBRYOS. ................................... 123 
FIGURE 4.4.1: A NOVEL THERAPEUTIC STRATEGY: MEK INHIBITORS TO TREAT CAMP-MEDIATED 
ANXIETY. ...................................................................................................................................... 129 
FIGURE 5.1.1: SCHEMATIC OF THE SHOALING ASSAY AND THE NOVEL TANK ASSAY. ........................... 134 
FIGURE 5.3.1: VISUALISATION OF THE ETHOVISION OUTPUT FROM A NOVEL TANK TEST. ................... 136 
FIGURE 5.3.2: BUSPIRONE CAUSES SIGNIFICANT INCREASES IN TIME SPEND IN THE TOP OF THE NOVEL 
TANK. ........................................................................................................................................... 138 
FIGURE 5.3.3: BEHAVIOURAL ANALYSIS OF THE ROLIPRAM EFFECT ON ADULT ZEBRAFISH. ................ 140 
FIGURE 5.3.4 PD0325901 TREATMENT DOES NOT CAUSE AN ANXIOLYTIC PHENOTYPE IN THE NOVEL 
TANK. ........................................................................................................................................... 142 
FIGURE 5.3.5: PLACEMENT IN TANK IN THE SHOALING ASSAY AFTER ROLIPRAM AND PD0325901 
TREATMENT. ................................................................................................................................. 145 
FIGURE 5.3.6: INCREASED CORTISOL LEVELS IN ADULT ZEBRAFISH TREATED WITH 30µM ROLIPRAM. 147 
FIGURE 5.3.7: THE PDE4D GENE IN HUMANS AND ZEBRAFISH............................................................. 148 
FIGURE 5.3.8 ADULT PDE4D-/- ZEBRAFISH HAVE A DECREASED SHOALING BEHAVIOUR. ..................... 150 





FIGURE 5.4.1: SCREENSHOT DEPICTING THE ERRORS IN TRACKING OCCURRING IN ETHOVISION XT9. 154 








List of tables 
TABLE 2:1: LIST OF COMPOUNDS USED IN PROJECT ................................................................................ 32 
TABLE 2:2: TABLE OF WATER QUALITY PARAMETERS IN THE AQUATIC HABITATS STAND-ALONE FLOW-
THROUGH SYSTEM .......................................................................................................................... 34 
TABLE 2:3: ACCEPTABLE VALUES OF COMPONENTS OF THE NITROGENOUS CYCLE IN THE AQUATIC 
HABITATS STAND-ALONE FLOW-THROUGH SYSTEM. ..................................................................... 35 
TABLE 2:4: LIST OF GENES CONTAINED IN THE GENORM REFERENCE GENE KIT FROM PRIMERDESIGN. 56 
TABLE 3:1: EFFECT OF COMPOUNDS ON THE BEHAVIOUR OF 5DPF WT LARVAE TREATED WITH 5MM 
PTZ. ............................................................................................................................................... 82 










1.1      Introduction 
The number of people suffering from mental illness in the 21
st
 century is increasing. 
In the UK alone it is predicted that 1 in 6 adult experiences some form of mental 
illness in their lifetime, which makes mental illness a major contribution to the health 
care costs in the UK per year (Choices 2013). The consequences of mental illness are 
not only devastating for the patients, but also for the relatives. Due to the increasing 
number of people affected by mental illness there is a growing need for new 
treatments. However, the number of drugs being approved and introduced into the 
clinic is declining, and the cost of developing new drugs is increasing. Especially in 
the area of mental illness, the development of new drugs is very limited, which 
reflects poorly on the need for new treatments (Craven 2011). Despite this need for 
new treatments, there has been an increase in the number of pharmaceutical 
companies that pull out of research and drug development in the field of psychiatric 
illness (Craven 2011), due to reasons primarily attributed to long development 
timelines, which often ends with a very low success rate in the final stage of clinical 
trials (Agid et al. 2007; Craven 2011; O’Brien et al. 2014). These factors together 
with the loss of revenue due to expiring patents, together with very high research 
costs, have made pharmaceutical companies less inclined to take risks when 
venturing into new, un-explored areas of drug development (Craven 2011). 
Historically, the use of rodent models in drug development has been a gold standard, 
but the use of these models in drug development screens is time-consuming, low-





concern about the number of rodents used for research and drug development, and a 
wish to reduce these numbers (Festing and Wilkinson 2007). Thus the need for a 
complementary model which can bridge the gap between in vitro studies and rodent 
studies is eminent, that can help to cut down on the number of rodents being used in 
research and to decrease some of the research costs which are limiting the discovery 
and development of new drugs. A possible vertebrate model organism that could fit 
this purpose is the small freshwater teleost, Danio rerio, the zebrafish.  
 
1.1.1 The zebrafish embryo model 
 
One of the main advantages of zebrafish as a model organism is the ability to use 
both the larval and the adult stage of the fish. Zebrafish embryos and larvae have 
been a favourite model organism in genetics and development for almost three 
decades, and as a vertebrate model it offers an excellent compromise between higher 
vertebrate models and popular invertebrate models. The zebrafish is easy to maintain 
at a low cost, they produce a high number of offspring as one breeding pair can 
produce approximately 200 embryos a week, and the development of the embryos is 
rapid. Moreover, the zebrafish embryos develop ex utero, at 28°C and in a 
transparent chorion, which allows for the visualization of developmental progress in 
a standard light microscope. The potential of the zebrafish as a model organism in 
genetics and development, was solidified by the publication of a large mutagenesis 





the regulation of behaviour, development and visual function (Felsenfeld 1996; 
Granato et al. 1996; Haffter et al. 1996).  The screen was performed by recovering 
mutants from an N-ethyl-N-nitrosourea (ENU) mutagenesis screen, depending on a 
specific phenotype. Granato and colleagues identified mutants with movement 
defects, representing 30 different genes shown to be important in the development of 
movement in zebrafish larvae (Granato et al. 1996).  
Furthermore, broad use of zebrafish in research has expanded immensely, and in 
2000 Peterson and colleagues published a proof-of-principle paper, using small 
molecules to elucidate gene function on development (Peterson et al. 2000).  Using 
available transgenic and mutant lines available to the zebrafish community (Peal et 
al. 2011) a wide range of biological processes, amongst them melanocyte 
development and regulation (Colanesi et al. 2012), cardiac function (Peal et al. 
2011),  light response (Kokel et al. 2010) and sleep regulation (Rihel et al. 2010) has 
been studied in zebrafish. 
1.1.1.1 The movement repertoire in zebrafish 
One of the main objectives when studying behaviour is to understand how the 
function of the nervous system works. To elucidate on the function of the genes 
involved in neuronal development and function, the use of genetic models can help 
to reveal what developmental and genetic pathways underlying these behaviours, and 
ultimately help to develop new and better types of treatments.   
The zebrafish embryo develops into free-swimming larvae at 4-5 days post 





embryo develop spontaneous movements, consisting of coil-movements of the tail 
(Fero, Yokogawa, and Burgess 2011), and at 21 hpf the zebrafish respond to touch. 
At 30 hpf the fish responds to a flash of bright light (Kokel et al. 2010), and at the 
time of hatching (3 dpf)  they  begin to engage in evoked swimming behaviour 
(Brustein et al. 2003). The swim bladder inflates around 4 – 5 dpf, enabling the  
larvae to engage in free swimming behaviours, mainly characterized by a 
combination of burst and glide movements (Fero, Yokogawa, and Burgess 2011). 
This also allows the larvae to engage in food-seeking behaviours. By utilizing the  
rapid development of the nervous system combined with the small size, several 
reports have demonstrated the usability of zebrafish larvae in neuroscience.  
 
Figure 1.1.1: Developmental timeline of larval behaviour. 
The development of the zebrafish larvae is rapid, for that of a vertebrate organism.  The 
earliest movement displayed by the developing zebrafish embryo is the coil movement of the 
tail, visible around 17 hpf, which can be provoked by a touch to the tail of the embryo. At 21 
hpf the embryo respond to high-intensity light flashes, and shortly thereafter (around 48 hpf) 
the first swimming episodes can be observed, although these are limited due to the un-
inflated swim bladder, which is not inflated before 4-5 dpf. The inflation of the swim bladder 
also promotes the free swimming behaviour of the larvae, and the active feeding behaviour. 






1.1.2 Translational validity of zebrafish in anxiety research 
 
The translational validity of zebrafish in behavioural science has been demonstrated 
during the last decade.   Important contributions to this have come from studies using 
mutants generated from forward genetic screens, compounds known to target specific 
neurotransmitter systems in humans and rodents and testing them in zebrafish 
models.  
Compounds targeting specific neurotransmitter systems, and with known behavioural 
effect in rodent models of anxiety, has been tested in zebrafish models of anxiety. 
Levin et al. use the novel tank test, and show that nicotine causes an anxiolytic effect 
in adult zebrafish, when they are placed alone into a novel environment. This causes 
them to explore more of the tank, reduce the number of erratic movements and 
bottom dwellings (Levin, Bencan, and Cerutti 2007).  
The light-dark preference test is a test of boldness and has been demonstrated as a 
valid assay to asses anxiety-like behaviours in zebrafish (Maximino, da Silva, et al. 
2011; R. E. Blaser, Chadwick, and McGinnis 2010; Maximino et al. 2010; 
Steenbergen, Richardson, and Champagne 2011b). Utilizing the zebrafish natural 
preference for the dark area of the tank, this assay is comparable to the light-dark test 
in rodents, a test often employed to test for anxiolytic effects of compounds (Schmidt 
and Müller 2006). In zebrafish, the pharmacological modulation using known 
anxiolytic compounds, buspirone and fluoxetine, increases the time the fish spend in 





with less erratic behaviours when the fish are in the white compartment of the test 
tank (Maximino et al. 2013).  
In 2009, Egan and colleagues show that the physiological effect of known anxiogenic 
and anxiolytic compounds can be measured on both the behavioural and at the 
neuroendocrine level, in adult zebrafish. By extracting cortisol from whole adult fish, 
they show that stressing the zebrafish through exposure  to alarm pheromone or 
anxiogenic compounds,  causes an increase in whole body cortisol levels (Egan et al. 
2009). Cortisol is also the main stress hormone employed by humans, whereas mice 
use corticosterone. Cortisol is produced in the head kidney of fish, which 
corresponds to the adrenal gland in mammals. The Hypothalamus – Pituitary –  
Adrenal/Hypothalamus-Pituitary-Interenal (HPA/HPI) axis is responsible for the 
control and release of cortisol in response to stress and anxiety in humans and fish 
(Ramsay et al. 2006).  
Taken together, these reports suggest that the translational value of zebrafish 
behaviour is comparable to that of rodents in behavioural research.   
1.1.2.1.1 Behavioural assays in larvae zebrafish 
The major advantage of the zebrafish in neurobiological research has been the use of 
the translucent, rapid developing embryo. Despite the primitive developmental stage 
of the larvae, it offers an unique opportunity to study the effect of genetic mutations 
or chemical modulators on both neurodevelopment and behavioural output (Granato 





The small size of the fish and the large number of offspring generated by a single 
breeding pair of adult fish, has been utilized in genetic and chemical behavioural 
screens, and facilitating the use of zebrafish in high-throughput chemical screens 
increasingly popular (Kokel et al. 2010; Rihel et al. 2010).  
Modulation of behaviour has also been developed in more low-throughput settings,  
including tests for evaluation of anxiogenic- and anxiolytic-like behaviours, for  
which the light dark-test (Steenbergen, Richardson, and Champagne 2011b) and the  
open field test have been described in zebrafish larvae (Richendrfer et al. 2012; 
Schnörr et al. 2012). Other behavioural tests complementing rodent assays have been 
developed in zebrafish larvae, including locomotor assays (L. Ellis, Seibert, and  
Soanes 2012), pre-pulse inhibition (Best et al. 2008), anxiety (Richendrfer et al. 
2012) and seizure (S. C. Baraban et al. 2005).  
The use of larvae zebrafish in these behavioural tests instead of rodents, could serve 
as an initial screening platform for neuroactive compounds, thereby reducing the 
number of rodents used in research. 
 
1.1.3 Understanding behaviour 
Modelling human behaviour using animals has long been recognized as a valuable 
tool in biomedical research, and especially in the quest to understand the genetics 
and biology behind illnesses of the mind, have they proved very useful (Cash-Padgett 
and Jaaro-Peled 2013, 1; Clapcote et al. 2007; Egan et al. 2009; Schmidt and Müller 





neurochemistry of the brain, thus by using animals the understanding of how 
behaviour correlates to neurochemical or developmental defects have greatly aided in 
the understanding of the development and management of diseases of the mind. 
Furthermore the majority of drugs available for treating mental illness has been 
discovered and developed using animal models of behaviour, further underlining the 
importance of understanding behaviour.  
1.1.3.1 Symptoms of anxiety and depression 
1.1.3.1.1 Anxiety  
As described previously, anxiety is the most prevalent psychiatric disorder in the 
western world. Anxiety is a feeling of apprehension or fear, and can often be 
precipitated by stress. Fear is the emotional response to a real or perceived imminent 
threat, whereas anxiety is the anticipation of future threat, therefore it is a preparation 
for future danger and consists of avoidance behaviours (Adhikari 2014). Anxiety is a 
natural feeling, and healthy individuals often experience moments of anxiety. When 
the feeling become persistent and disruptive, it progresses into a pathological state. 
Symptoms of anxiety disorders are often described as a disturbance in the mood and 
thought process, which leads to excess worrying and apprehension of fear. These 
symptoms are often followed by more physical reactions, like dizziness, increased 
blood pressure and heart rate and insomnia (Adhikari 2014). Anxiety is divided into 
a range of different symptoms, covering generalized anxiety disorder, obsessive- 





1.1.3.1.2 Depression  
It is not rare for a healthy person to experience feelings associated with depression. 
Feeling sad or depressed is not uncommon, but in healthy persons these feelings will 
often pass. This is not the case in people suffering from depression. The feelings of 
hopelessness, sadness and emptiness are often persisting, which eventually will lead 
to a chronic state of sadness, low energy and altered temperament. Anhedonia and 
suicidal thoughts are often associated with depression, along with cognitive deficits. 
  
1.1.4 Modelling anxiety and depression in rodent models 
Rodents have been a favoured model in behavioural science for many years. 
Especially in the drug discovery field the use of mice and rats been extensively 
utilised. The innate behaviour of rodents is well documented, and therefore the 
chemical modulation of these behaviours has been used to elucidate on the function 
of potential drug candidates for the treatment of mental disorders in humans 
(Fernando and Robbins 2011).  
Rodents have an innate drive to explore a new environment, a behaviour which can 
be manipulated using compounds with known anxiogenic or anxiolytic function. For 
this the open-field exploration test has proven useful. In this test, the animal is placed 
into an arena, and the light conditions can be altered, depending on the natural 
preference of the animal. Anxious animals show a less degree of exploration and stay 
close to the walls of the arena, a behavioural trait commonly described as 





this assay is the amounts of time spend in the centre of the arena and the total 
distance moved. The total distance moved is an important parameter, as this indicates 
if there is a potential side effect of the compound, causing decreased locomotor 
behaviours (Prut and Belzung 2003). When mice are treated with anxiolytic 
compounds, they spend more time at the centre of the arena, and show a greater 
degree of exploration and movement (Prut and Belzung 2003).  
Another test commonly used in anxiety research is the elevated plus maze. In this test 
the animal is placed on a maze consisting of two open arms and two closed arms. 
The whole maze is elevated 60-80 cm above the floor, to stress the animal. Animals 
displaying anxiogenic-like behaviours will spend significantly more time in the 
closed arms, less time exploring and less time rearing up to examine their 
environment (Pellow and File 1986). These parameters can be altered when treating 
animals with anxiolytic compounds e.g. buspirone, a 5-HT1A agonist, buspirone,  
1.1.4.1 Current drug treatments for anxiety 
The treatment of anxiety often consists of a combination of cognitive treatment and 
pharmacological treatment. The goal of the cognitive treatment is to help the patients 
with managing the negative thoughts and behavioural patterns, which is often the 
disablitating factors in anxiety disorders. 
Drug treatment is often divided into acute and maintenance treatment. The acute 
treatment is administered during a panic attack and has a fast acting effect, whereas 
the maintenance treatment is a chronic treatment, often used in an attempt to fine-





 A majority of the treatments available for treating anxiety today have been validated 
using some of the behavioural assays described above. Below is a brief description of 
the most common anxiolytic treatment approaches used in the clinic.  
1.1.4.1.1 Targeting the gamma-amino butyric acid receptor 
Abnormal neuronal excitability is often due to deregulation of excitatory or 
inhibitory neurotransmission. In the central nervous system (CNS) glutamate is the 
major excitatory neurotransmitter, whereas gamma amino butyric acid (GABA) is 
the inhibitory. A deregulation of any one of these two neurotransmitters can lead to 
adverse neurotransmission, and thereby psychiatric disorders, like depression and 
anxiety. Therefore, the focus of current treatments for anxiety and depression has 
been focusing on the regulation and modulation of these two neurotransmitter 
signalling pathways.   
Barbiturates are a very effective class of compounds, with strong sedative effects. 
This is thought to be archived through its blockage of the AMPA-receptor, inhibiting 
the excitatory mechanism of glutamate. Furthermore, it also binds to the gamma 
amino butyric acid (GABA) A receptor, as an allosteric modulator, thereby 
potentiating the inhibitory neurotransmission of GABA. The broad effect of 
barbiturates can cause a wide variety of side-effects observed in patients treated with 
these compounds, including sedation, slurred speech, dependence and ataxia (López-
Muñoz, Ucha-Udabe, and Alamo 2005; Cryan and Sweeney 2011).  
These adverse effects of barbiturates have made them less favourable in treatment of 





The development of another class of compounds targeting the GABAA-receptor came 
with the development of the benzodiazepines. This class of compounds bind to the 
benzo-site of the GABAA-receptor, as an allosteric modulator, prolonging the 
opening of the channel, thereby enhancing the GABA-signalling. The compound is 
not, contrary to the barbiturates, capable of inducing a constant opening of the 
channel, which makes the risk of over-doses very low. Therefore, the use of 
benzodiazepines has been favoured over the use of the barbiturates, although there 
are aversive effects associated with the treatment (Argyropoulos and Nutt 1999). 
Generally, compounds that modulate GABA signalling are fast acting, making them 
effective in acute treatment of e.g. panic attacks. This is contrary to the most recent 
developed anxiolytic compounds, which are in general slower in their mechanism of 
action.  
1.1.4.1.2 Antidepressants used for the treatment of anxiety 
Anxiety and depression are often co-morbid, which means that patients  diagnosed 
with one, often show symptoms of the other as well (Cryan and Sweeney 2011). It is 
therefore not surprising that compounds targeting the same neurotransmitter systems 
are used to treat both indications. These systems include the serotonin (5.HT) and the 
noradrenalin (NA) systems. Anxiolytic treatment is often targeting the serotonin 
system. Serotonin in a neurotransmitter, which acts through binding to the 5-HT-
receptors.  
The first line of treatment for anxiety is using a selective serotonin re-uptake 





fluoxetine (Prozac®). The mechanism of action of SSRI is not well understood, but 
the prolonged availability of serotonin in the synaptic cleft is one of the proposed 
mechanisms.  
From a clinical trial  using a benzodiazepine in rats, it was observed that the rats 
treated with benzodiazepine had a much lower serotonin-turnover rate compared to 
that of vehicle treated rats  (Wise, Berger, and Stein 1972). These data led to the 
suggestion, that serotonin play an important role in anxiety. This has been further 
substantiated from genetic studies, as mice lacking the 5-HT1a-receptor show an 
increase in anxiety-like behaviours in the elevated plus maze and the open field test 
(Toth 2003). The realization that serotonin plays an important role in anxiety resulted 
in the development of compounds specifically targeting this pathway. Partial 5-HT1a 
agonists, like buspirone, produces anxiolytic-like effects in  rodent models, and have 
been used to treat anxiety in humans (Cryan and Sweeney 2011).   These compounds 
utilized an alternative approach to treating anxiety, which was not through the 
GABA-receptor modulation. However, due to the slow onset of action of serotonin 
partial agonists, compared to that of benzodiazepines, the use of Buspirone to treat 
anxiety is limited (Hoffman and Mathew 2008).  
The above mentioned treatment strategies, have all been in clinical use for several 
years(Wise, Berger, and Stein 1972; Hoffman and Mathew 2008). The lack of new 
treatments developed for the treatment of psychiatric illness is staggering. Although 
the constant development of new and better animal models, used to model the  





compounds approved and introduced into the clinic since the approval of the first 
SSRI, fluoxetine, in 1987 (Cryan and Sweeney 2011).  
Therefore, there is a need for an alternative approach to treat psychiatric illness. One 
alternative could be to target the range of intracellular components of the signalling 










Figure 1.1.2: Schematic drawing of the intracellular signalling pathways involved in 
regulating neurotransmitter signalling.  
Serotonin, dopamine and norepinephrine all signal through G protein coupled receptors, and 
cAMP. Upon neurotransmitter binding to the receptor, an increase adenylate cyclase is 
activated, causing an increase in cAMP levels. Activation of PKA by increase in cAMP 
levels, ultimately results in the translocation of the cyclic AMP Response Element Binding 
protein (CREB) to translocate to the nucleus, resulting in gene transcription (Drawing from 






1.1.4.2 The cAMP signalling pathway 
The cyclic adenosine 3’5’ monophosphate (cAMP) is a small secondary messenger. 
It is the key component in a ubiquitous second messenger signalling system, that 
relay effects of extracellular neurotransmitters or hormones, when they bind their 
designated receptors (Beavo, Francis, and Houslay 2006). The formation of cAMP is 
catalysed by adenylate cyclase (AC), an enzyme that catalyses the synthesis of 
cAMP from ATP. To date ten adenylate cyclase isoforms have been identified. Of 
these 10 isoforms, 9 have been identified as being highly expressed in the brain, 
indicating the importance of cAMP signalling in the nervous system (Chern 2000).  
Several neurotransmitters important for the function and modulation of behaviour 
and memory processes are known to signal through the cAMP cascade, via the G 
proteins coupled receptors (GPCR; Figure 1.1.3). Serotonin, adrenergic and GABA 
receptors are among some of the neurotransmitters that signal through G protein 
couple receptors and the cAMP cascade (Figure 1.1.2)  (Lauder 1993).  
G proteins are guanine nucleotide binding proteins. They act as a signal transducer, 
mediating the signal of ligand binding to the receptor, across the cell membrane to 
the effector systems, like adenylate cyclases. The G protein can either activate or 






Figure 1.1.3: Schematic of the activation of the adenylate cyclase through a G protein 
coupled receptor.  
A schematic drawing that illustrates the stimulation process of cAMP production, through G 
protein activation. Upon ligand binding, the G-protein coupled receptor is activated, and the 
α-subunit is released, and GPT is bound. The GTP-binding subunit directly activates the 
adenylate cyclases which catalyse the formation of cAMP (drawing from K. Anastasaki, 
PhD Thesis, 2011). 
 
Each G protein is a heterotrimeric protein consisting of three subunits: α, β, γ. There 
are four families of G proteins, based on the similarity of the α-subunit. They are 
called Gs, Gi, Gq and G12 (Nicol and Gaspar 2014). The Gs activates all membrane 
bound AC enzymes, and thereby cause an increase in cAMP levels. The Gs family 
can be activated by Forskolin treatment (Seamon, Padgett, and Daly 1981). Gi 
proteins inhibits the cAMP production through AC inhibition, causing a decrease in 
cAMP levels (Nicol and Gaspar 2014).  
Cyclic AMP has been shown to be involved in regulating metabolism, cell growth 
and differentiation, muscle contractions (Stork and Schmitt 2002), memory 





secretion (Yajima et al. 1999). When activated, cAMP interacts with several 
downstream effectors. The first described target of cAMP was the protein kinase A 
(PKA). PKA is a serine/threonine kinase, consisting in its inactive state, as a tetramer 
(Taylor et al. 2005). The tetramer consists of two regulatory units and two catalytic 
units. When cAMP levels increase, four cAMP molecules bind to the regulatory 
subunits of the holoenzyme, causing the release of the catalytic units, thus activating 
PKA, which results in a release of the catalytic (C) subunits from the regulatory (R) 
subunits (Taylor et al. 2005), leading to a range of cellular responses, ultimately 
leading to the phosphorylation of the transcription factor cAMP Response Element 
Binding protein (CREB). CREB binds to the cAMP response element present in the 
promoter region of the majority of cAMP regulated genes (Carlezon Jr, Duman, and 
Nestler 2005).  Other downstream effectors of cAMP include the Exchange Protein 
activated by cAMP (EPAC) (Bos 2006), and the mitogen activated protein kinase 
pathway (Waltereit and Weller 2003).  
1.1.4.3 Regulation of cAMP signalling by the phosphodiesterase 
family 
The regulation of cAMP signalling is tightly controlled by the phosphodiesterase 
(PDE1-11) family of proteins. The PDEs are the sole mechanism of cAMP-
hydrolysis in the cell, and thereby cAMP homeostasis, making this group of proteins 
extremely important. Their functional importance is reflected in the myriad of 
different isoforms so far identified (Beavo, Francis, and Houslay 2006) This diverse 





genes so far (Beavo, Francis, and Houslay 2006). Through alternative splicing and 
alternative promoter usage, these genes encode more than 100 different isoforms of 
PDEs (Marco Conti, Mika, and Richter 2014). 
Of the many different isoforms of PDE that exists, the PDE4 family has been 
described extensively (M. Conti et al. 2003; Beavo, Francis, and Houslay 2006; 
Miles D. Houslay, Baillie, and Maurice 2007). PDE4s are highly expressed in the 
brain and cells of the immune system. The PDE4 family consists of four genes, 
PDE4A, 4B, 4C and 4D (Beavo and Brunton 2002), and thus far there have been 
identified more than 20 different isoforms of PDE4 proteins, all of which exclusively 
catalyse the hydrolysis of cAMP, thus regulating the downstream signalling pathway 
of cAMP.  PDE4 proteins contain a unique amino acid sequence, called the upstream 
conserved region (UCR) 1 and 2. Depending on the isoform, these two regions are 
present in the protein, and are important in the regulation of the activity of the 








Figure 1.1.4: Structural organisation of the PDE4 family.  
The protein structure and organisation of the different isoforms of Pde4 proteins are highly 
similar. Each family contain different splice forms, resulting in long-form, short form and 
super short form. The regulation of the different isoforms is determined by the presence of 
the phosphorylation sites present in the different motifs (Figure from O’Donnell and Zhang, 
2003, Trends in Pharmacology, license no. 3564841347281).  
 
The UCR1 contains a PKA phosphorylation site, allowing for the phosphorylation of 
the PDE4 protein by PKA. This cause a conformational change in the structure of the 
PDE4 protein, allowing UCR1 to interact with UCR2, thereby activating the PDE4 
enzyme activity  (Beard et al. 2000). Thus the regulation of PDE4 and cAMP are 
through a feedback loop, where cAMP regulates PDE4 expression and activity, and 
PDE4 regulates cAMP levels in vivo. 
The function of PDE4 has largely been discovered through studies using the highly 
specific PDE4-inhibitor, Rolipram (S J MacKenzie and Houslay 2000). Rodent 
studies has demonstrated that Rolipram has antidepressant, anxiolytic and cognitive 
enhancing properties (Lelkes et al. 1998; Y.-F. Li et al. 2009a). Furthermore, there 





asthma and chronic obstructive pulmonary disease (COPD). This effect is likely due 
to the decreased production of TNFα and cytokines, following PDE4-inhibition (Zhu, 
Mix, and Winblad 2001). Roflumilast, the first PDE4-inhibitor approved for clinical 
use, et, is approved for COPD treatment (Hatzelmann et al. 2010).  
Rolipram was withdrawn from clinical development, due to its emetic side effects, 
(Heaslip and Evans 1995). However, Rolipram is still used extensively used as a tool 
compound to modulate cAMP levels through PDE4-inhibition.  The development of 
isoform specific PDE inhibitors has proven extremely difficult, due to the high 
degree of structural similarities (Burgin et al. 2010, 4; Boswell-Smith, Spina, and 
Page 2006).  
To gain insight into the specific function of different PDE4 isoforms, the 
development of knockout models has greatly increased the current knowledge of the 
function of specific PDE4-isoforms, and their involvement in regulating behaviour. 
To date, three knockout models in mice have been reported, for the three types of 
PDE4-genes primarily expressed in the brain; PDE4A, PDE4B and PDE4D. 
Interestingly, the behavioural phenotypes of PDE4A and PDE4B both show 
anxiogenic-like phenotypes. (Zhang et al. 2008; R. T. Hansen, Conti, and Zhang 
2014), whereas mice lacking a functional PDE4D display behaviours similar to that 
observed in rodents subjected to anti-depressant treatment (Zhang et al. 2002b). 
These findings suggest there are distinct functions of the different isoforms on PDE4 





be potentially powerful in the treatment of psychiatric illness or memory 
enhancement.  
The importance of the PDE4-function in psychiatric illness was further established 
when Miller and colleagues reported on the disruption of the PDE4B gene function 
in two patients with psychotic illness, further underlining the importance of PDE4-
signalling in mental illness (Millar et al. 2005, 1).  
1.1.4.4 Cyclic AMP in Stress and Anxiety 
From rodent studies it has been shown that the area of the brain responsible for the 
regulation of anxiety and stress are the prefrontal cortex and the amygdala (Ganella 
and Kim 2014). Mounting evidence from both behavioural and pharmacological 
studies have demonstrated the importance of the cAMP signalling pathway in the 
brain of rodent models of stress and anxiety (Davidson 2002). Rats subjected to 
stress show increased activity of cAMP in the response to different stressors, e.g. 
electrical foot shock, immobilisation and cold: The most extreme form of stress, e.g. 
foot shock, cause the highest increase in cAMP levels (Kant et al. 1982). Also in 
zebrafish has the modulation of cAMP been shown to regulate different behaviours. 
Using two types of phosphodiesterase inhibitors, Rolipram and Roflumilast, Wolman 
and colleagues show that cAMP is important for regulating learning, but not memory 
in zebrafish larvae,(Wolman et al. 2014) . Caffeine, another compound known to 
increase cAMP levels in vivo (Schreiner et al. 1986), has been shown to induce 
thigmotaxis in both larval and adult zebrafish, a behavioural phenotype often 





Richendrfer et al. 2012) This implies  that levels of cAMP can regulate behaviour in 
zebrafish, suggesting an important function for cAMP-regulation in behaviour, and 
thus potentially a promising target in treatment of mental illness.  
Potentially, behavioural research using zebrafish could be a useful approach to 
screen compounds for their ability to prevent or induce behavioural phenotypes 
associated with anxiogenic behaviour.  
1.1.4.5 Phenotypic drug screening 
Drug development is often driven by a target-based approach. Using cell-based 
assays many potential drug candidates are screened for specific effects on known 
targets (Benson et al. 2006). This approach is efficient, when the target is well known 
and characterized. However, for many types of psychiatric illness the genetics and 
biology is complex, and often the genetics unknown. Therefore, the target-based 
approach in drug discovery is not applicable to drug development in psychiatric 
illness. An alternative and possibly more successful approach would be the 
phenotype-based approach. Phenotype based drug screens screen for compounds 
modulating a specific behaviour, instead of compounds targeting a specific cellular 
target. Using this approach, Rovira and colleagues screened a library of FDA 
approved drugs on zebrafish larvae. Using a transgenic reporter line, they screened 
for compounds capable of inducing β-cell differentiation in the pancreas, important 
for insulin production. From this screen they identified two pathways important for 
β-cell differentiation in zebrafish, which have not previously been reported to be 





but used the swimming activity of zebrafish larvae as an output to identify 
compounds that block to reward-effects of nicotine and alcohol (Cousin et al. 2014). 
From this screen Cousin and colleagues identified a FDA approved anti-epileptic 
compound, Topiramate, as being able to attenuate the psychomotor stimulating 
effects of nicotine, and suggest that the treatment for cessation of smoking (Cousin et 
al. 2014).  
These studies demonstrate the functionality of zebrafish in phenotypic screens. The 
combination of using the zebrafish and compound libraries consisting of compounds 
already approved for other indications can help to propel the drug development 
process for mental illness forward. The zebrafish provides a cost-efficient, high-
throughput approach to screen compounds for specific phenotypes, making it a 
promising model in behavioural drug screens.  
 
1.1.4.5.1 Setting up a phenotypic screen in zebrafish larvae 
Using the zebrafish for phenotype based screens has been demonstrated as described 
above. However, there are a number of papers describing the use of zebrafish in 
screening for a specific phenotype or reversal of a phenotype. Baxendale and 
colleagues demonstrated how the use of a zebrafish model of epilepsy could be used 
to screen 2000 small bioactive compounds, for their effect to reverse the PTZ 
induced phenotype and suppression of the immediate early gene, c-fos expression 
(Baxendale et al. 2012), a marker for increased neuronal activity (Sheng and 





effect, and therefore, I used this to evaluate the potential of zebrafish in automated 






1.2 Aims of this thesis 
 
(i) To setup an automated method to analysis zebrafish larvae behaviour.  
(ii) Validate the automated method by testing drugs with known or un-known 
effects on zebrafish behaviour.  
(iii) Evaluate the effect of cAMP modulation on zebrafish larval behaviour.  
(iv) Setup behavioural assays in adult zebrafish 

















2.1.1  General buffer recipes 
PBS (pH7.4)1L 
NaCl  8g 
KCl  0.2g 
Na2HPO4  1.44g 
KH2PO4  0.24g 
ddH2O  up to 1L  
The buffer is sterile filtered before use.  
TBS 10x stock solution (1L) 
NaCl  87.66g 
Tris Base  12.11g 
ddH2O up to 1L. Adjust pH to 8.0 and sterile filtered before use. 
1M Tris Buffer (1L) 
Tris Base  121.1 g 
ddH2O   800 mL 







0.5M EDTA (pH 8.0), 1L 
Na2EDTA   186.1g 
ddH2O  500mL 
Adjust pH to 8.0 with 10M NaOH.  Fill up with ddH2O to 1L and filter sterilise. 
60 x stock of E3 embryo medium (1L) 
NaCl  17.2g 
KCl  0.76g 
CaCl2•2H2O   2.9g 
Mg2SO4•7H2O 4.9g 
ddH2O up to 1L, autoclave to sterilise. 
E3 Embryo Medium (1L) 
60x E3 stock solution  16.6ml 
ddH2O up to 1L. For storage of embryos 1ml of 0.5% Methylene Blue in aqueous 
solution is added to the 1x E3. 













Rolipram DMSO Tocris 
PD0325901 DMSO 
Tocris & University of 
Dundee 
IBMX DMSO Tocris 
Forskolin DMSO Tocris 
F152611 DMSO Lundbeck A/S 
F152497 DMSO Lundbeck A/S 
F152498 DMSO Lundbeck A/S 
F152497 DMSO Lundbeck A/S 
F152439 DMSO Lundbeck A/S 
Buspirone DMSO Sigma 
Pentylenetetrazole (PTZ) E3 Sigma 
Diazepam DMOS Sigma 
Ethosuximide DMSO Sigma 
Valproate E3 Sigma 
Allopregnanolone DMSO Sigma 
Alfaxalone DMSO Sigma 












Table 2:1: List of compounds used in project 
  
Acetazolamide DMSO Sigma 
Pentobarbital E3 Sigma 
Oxacarbamazepine DMSO Orgamol S.A. 
Lorazapam DMSO Sigma 
Retigabine DMSO NeuroSearch A/S 
Zonisamide DMSO NeuroSearch A/S 
Carbamazapine DMSO Sigma 






2.2.1  Fish husbandry 
Zebrafish are a fresh water fish, and in our facility the fish are kept in re-circulating 
stand-alone aquarium racks from Aquatic Habitats (PentAir, Florida, USA). Room 
temperature was kept at 23°C and the water temperature around 28°C. The room was 
on a diurnal light schedule, allowing 14 hours of light (7am to 9pm) and 10 hour of 
darkness (9pm to 7am).  
2.2.1.1 Setting up a zebrafish facility 
A stand-alone system from Aquatic Habitats were purchased and installed by MBK 
Installations (MBK Installations Ltd, Nottingham, UK). The stand-alone is equipped 
with an YSI-probe unit, allowing for the continued monitoring and adjustment of the 
water quality parameters, with an automated dosing system for salt (to control 
salinity and conductivity) and bicarbonate, to maintain pH values. The system was 
supplied with RO water and circulation was initiated. The probe head consists of a 
pH probe, an oxygen probe and a combined conductivity and temperature probe. The 







2.2.1.2 Water quality parameters 
Parameter Set value Recommended range 
pH 7.4 7.3-7.8 
DO 7.0 mg/ml 5-10 mg/ml 
Conductivity 700µS 400-1000µS 
Salinity 0.4 ppm < 2 ppm 
Temperature 28°C 27-30°C 
 
Table 2:2: Table of water quality parameters in the Aquatic Habitats stand-alone flow-
through system 
2.2.1.3 Filtration systems 
As the system is a re-circulating system, the water is filtered and sterilised through 
different steps. First step of water sanitation are the mechanical filters, consisting of a 
horizontal filter, with a pore size of 100 µm and a cylinder filter, with a pore size of 
25 µm. Activated carbon filters remove any traces of chlorine and lastly water is 
sterilized by passing through a UV-lamp unit.  
2.2.1.3.1  Bio filters 
The bio filters were initiated by adding 5 dpf old larvae into four 3L tanks, and 





additional 4 tanks of fry were added. During this ―seed‖ period, the water parameters 
were checked once a week, to monitor the establishment of the bio filters. This is 
done by monitoring the levels of the components of the nitrogenous cycle.   
The following parameters are measured once a week, to check that the bio filters are 
working properly: 
Parameter Acceptable value 
Total ammonia nitrogen <1 mg/L 
Nitrite (NO2
-
) <0.05 mg/L 
Nitrate (NO3
-
) < 20 mg/L 
 
Table 2:3: Acceptable values of components of the nitrogenous cycle in the 
Aquatic Habitats stand-alone flow-through system. 
  
2.2.1.4 Maintaining zebrafish 
Adult fish were fed three times a day with Zeigler Adult Zebrafish diet (MBK 
systems, UK). In the mornings and afternoons a supplementary feed with live 
artemia was included (MBK systems, UK). 
 
2.2.2  Raising zebrafish larvae 
Fertilized zebrafish embryos were collected shortly after onset of light in the fish 
room. Embryos were cleaned and sorted, and unfertilized or damaged embryos were 





dishes. ~50 embryos in a 9cm dish or ~100 in a 15 cm dish, in E3 with 0.005% 
Methylene blue (Sigma Aldrich, Denmark). The larvae were substituted with fresh 
E3 every day, and dead or sick embryos were removed to maintain a healthy clutch. 
At 5 dpf the larvae were introduced into the zebrafish system in 2 cm of system 
water, and fed with a fry feed, with granule size <100µM (ZM-000, ZM Systems, 
UK). Every second day 2 cm of system water was introduced into the tank, and when 
the fish are 21 days the water supply is turned on. At 21 days post fertilization, fish 
are fed ZM-100, a fry food with granule size of 80-200µM and two daily feeds of 
live artemia. Around 2 months of age the fish are fed an adult zebrafish diet (Zeigler, 
Aquatic Habitats, FL, US) three times a day, and two daily feeds of live artemia.  
2.2.3      Behavioural assays 
For this project, several behavioural assays were established in the lab. First and 
foremost, setting up of the automated tracking equipment was established, followed 
by two different assays to measure adult behaviour.  
2.2.3.1 Larvae behaviour assays 
2.2.3.1.1  Swimming activity 
WT embryos were raised in the incubator, with a 14/10 hour light/dark cycle, at 
28.5°C. At 5 dpf larvae were distributed into individual wells of a 96-well flat-
bottomed plate (Nunc MicroWell, P7491, Sigma-Aldrich), 1 larvae per well, in E3, 
and allowed to acclimatize in the incubator for 1 hour prior to treatment and testing. 





larvae were put back in the incubator until the next treatment was added or the 
experiment could be analysed. The multi well plate was moved to the testing setup, 
and placed in the DanioTrack (Noldus Information Technology, NL) for tracking. 
The EthoVision-software was programmed depending on the protocol needed. The 
plate is placed in the DanioVison box, and the lid is closed. The EthoVision software 
is opened, and the protocol of choice is loaded. The arena settings and the detection 
settings could be adjusted, so that optimal tracking is archived.  When the experiment 
finished, the larvae were either euthanized or collected in Eppendorf tubes and snap-
frozen in liquid nitrogen and kept at -80°C until further analysis were done.   
2.2.3.1.2   Data Analysis 
2.2.3.1.2.1  Normalizing data 
Each individual data set (well) in the experiment was then normalised to this value 
by dividing each individual well-value by the total average for the whole plate. 
Comparison of the median in each group, in each of the experiments, indicates 
whether it is valid to pool all the data into one group, and analyse them together. The 
normalized data from the dark-experiments were analysed using a Bootstrap method. 
Using this method we analysed the data from the seven individual experiments 
pooled together. The Bootstrap method allocates the normalised means into bins, 
creating defined groups of data. These data were plotted as histograms, and were 






2.2.3.1.2.2 Statistical analysis 
For statistical analysis GraphPad Prism 5 and R (v3.0.2; www.r-project.org) software 
were used. Test included One-Way and Two-way ANOVA, followed by Tukey’s 
post-test (One-Way ANOVA) or Bonferroni’s posthoc test (Two-Way ANOVA). For 
data that was found to be non-normal distributed and with unequal variances across 
groups, 95% confidence intervals of the group means and the difference between 
group means were estimated by bootstrapping the data (CIs were bias-corrected and 
accelerated and based on 10.000 resampling’s). Means were considered significantly 
different when the bootstrapped 95% CI (of the difference between means) did not 
include zero. 
2.2.3.1.3  Visual Motor Response 
5 dpf zebrafish larvae were distributed into individual wells of a 96-well plate (Nunc 
MicroWell, P7491, Sigma-Aldrich) in 100µL of E3. After the fish were allocated to 
the individual wells, they were examined using a stereo microscope (Zeiss, 
Denmark), to make sure all larvae are at the same developmental stage and the any 
dead or un-healthy larvae are replaced prior to the experiment begins. The larvae 
were allowed to acclimatize for 1 hour before drugs were added. All larvae received 
the same number of pipetting events and larvae that did not receive any drug 
treatment were mock treated with vehicle or E3. After treatment the multi-well plate 
is placed in the DanioTrack (Noldus Information Technology, NL), and the Visual 






2.2.3.1.3.1  Visual Motor Response Protocol 
1: Start of protocol 
2: 10 min dark  
3: 10 min light 
4: 10 min dark  
Steps 3&4 three are repeated 3 times in total 
End of protocol  
2.2.3.1.4  Data analysis 
The locomotor analysis was done by analysing the distance travelled in 2 minute 
time bins, and exported in Excel-format. The date was then transferred to GraphPad 
Prism, and plotted using an X-Y graph format. Average distance moved during light 
and dark periods were calculated and compared to that of the DMSO control fish. 
The total distance moved in all the light and dark periods were calculated as fractions 







2.2.3.2 Adult behavioural assays 
2.2.3.2.1  Shoaling assay 
Fish used in the shoaling assay were raised in the facility, at a stocking density not 
higher than 4 fish per litre of water. On the day of the assay, adult fish were removed 
from the zebrafish room, and moved to an adjacent room, and allowed to habituate to 
the room for 2 hours prior to testing. After video capture, the fish were euthanized in 
ice water, and snap frozen in liquid nitrogen and stored at -80°C, until further 
analysis was done.  
2.2.3.2.1.1  Drug treatment 
For drug experiments, the fish were treated for 20 minutes in the test tank (Small 
Geo tank, Ferplast, Italy), which had the following dimensions; L:18 x D: 11.5 x H: 
14 cm, and contained a volume of 1L. The compound or vehicle was added to the 
water, with a final DMSO concentration of 0.001%. The group of fish were 
transferred to the tank, and incubated in the compound for 20 minutes prior to 
recording.  
2.2.3.2.1.2  Video recordings 
Movies were recorded in AVI for MPEG4 format, and recordings were made from 
the side and from the top using a digital camera (Panasonic Lumix DMC-TZ8 or 
Canon IXUS 80 IS). The tank was placed on a white surface and with a white back 
ground on a RS 2 XA camera stand (Kaiser, Germany). The side recordings were 





the tank, and the behaviour was captured. When capturing movies from the top, the 
camera was mounted on the camera stand, with a distance from the tank of 
approximately 50 cm.  
2.2.3.2.1.3  Data analysis 
After capture, the data was analysed using either Actual Track (Actual Analytics, 
Edinburgh, UK) or EthoVision XT9. For the software to calculate the distance 
travelled and time spend in different zones, the user needs to define the area of 
interest and the dimensions of this area. This is what the software uses as a reference 
parameter, when calculating the x-y coordinates used to generate the data. For the 
side tracking, the entire arena was divided in two equal sized half’s, for the further 
determination of the time spend at the top and bottom of the tank. In the EthoVision 
XT9, there is a multiple animal tracking module, which can be used to track multiple 
fish.  
2.2.3.2.2  Novel Tank Test 
The novel tank test was performed in a trapezoid tank, measuring 27 (L) x 15 (H) x 
10 (W) cm (Aquatic Habitats, FL, US). The tank was placed on a level, white 
surface, against a white background. The fish used for the experiment were AB/TL 
fish (6-12 months of age) or Pde4d+/+ or pde4d-/-. The fish were stocked at a 
stocking density of maximum 4 fish per litre, to avoid stress through crowding.  
 On the day of the test, the fish were moved into the testing room in their home tank, 





2.2.3.2.2.1  Drug treatments  
For experiments involving drug treatment, the fish were treated in a 1 L beaker 
(Pyrex, VWR, Denmark) in 200 mL of system water containing the compound or 
0.001% DMSO. The pre-treatment time was 20 minutes, and after treatment the fish 
was gently poured into the test tank, containing 1.8 L of system water.  
After each trial the tank was cleaned and re-filled with fresh system water.  
2.2.3.2.2.2  Video Recordings 
Movies were recorded in AVI for MPEG4 format, and recordings were made from 
the side and from the top using a digital camera (Panasonic Lumix DMC-TZ8 or 
Canon IXUS 80 IS). The tank was placed on a white, level surface and against a 
white background. Movies were recorded from the side, for 6 minutes. The camera 
was placed on a level surface approximately 80 cm away from the tank, and the 
behaviour was captured.  
2.2.3.2.2.3  Data analysis 
The data was analysed using EthoVision XT9 (Noldus Information Technology, 
NL). The arena was defined in the software, and the top half of the tank was 
indicated as the top half of the area filled with water. The parameters measured were 
time spent in top of zone, latency to enter the top zone and total distance moved. 
Moreover, the frequency of erratic movements and freezing incidents, and total time 
of erratic and freezing episodes, was also determined.  Data was plotted using 





2.2.4  Drug treatments 
2.2.4.1 Rolipram 
50 mg of Rolipram (Tocris Biosciences, Bristol, UK) was dissolved in 3.6mL of 
DMSO to make a stock concentration of 50mM. The stock was frozen at -20ºC in 
20µL aliquots, and stored for 4-8 months. Larvae behavioural assays were done 
using a final concentration of 15µM of Rolipram, and adults were treated with a final 
concentration of 30µM Rolipram.  
2.2.4.2 PD0325901 
10 mg of the MEK inhibitor, PD0325901 (MW = 482.19 g/mole), was purchased 
from Dundee University (Hilary McLaughlan, University of Dundee, UK), or Tocris 
(Tocris bioscience, Bristol, UK) and diluted in 2.07 mL of DMSO to make up a 10 
mM stock. This stock was stored at -20°C in 10 µL aliquots for 1 year. After thawing 
the aliquot was not frozen again.  
2.2.4.3 IBMX 
10 mg of IBMX (MW=222.24 g/mole) was purchased from Tocris (Tocris 
Biosciences, Bristol, UK) and diluted in 7.5 mL of DMSO to make a stock 
concentration of 30mM. 20µL aliquots of the stock were stored at -20°C for up to 1 
year. 5 dpf embryos were treated with a maximum of 30µM IBMX for 1 hour. The 






10 mg of Forskolin (MW: 410.51 g/mole) was purchased from Tocris (Tocris 
Biosciences, Bristol, UK) and diluted in 3.25 ml of DMSO, to make up a stock 
solution of 7.5mM. 20µl aliquots were made up, and stored at -20°C. Once defrosted, 
the stock was not re-frozen.   
2.2.5  Drug screens 
2.2.5.1 PDE inhibitor screen 
5 dpf WT zebrafish larvae were added to 96 well plates (Nunc MicroWell, P7491, 
Sigma-Aldrich), 1 larvae per well. The larvae were allowed to acclimatise in the 
incubator for 1 hour before the compounds were added, in a concentration curve 
format. Each compound was tested in concentrations 10nM, 30nM, 100nM, 300nM, 
1µM, 3µM and 10µM, with a final amount of DMSO of 0.1% in E3. 100µL of each 
compound was added to each well, totalling of 12 larvae per concentration. The 
effect of the compound was tested during constant light for 1 hour. Data was 
analysed as total distance moved, and statistical analysis was done, using a one-way 
ANOVA, followed by a Tukey’s post-test.  
2.2.5.2 PTZ screen 
Five day old larvae were sorted and added into individual wells of a 96-well plate 
(Nunc MicroWell, P7491, Sigma-Aldrich, Denmark) in 100µL of E3. The larvae 
were allowed to acclimatise for 1 hour in the incubator. After one hour, 50µL of 





format. Larvae were incubated for 1 hour in the incubator after the drugs were added. 
After one hour, 50µL of 20mM of PTZ was added, resulting in a final concentration 
of 5mM PTZ.  Immediately after PTZ addition the 96-well plate was placed in the 
DanioVison chamber, and the VMR protocol was loaded. The data was exported as 
an Excel sheet, and the graph plotted using GraphPad Prism 5.  
2.2.6  Protein analysis 
2.2.6.1 Protein extraction 
After compound treatment embryos were snap frozen liquid nitrogen, and 100µL of 
lysis buffer was added, and the embryos were transferred to a screw-cap tube 
containing ceramic beads (Precellys, VWR Denmark). The fish were homogenised 
using a PreCellys 24 tissue homogenizer for 3x30 seconds, at 5000 rpm. Samples 
were transferred to ice, and spun at 10000 rpm for 15 min. Supernatant was removed 
and stored at -80°C until protein quantification. 
2.2.6.1.1  10 ml lysis buffer for protein extraction 
Tris-HCl   20 mM, pH7.5 
NaCl  150 mM 
EDTA  1 mM 
EGTA  1 mM 
Triton-X-100 1%  1 % 
Sodium Pyrophosphate 2.5 mM 
β-glycerophosphate 1 mM 





Before use a final concentration of 1mM Na3VO4 was added, and 1 tablet of protease 
inhibitors (ComPlete Mini, Roche, Denmark) and 1 tablet of phosphatase inhibitors 
(PhosStop, Roche, Denmark) was dissolved in the buffer.  
2.2.6.2 Protein determination 
To determine the concentration of extracted proteins, a DC protein assay was 
performed, using the Bio-Rad DC assay (Bio-Rad, Denmark). The assay was done in 
a 96-well plate format. The A’ reagent was made up, by adding 20µL of reagent A to 
each ml of reagent S that is needed for the assay. A standard curve using bovine 
serum albumin (BSA) was prepared for each assay. The following standards were 
prepared from a stock of 1.5 mg/ml of BSA: 0, 0.25mg/ml, 0.50 mg/ml, 1.0mg/ml 
and 1.5mg/ml. The standard curve was prepared in the same buffer used for the 
protein extraction. 5µl of standards and samples were added in triplicate to the 96-
well plate. The 25µl of Reagent A’ was added to each well, followed by 200µL of 
reagent B. The reaction was incubated at room temperature for a minimum of 15 
minutes, before absorbance was measure at 690 nm using a plate reader. The 
standard curve was plotted in Excel, and protein concentration of unknown samples 








2.2.6.3 Western Blotting 
2.2.6.3.1  Buffers for Western Blotting 
2.2.6.3.1.1 Running buffer 
To make a 1 L of 10x stock 
SDS  10g 
Tris-Base  36.3g 
Glycine   144 g.   
100 ml stock is diluted in 900 mL of dH2O and used for running the gel.  
2.2.6.3.1.2  Transfer buffer (Towbin) 
10 x stock solution: 
Tris-base (0.25M) 30.3g 
Glycine (1.92 M) 144g 
dH2O add   1 L 
To make 1 x Towbin buffer: 
10x stock solution 100ml 
Methanol  200ml 
dH20  700ml 
2.2.6.3.2  Sample preparation 
The samples from the protein extraction were prepared by adding 3 x Blue Loading 





of 3 x DTT (Cell Signalling Technology, AH Diagnostics, DK). The samples were 
prepared, so that the samples contain a final loading buffer and DTT of 1x. Prior to 
loading on the gel, the samples were denatured in a heat block at 95°C for 5 min, and 
immediately placed on ice, until the gel was ready to load.  
2.2.6.3.3  SDS page  
A precast polyacrylamide gradient gel (4-20% MINI protean TGX gel, Bio-Rad, 
Denmark) was prepared and mounted in the electrophoresis chamber (Bio-Rad, 
Denmark) and filled with 1 x running buffer. A total of 15mg of protein from each 
sample was loaded in the gel, and 5 µL of Spectra multicolour broad-range protein 
ladder (Thermo Scientific, VWR, Denmark) was loaded as a marker. The gel was run 
at a constant voltage of 120V for 50 minutes, or until the loading buffer had run off 
the bottom of the gel.  
2.2.6.3.4  Protein Transfer 
The transfer buffer was made up (see 2.2.6.3.1.2) and 200 ml was poured into a tray 
containing 4 pieces of Whatman paper and 2 sponges. The FL-Immobilon PVDF 
membrane (Millipore, Denmark) was prepared by quickly soaking it in 100% 
methanol, and rinsing it in transfer buffer. The gel cassette was opened, and the gel 
was washed in transfer buffer prior to assembling the transfer cassette. The cassette 
was assembled on the clear side of the transfer cassette, with 1 sponge, 2 pieces of 
Whatman paper, PVDF membrane, gel, 2 pieces of Whatman paper and 1 sponge. 
Air bubbles were removed with a roller after the membrane and gel had been placed 





module, with the black side facing the black face in the electrode module. The 
module was put in the buffer tank, and an ice block was placed next to it. Transfer 
buffer was poured in, until the cassette was covered, and a magnet was placed into 
the tank. The transfer unit was placed on a magnetic stirrer and the transfer was 
performed at 100V for 30 minutes.  
2.2.6.3.5  Protein detection 
After transfer the transfer sandwich was disassembled and the membrane was rinsed 
in TBS. To block for unspecific binding of the antibody, the membrane was 
incubated in Odyssey blocking buffer (Li-Cor Biosciences, UK) for 1 hour with 
constant agitation at room temperature. After blocking, 5 ml of primary antibody 
solution was poured on and the membrane was incubated over night at 4 °C with 
constant agitation. Next day the primary antibody was removed, and the membrane 
was washed 3 x 10 minutes in TBS + 0.1% Tween (TBS-T). After washing 5 ml of 
secondary antibody solution was added, and the membrane incubated for 1 hour at 
room temperature, under constant agitation and protected from light, to avoid photo 
bleaching of the secondary antibodies. Both primary and secondary antibodies were 
diluted in the blocking buffer. After incubation with the secondary antibody, the 
membrane was washed for 3 x 10 min in TBS-T under constant agitation, and before 
imaging the membrane was washed for 5 min in PBS. To detect protein expression, 





2.2.7  Cortisol determination 
To determine whole-body levels of cortisol in adult fish, cortisol extraction was 
performed, followed by an enzyme immunoassay.  
2.2.7.1 Cortisol extraction 
Adult fish were euthanized in ice water and snap frozen in liquid nitrogen. For 
cortisol extraction the fish were allowed to slowly defrost on ice. The fish were 
weighed and cut into smaller pieces, on ice. Using a hand held homogenizer (Tissue 
master homogenizer, Omni International, UK) the fish were homogenized in a 50ml 
falcon tube, containing 1 mL of ice cold, sterile filtered PBS. Following 
homogenization, 2 mL of diethyl ether (Sigma Aldrich, DK) was added to the tube 
and the tube was vortexed for 2 min. Samples were then spun down at 3,000 rpm for 
15 min. After spinning the tubes were snap-frozen in liquid nitrogen and the solvent 
layer containing the cortisol was transferred to a glass tube. The ether was 
evaporated overnight in the fume hood. Next day the samples were transferred to an 
Eppendorf tube, and re-constituted in ice cold PBS. The samples were kept in the 
fridge overnight, before being assayed the next day. 
2.2.7.2 Cortisol assay 
For the cortisol determination the High Sensitivity salivary Cortisol enzyme 
immunoassay kit from Salimetrics were used (Salimetrics Europe Ltd, UK). The 





prism, and the concentration of the unknown samples was extrapolated from the 
curve.  
2.2.8  Cyclic AMP assay 
To determine the total levels of cAMP an Elisa assay was performed. This assay is a 
direct Elisa assay, where a multi-well plate is coated with anti-cAMP. The cAMP in 
the sample compete with the cAMP is the conjugate, thus the higher levels of cAMP 
in the sampled, the lower colorimetric signal.  
2.2.8.1 Cyclic AMP extraction  
5dpf old zebrafish larvae (n=15 per treatment per experiment) were treated with 
0.1%DMSO, 15µM Rolipram, 7.5µM Forskolin, 1.5µM PD0325901 or the 
combination of Rolipram + PD0325901, Forskolin + PD0325901 or DMSO + 
PD0325901 for 1+1 hour, and then euthanized by snap freezing in liquid nitrogen. 
Cyclic AMP were extracted using 200µL 0.1M HCL and samples were homogenized 
using a hand-held homogenizer with pestle (Pellet-Pestle, VWR, DK). Following 
homogenization samples were sonicated for 15 seconds (MFI Sonicator, MSE, Svend 
Schröder, Denmark). After sonication the samples were incubated on ice for 15 min, 
followed by centrifugation at 13,000 rpm for 15 min at 4°C. After centrifugation 
supernatant was removed and transferred to Eppendorf tube, and stored at -80°C 





2.2.8.2 ELISA assay 
The concentration of cAMP in each sample was determined using a Direct Elisa 
cAMP kit (Enzo Life sciences, AH diagnostics, Denmark). The samples with 
extracted cAMP were diluted 1:1 in 0.1M HCL and assayed in duplicates. To 
increase the sensitivity of the assay, all the samples and standards were acetylated, 
using the kit that was provided by the manufacture. The manufactures instructions 
were followed and the cAMP levels were determined.  All samples and standards 
were assayed in duplicates, and extra care was taken when wells were washed. All 
excess washing buffer was blotted off on tissue paper between each wash, and a total 
of four washes were performed. The absorbance was read using a plate reader 
(MultiSkan Ascent, Thermo Labsystems), at a wavelength of 450 nm.  
2.2.8.3 Data analysis 
The data were analysed using GraphPad prism 5. The absorbance was plotted against 
the concentration of the standards, and unknown samples were extrapolated from the 
standard curve, that was fitted using a linear regression function in GraphPad prism 
5. The cAMP levels were adjusted according to total protein concentration, measured 
using the Bio Rad DC protein assay (see 2.2.6.2) 
2.2.9  Quantitative PCR 
To determine the gene expression levels of c-fos genes in larvae treated with PTZ 





2.2.9.1 RNA Extraction and quantification 
After respective compound treatments the 5 dpf old larvae (12 per group) were 
transferred to RNAse/DNAse free tubes, and euthanatized in liquid nitrogen. Total 
RNA was extracted using the RNEasy Micro Kit (Qiagen, DK).  RLT buffer 
containing 1% β-mercaptoethanol was added to the larvae and incubated at room 
temperature for 15 minutes. Following incubation, the larvae were homogenised 
using a hand-held homogeniser (Pellet-Pestle, VWR, DK), before nuclease-free 
water containing 1.7% of proteinase K was added, and samples were incubated at 55 
°C for a minimum of 15 minutes, to ensure that the larvae had completely dissolved. 
After incubation, the samples were centrifuged at 13,000 rpm for 3 minutes. The 
supernatant was collected and mixed gently with 100% ethanol, corresponding to 
half of volume of the supernatant, and loaded onto the column. The column was spun 
at 10,000 rpm for 15 seconds (s) and the flow through discarded. After the first wash 
with RW1-buffer, and on-column DNAse 1-digestion was performed, to remove all 
traces of genomic DNA. The column was washed with 2 additional wash steps and 
one ethanol wash, before the RNA is eluted with nuclease-free water.  
After elution, the RNA concentration was determined using the NanoDrop 2000 
(Fisher Thermo Scientific, Mytogen, DK).  
2.2.9.2  Reverse Transcription 
The RNA was reverse transcribed to cDNA using the Precision nanoScript ™ 2 
Reverse Transcription kit (PrimerDesign Ltd, UK). Using  Oligo-dT primers 





concentration of cDNA was determined using the NanoDrop 2000 (2000 (Fisher 
Thermo Scientific, Mytogen, DK).  
2.2.9.3 GeNorm reference kit 
Errors do occur throughout the PCR process, meaning that the precise amount of 
cDNA loaded into each well of the qPCR reaction is uncertain. Therefore, the need 
to normalise the data when doing quantitative PCR is important. One way to do this 
is to analyse the expression of certain housekeeper genes as reference genes, and 
uses the expression levels of these genes to normalise the expression level of your 
gene of interest against. Some important features when selecting which housekeeper 
gene to use are listed in the MIQE guidelines (Bustin et al. 2009), which also specify 
the importance of normalising to more than one reference gene. To determine which 
reference genes to use, I used the geNorm reference gene selection kit for zebrafish 
(PrimerDesign Ltd, UK), which was specifically designed upon request by our 
laboratory. The geNorm kit consists of assays for 12 reference genes from the 
zebrafish genome, and it measures the gene stability as the average pairwise variation 
between a particular reference gene and all other reference genes in a given samples. 
Using the inter-gene stability, the geNorm ranks the reference genes according to 
their expression stability in the cDNA from different tissue samples (Vandesompele 
et al. 2002).  
The geNorm analysis of expression of the 12 reference genes was measured in a 






The zebrafish geNorm reference gene selection kit targeted the following genes: 16S 
ribosomal RNA (16S), cytochrome P450 K (cyp2k), topoisomerase II (top2), beta 
actin 1 (bact1), tyrosine 3-monooxygenase (ywhaz), succinate dehydrogenase 
complex, subunit a (sdha),  glyceraldehyde-3-phosphate dehydrogenase (gapdh), 
ATP synthase (atp5d), Ribosomal protein L13A (rpl13a) and NADH dehydrogenase 
(nadh). The data from the geNorm qPCR was analysed using qBase PLUS software 
(Biogazelle, NL), which ranks the relative stability of each reference gene in the 
samples and determine the number of reference genes needed to normalise the data 
from the given samples (Vandesompele et al. 2002). 
All the primers for the zebrafish geNorm reference gene kit were designed by 
PrimerDesign Ltd. However, the company does not give out the sequences for 







AF036006 813 107 
actb1 
NM_131031 144 116 
ATPsynth 
BC083308 709 128 
CYP2K17 
DQ097890 852 112 
EIF1B 

























Table 2:4: List of genes contained in the geNorm Reference Gene kit from 
PrimerDesign.  
2.2.9.4 Quantitative PCR 
Quantitative analysis of specific genes of interest within the cDNA samples was 
determined using Precision-iC SYBR green master mix (PrimerDesign Ltd, UK) 
with the CFX96 Real-Time PCR Detection System (Bio-Rad, Denmark).  
Duplicate reactions were performed in 20 μl volumes containing 10 μl Precision-iC 
SYBR green master mix (PrimerDesign Ltd.), 300 nM primer (PrimerDesign Ltd, 
UK), 15 ng cDNA and made up to 20 μl with nuclease-free water. The following 
cycling conditions were used: initial activation at 95 °C for 10 min, followed by 40 
cycles of 95 °C for 15 sec, and 60 °C for 1 min.  
Data was collected during each cycling phase. Melt curve analysis, to ensure each 





RT- samples and no-template controls (NTCs) were run alongside all reactions to 
assess contamination. Quantification cycle (Cq) values were determined using Bio-
Rad CFX96 Manager 3.0 software.  
2.2.9.4.1 Analysis of qPCR data 
The relative gene expression of the gene of interest (GOI) was normalised against the 
expression levels of the reference genes (RG). The relative level of gene expression  
is calculated using the below listed method.   
The average reference gene expression was calculated using the following formula: 
           
                
 
 
The normalized expression of the GOI: 
               
The normalised expression of the GOI  
          
To determine the fold-change in gene expression between the different samples: 
Control sample     – Treatment sample     =      
















3.1  Introduction 
Small molecules can be screened in zebrafish embryos either manually or 
automatically. The manual approach allows for the concurrent screening for different 
effects in one screen, e.g. development of pigmentation and patterning, general 
development, morphology and movement defects. Compounds identified using this 
approach can then be divided into phenoclusters based upon their particular effect, 
allowing the compound to be studied in more detail (Colanesi et al. 2012). 
Neuroactive compounds are identifiable through a simple touch assay, where a gentle 
prod with an insect pin can evoke a swimming response in the larvae. To monitor 
and report changes in basal behaviour an automated tracking system is employed 
which allows for the tight and standardised control of external stimuli, e.g. light and 
sounds, and is unbiased in the analysis of the behaviour. Light and sound are two 
types of external factors that are known to affect zebrafish behaviour and swimming 
activity (Best et al. 2008; MacPhail et al. 2009). Five-day-old zebrafish larvae can 
recognise changes in light and register different types of sound stimuli, therefore 
light and sound are often useful when modulating the swimming activity and 
behaviour of zebrafish. This is often desirable when studying the behaviour of young 
larvae, below 5 dpf, as their basal swimming activity is generally low (Budick and 
O’Malley 2000). 
3.1.1 Automated analysis of zebrafish behaviour 
A significant progress in automated analysis of zebrafish behaviour was the  





Granato 2007) and commercial companies (Noldus, Spink, and Tegelenbosch 2001). 
This facilitated the quantifiable analysis of specific behaviours,  such as general 
locomotor activity (Irons et al. 2010), non- associative learning (Best et al. 2008), 
light adaptive behaviours (Burgess and Granato,  2007b) and seizure activity 
(Afrikanova et al. 2013). Moreover, the small size of the larvae allows for the 
screening in 96-well format, thus greatly increasing the number of compounds that 
can be screened in a day (Bruni, Lakhani, and Kokel 2014). Further developments to 
increase throughput have been the development of systems for automated embryo 
sorting and distribution and automated compound addition.  
3.1.1.1 Large scale small molecule screens in zebrafish larvae 
Kokel and colleagues (2010) screened approximately 14000 small molecules, a 
selection of different of compound libraries with known and un-known functions. 
The behavioural output was a light-induced behaviour, termed the photomotor 
response (PMR), and observed in 30 hours post fertilization (hpf) old embryos. The 
screen identified 1627 hits, which were phenotypically clustered. Analysis of these 
compounds showed that they targeted similar pathways (Kokel et al. 2010). Another 
study described the identification of molecular pathways involved in the regulation 
of rest/wake behaviour in zebrafish larvae (Rihel et al. 2010). Using automated 
analysis of behaviour, Rihel and colleagues screened 5648 compounds on 4 dpf 
larvae, and continuously monitored the activity for a total of 3 days. Behavioural 
parameters included rest latency, waking activity, number and duration of rest bouts, 





recorded, and the data was used to phenotypically cluster the compounds. Further 
analysis found that the behavioural profile and the therapeutic activity of the 
compounds often correlated. For example, a class of compounds all causing highly 
increased waking activity were all agonists of sodium channels. Using this approach, 
they identified 547 compounds specifically altering the rest/wake cycle of zebrafish 
larvae (Rihel et al., 2010). 
3.1.2 Available commercial tracking software solutions 
The first commercially available zebrafish tracking equipment was the 
ZebraBox/ZebraLAB (ViewPoint, France). The system consists of a box with an 
infrared light source and a camera, capable of recording movies with 30 frames per 
second (Figure 1.1.1). The ZebraLab software controls the box and analyse the 
swimming activity of the larvae. The infrared light source allows for behavioural 
monitoring in the dark, as the fish do not see infrared light (Emran et al. 2010). 
Initially our laboratory used the ZebraBox to analyse larval behaviour, measuring 
swimming distance, velocity, and placement. However, the available version of 
ZebraLab had very limited flexibility with respect to off line data analysis and did 
not permit analysis of externally recorded movies of zebrafish movement. Current 
versions of the ZebraBox and the software have been greatly updated, and now have 
a fully flexible software platform, capable of analysis recorded data retrospectively 
(www.viewpoint.fr). In 2010, Noldus introduced the DanioVison system (Noldus 
Information Technology, NL), which consists of the DanioVison chamber for 
recording the behaviour of larval zebrafish, and the software platform, EthoVision 





separately acquired movies can be loaded into the software enabling automated 
analysis of adult zebrafish behaviour.  
 
Figure 3.1.1: The two commercially available tracking systems.  
A: The DanioVison from Noldus Information Technology, NL.B: Screenshot from the 
acquisition module in EthoVision XT9, the software used by DanioVison (Noldus, NL) C: 
The ZebraBox from ViewPoint, Fr. Both systems consists of a tracking box with LED lights, 
an infrared light source, and an infrared camera, capable of recording movies at 30 frames 






3.1.3 Epilepsy models  
Epilepsy is a heterogeneous group of disorders, characterised by a predisposition for 
spontaneously occurring seizures (Jacobs et al. 2009). The seizures are the result of 
an imbalance in the excitation and inhibition of neural signalling, ultimately leading 
to a synchronous discharge of neurons in the brain (Cunliffe et al. 2015). It is a 
common neurological disorder, affecting around 65 million people worldwide 
(Thurman et al. 2011).  A wide range of anti-epileptic drugs (AED) are available in 
the clinic, however 30% of patients suffering from epilepsy do not respond to 
treatment with the available AEDs (Perucca and Tomson 2011). The reason for this 
is most likely due to the heterogeneity of the syndromes, commonly caused by 
multiple genetic mutations (Reviewed in Jacobs et al., 2009).  
3.1.3.1 Genetic models of epilepsy 
Genetic models in rodents have aided in the understanding of epileptogenesis and 
epilepsy on the molecular and genetic level (Singh et al. 2008; Yu et al. 2006). 
Genetic models often recapitulate some of the aspects of the human disease, such as 
spontaneous, infrequent seizures (Martin et al. 2010). Martin and colleagues 
generated a knock-in transgenic mouse that harboured a specific mutation in SCN1A, 
a voltage-gated sodium channel. Mutations in this channel are known to be 
associated with several forms of epilepsy (Reviewed in Escayg and Goldin, 2010). 
Heterozygous mutants have a normal lifespan but a reduced threshold to seizures. 
However, homozygous mice show very frequent generalized seizures, and have 





ENU-mutagenesis screen, a zebrafish harbouring a mutated version of the 
homologous gene in zebrafish, scn1Lab, has also been identified. This mutant shows 
some of the same features observed in the mouse model of SCN1a; for example the 
homozygous fish die around 10-12 dpf and have spontaneous seizure activity (Scott 
C. Baraban, Dinday, and Hortopan 2013). Baraban and colleagues screened a library 
consisting of 320 FDA US approved and toxicology tested compounds, on 5dpf old 
scn1Lab homozygous mutant larvae, screening for compounds capable of 
suppressing convulsions. Using this approach they identified the antihistamine 
clemizole,, which was capable of suppressing seizure activity in the mutants (Scott 
C. Baraban, Dinday, and Hortopan 2013). This study demonstrates the possibilities 
of using zebrafish genetic models of epilepsy.  
3.1.3.2 Pentylenetetrazole-induced model of epilepsy 
For over 60 years drug discovery within epilepsy research have been based on 
chemically induced seizure models in rodents, (Reviewed in Löscher, 2011), and in 
particular, the pro-convulsive drugs, pentylenetetrazole (PTZ) and pircrotoxin, are 
still used extensively in epilepsy and seizure research.  
PTZ is a  gamma-amino butyric (GABA) receptor antagonist used to induce seizures 
through its binding to the GABAA receptors (S. L. Hansen, Sperling, and Sánchez 
2004; Löscher 2011).  PTZ causes tonic-clonic like seizures in rodents, causing the 






3.1.3.2.1 GABA signalling 
GABA is the major inhibitory neurotransmitter in the central nervous system 
responsible for the hyperpolarization of neurons at the end of an action potential 
(Treiman 2001). The GABA(A) receptor is a pentameric ligand-gated ion channel, 
which is widely expressed in the brain and CNS (Olsen and Sieghart 2009). There 
are multiple subtypes of the receptor due to the molecular diversity of the different 
subunits comprising the receptor (Olsen and Sieghart 2009). Each subunit possesses 
specific binding sites, which, depending on subunit-composition, regulate the 
receptor activity. The function of the channel is to regulate the Cl
-
 influx into the cell, 
leading to a hyperpolarization of the membrane, which blocks the immediate firing 
of another action potential. 
Several AEDs have been shown to bind to the GABA receptor and act as a positive 
allosteric modulator (PAM) like diazepam, which enhances the GABA activity, thus 
causing relaxation, sedation and anxiolytic effects (S. L. Hansen, Sperling, and 
Sánchez 2004). The GABA receptor plays an important role in seizure activity, 
which makes this neurotransmitter and its receptor a favourable target for anti-
seizure drug development.  
3.1.3.3 PTZ-models in zebrafish larvae 
Baraban and colleagues reported in 2005 on the effect of PTZ in larval zebrafish. 
This group showed that 7 dpf old larvae respond to PTZ treatment in a dose 
dependent manner, manifested as 3 defined stages of convulsive behaviour, and 





known AED’s, like diazepam and valproate, could reduce the abnormal electrical 
discharge induced by PTZ (S. C. Baraban et al. 2005). This has since led to several 
reports on the use of zebrafish in AED research  (Afrikanova et al. 2013; Baxendale 
et al. 2012; Berghmans et al. 2007; Gupta, Khobragade, and Shingatgeri 2014), all of 
which describe the use of PTZ at concentrations of 15-20 mM, which induces 
convulsions in the zebrafish larvae. Compounds with known AED effect were 
screened, for either a protective effect against the PTZ induced convulsions 
(Afrikanova et al. 2013; Baxendale et al. 2012; Berghmans et al. 2007),  a reversal or 
an improvement of PTZ induced seizures (S. C. Baraban et al. 2005). The locomotor 
assay described in these studies were performed under constant darkness, to avoid 
photo bleaching of compounds (Afrikanova et al. 2013; Berghmans et al. 2007). 
Tracking larvae during constant darkness can, in some situations, lead to the 
identification of false positives, which is partly due to the sedative effects caused by 
a majority of compounds used to treat seizures (Nadkarni and Devinsky 2005), and 
the properties of the natural swimming response in zebrafish larvae (MacPhail et al. 
2009). In constant darkness, zebrafish larvae will initially have a high level of 
baseline swimming activity, which after 10-20 min will drop and become a low, 
steady-state level of activity (MacPhail et al. 2009). Under changing light conditions, 
however, zebrafish larvae show a distinct movement pattern, induced by regular 
intervals of light and dark periods, a response known as the Visual Motor Response 
(VMR) (MacPhail et al. 2009; Steenbergen, Richardson, and Champagne 2011a). 
Therefore, this assay might be more suited for screening for compounds, allowing 





3.1.4 Aim of chapter 
Zebrafish embryos can be part of a very useful screening platform for testing and 
screening small molecules with neuroactive effects. The NeuroSearch (Copenhagen, 
Denmark) library consisted of a collection of ~200,000 compounds developed 
mainly for treating central nervous system disorders, e.g. epilepsy, Huntington’s 
disease, depression, anxiety, and neuroinflammation. As part of my collaborative 
PhD with NeuroSearch, we set up an automated screening method for identifying 
compounds with neuroactive effects. The aim of this chapter was to implement a 
zebrafish model of chemically induced seizures in zebrafish larvae that would be 
able to discriminate between compounds with a sedative effect and true seizure-






3.2   Results 
3.2.1 Sub-convulsive levels of PTZ induce a distinct change in the 
PTZ response 
Using the VMR, the effect of increasing concentrations of PTZ was tested on the 
swimming activity on five dpf larvae (Figure 3.2.1). PTZ perturbed the orderly 
activity pattern of the VMR in a concentration dependent manner. From previous 
reports using PTZ in zebrafish, it is known that a high level of PTZ (15 – 20 mM) 
will induce seizure activity causing an increase in the swimming activity (Afrikanova 
et al. 2013; S. C. Baraban et al. 2005; Berghmans et al. 2007). Under control 
conditions, alternating light-dark cycles induced changes in the swimming activity of 
the larvae. In the light phases, the fish displayed quiescent levels of activity, whereas 
in the dark phases their activity regularly increased above 200 mm/2min (Figure 
1.2.1A). Exposure to 1mM PTZ resulted in a small increase in swimming activity in 
both light and dark periods. The larvae exposed to the low concentration of PTZ 
(1mM) also showed a delay in decreasing locomotor activity during the dark periods. 
An intermediate concentration of PTZ (5mM) resulted in a striking change in the 
responsiveness to the alternating lighting conditions, a reversed dark-light locomotor 
pattern. Larvae responded to darkness with no or very low levels of activity, but with 
the onset of visible light the swimming activity increased instantly. Larvae treated 
with the highest tested dose of PTZ, 15 mM, did not respond to changes in the light-
dark cycles and showed an overall increase in activity, which decreased gradually 






Figure 3.2.1 A: Pentylenetetrazole (PTZ) induces a behavioural phenotype in 
larval zebrafish.  
Plots of 5 dpf old zebrafish treated with increasing concentrations of PTZ. Tracking 
performed under alternating light conditions, 10 min dark (black bar) and 10 min light (white 
bar), for a total of 70 min. Data are presented as mean +/- SEM of 12 larvae. Embryo media 
(E3) are used as vehicle control, and the swimming activity of the PTZ treated larvae are 
compared to that of E3-treated larvae. B: The distinct concentration-dependent locomotor 
profile of PTZ in five dpf larvae visualised as the tracking plots from the DanioVison-
system. The red tracks are the movement of the individual larvae plotted over a two-minute 






3.2.2 Poor effect of compounds on the PTZ-induced phenotype  
The intermediate concentration of PTZ leads to a highly specific and reproducible 
behavioural phenotype. To investigate if this phenotype it seizure related, I  next 
investigated whether compounds previously been reported to be effective in the PTZ-
assay using the higher concentration of PTZ or compounds with known GABA-
receptor function, could reverse the inverted VMR behaviour caused by low 
concentrations of PTZ (5mM). Fourteen compounds were tested in a dose-curve 
response in combination with 5mM PTZ. The compounds were not tested alone, as 
the criteria for efficacy in this assay is only a reversal of the phenotype. Of the 14 
compounds tested, five compounds showed a complete or partial reversal of the PTZ-
induced phenotype (Table 3:1). Of these five compounds, three were classic AEDs, 
namely diazepam, ethosuximide and valproate, and two were neurosteroids, 
alfaxalone and allopregnanolone. 
3.2.2.1 Effect of valproate and ethosuximide 
Treatment with ethosuximide, a Ca
2+ 
channel blocker, could not reverse the VMR-
response at the majority of doses tested in the assay except at the two highest doses 
tested (10mM and 30mM). At these concentrations the larvae showed a higher 
swimming activity when tracked in the dark, compared to the lower doses (100µM – 
3mM), however the sedating effect of ethosuximide affected the general locomotor 
activity of the larvae, making the effect minor (Figure 3.2.2). A similar dose-







channel blocker, and at the highest concentrations, the compound caused a decreased 







Figure 3.2.2: Ethosuximide cause partial rescue of PTZ phenotype. 
Ethosuximide partially reversed the light/dark switching in phenotype, induced by 5mM of 
PTZ treatment. Tracking curve of 5dpf old zebrafish larvae treated with increasing levels of 
diazepam. 10mM of ethosuximide show partial reversal of the light/dark response, whereas 
30mM ethosuximide dose cause a complete sedation of the larvae. Data plotted as mean+/-







Figure 3.2.3: Tracking plots of valproate dose curve with 5mM PTZ.  
Tracking curve of 5dpf old zebrafish larvae treated with increasing levels valproate. At 1mM 
of valproate, there is a partial reversal of the light/dark behaviour, caused by 5mM PTZ 
treatment. Data plotted as mean+/-SEM of 12 larvae treatment group. The depicted results 





3.2.3 Diazepam-rescue of PTZ-induced phenotype 
At concentrations up to 100 nM, diazepam, a GABAA receptor agonist, showed no 
effect on the larvae phenotype (Figure 3.2.4). However, treatment with 300 nM 
diazepam caused a decreased responsiveness in the light periods, as well as the 
subsequent dark periods. Subjected to a concentration of 1µM diazepam, larvae 
displayed a reversal in the PTZ-induced VMR response, similar to that seen with 
valproate and ethosuximide. At this concentration, there was also a slight sedating 
effect on the larvae, visible as a reduction in larval swimming activity (Figure 3.2.4). 
When tested at concentrations of 3 and 10 μM, the larvae showed a marked reduction 
in swimming activity with no significant response to the alternating light and dark 







Figure 3.2.4: The classic benzodiazepine, Diazepam, can partially reverse the light/dark 
switching in phenotype, induced by 5mM of PTZ treatment.  
Tracking curve of 5dpf old zebrafish larvae treated with increasing levels of diazepam. 1µM 
of diazepam show partial reversal of the light/dark response, indicating that the partial rescue 
observed could be masked by the sedative effect of the compound at the higher doses. Data 





3.2.4 Neuroactive compounds protect against the 5mM PTZ 
induced locomotor phenotype 
Alfaxalone, a synthetic neurosteroid, tested at a concentration range from 100 nM to 
30 μM, showed a dose-dependent effect on locomotion and VMR. Alfaxalone at 
1µM completely reversed the 5mM PTZ-induced VMR phenotype (Figure 3.2.5) 
which, resulted in a VMR response resembling that of DMSO treated larvae. The 
VMR response was also reversed at a concentration of 3 μM alfaxalone, however at 
this concentration, the activity levels during the dark period were reduced indicating 
that the compound was mildly sedating at this concentration (Figure 3.2.5). The 
sedative effect of alfaxalone was prominent at concentrations of 10 μM and 30 μM, 
where larval locomotor activity was completely absent even though the larvae were 
still alive and displayed an active beating heart. The other neurosteroid tested, 
allopregnanolone, also reversed the PTZ-induced phenotype. However, the 
concentration required was higher than that needed when treating with        






Figure 3.2.5: Alfaxalone efficiently reverse the PTZ-induced phenotype.  
Graphs from a 96-well experiment, showing the effect of the synthetic neurosteroid, 
alfaxalone, on the swimming activity of dpf old zebrafish larvae treated with 5 mM PTZ.T 
The 3 highest concentrations of the compound is highly sedative, but larvae had a visual 
heartbeat,  at the end of the experiment. Tracking performed during 10 min intervals of dark 
(black bar) and light (white bar) for a total of 70 min. There are 12 larvae in each treatment 






Figure 3.2.6: The neurosteroid, allopregnanolone reverses the PTZ-induced phenotype 
Graphs from a 96-well experiment, showing the effect of the neurosteroid allopregnanolone, 
on the swimming activity of 5 dpf old zebrafish larvae treated with 5 mM PTZ.T The 3 
highest concentrations of the compound is highly sedative, but larvae had a visual heartbeat,  
at the end of the experiment. Tracking is performed during 10 min intervals of dark (black 
bar) and light (white bar) for a total of 70 min. Each graph represents the average distance 





3.2.4.1 The sedative effect of diazepam can be suppressed by co-
treatment with neurosteroids 
Both diazepam and the neurosteroids bind to the GABAA-receptor, but at different 
subunits. From mice it has been suggested that a combination of a neurosteroid and a 
benzodiazepine have a beneficial effect on seizures (Gasior et al. 1997). From the 
current screen, both of these compounds are effective in the PTZ-model; therefore 
we tested if a combination of diazepam and alfaxalone would potentiate the effects of 
the two compounds on reversing the PTZ-induced VMR responses. A sub-threshold 
concentration of 0.3 μM alfaxalone, which did not have any effect on the PTZ-
induced phenotype in larvae (Figure 3.2.5), and had no visible sedative effects, was 
applied together with increasing concentrations of diazepam, as tested earlier. The 
combination with alfaxalone significantly potentiated the effect of diazepam on the 
PTZ-induced phenotype (Figure 3.2.7). The minimal effective concentration (MEC) 
of diazepam capable of reversing the effect of PTZ was lower, in combination with 
alfaxalone, when compared to the effective dose in the diazepam-only experiments. 
Hence, 0.1µM of diazepam resulted in a reversal of the PTZ induced light/dark 
response in combination with a low level of neurosteroid, compared to 10µM 






Figure 3.2.7: Combinational treatment with alfaxalone abolishes sedative effect of 
diazepam. 
Graphs from a 96-well experiment, showing the swimming activity of 5 dpf old zebrafish 
larvae treated with a combination of the synthetic neurosteroid, alfaxalone, and increasing 
concentrations of diazepam. Tracking plotted in 10 min intervals of dark (black bar) and 
light (white bar) for a total of 70 min. Each graph represents the average distance moved by 







  Fraction of control    Fraction of control 
Therapeutic Concentration Light Dark  Therapeutic Concentration Light Dark 
         
PTZ 5 mM 2.16 0.76      
         
Acetazolamide 1 µM 2.34 0.62  Lorazepam 300 nM 1.86 0.67 
 3 µM 2.35 0.54   1 µM 1.74 0.67 
 10 µM 2.15 0.63   3 µM 1.65 0.61 
 30 µM 2.23 0.58   10 µM 1.47 0.57 
 100 µM 1.97 0.58   30 µM 1.15 0.42 
 300 µM 1.81 0.68   100 µM 1.00 0.44 
         
Alfaxalone 100 nM 1.84 0.43  Oxcarbazepine 1 µM 1.98 0.72 
 300 nM 1.12 0.32   3 µM 2.30 0.78 
 1 µM 1.20 1.02   10 µM 1.93 0.72 
 3 µM 0.65 0.72   30 µM 2.12 0.81 
 10 µM 0.04 0.01   100 µM 2.01 0.85 
 30 µM 0.02 0.01   300 µM 2.33 1.08 
         
Allopregnanolone 10 nM 2.45 0.77  Pentobarbital 1 µM 1.77 0.97 
 30 nM 2.30 0.77   3 µM 1.74 0.89 
 100 nM 1.71 0.64   10 µM 1.54 0.77 
 300 nM 1.07 0.85   30 µM 1.28 0.52 
 1 µM 0.64 0.54   100 µM 0.82 0.40 
 3 µM 0.15 0.11   300 µM 0.01 0.05 
         
Carbamazepine 1 µM 1.77 0.74  Phenytoin 10 µM 1.93 0.82 
 3 µM 1.79 0.77   30 µM 2.01 0.81 
 10 µM 1.82 0.80   100 µM 2.03 0.78 
 30 µM 1.77 0.79   300 µM 1.91 0.75 
 100 µM 1.66 0.84   1 mM 1.73 0.72 
 300 µM 0.16 0.08   3 mM 1.51 0.63 
         
Diazepam 30 nM 1.87 0.52  Retigabine 100 nM 1.90 0.63 
 100 nM 1.65 0.50   300 nM 1.91 0.63 
 300 nM 1.39 0.48   1 µM 1.23 0.26 
 1 µM 1.05 0.49   3 µM 0.41 0.14 
 3 µM 1.08 0.38   10 µM 0.14 0.06 
 10 µM 1.01 0.39   30 µM 0.02 0.01 
         
Ethosuximide 100 µM 2.05 0.90  Valproate 10 µM 2.50 0.48 
 300 µM 1.78 0.77   30 µM 2.35 0.53 
 1 mM 1.65 0.80   100 µM 2.21 0.57 
 3 mM 1.37 0.66   300 µM 1.80 0.55 
 10 mM 0.74 0.76   1 mM 1.00 0.50 
 30 mM 0.47 0.26   3 mM 0.52 0.28 
         
Levetieacetam 100 µM 2.26 0.87  Zonisamide 1 µM 2.40 0.83 
 300 µM 2.21 0.84   3 µM 2.28 0.80 
 1 mM 2.23 0.87   10 µM 2.19 0.74 
 3 mM 2.09 0.78   30 µM 2.33 0.74 
 10 mM 2.06 0.84   100 µM 1.90 0.66 
 30 mM 1.90 0.85   300 µM 1.95 0.73 







Table 3:1: Effect of compounds on the behaviour of 5dpf WT larvae treated with 5mM 
PTZ.  
Data represented as fractions of movement in fish treated with PTZ and compounds, 
compared to the fraction of movement by fish treated with DMSO only. The average 
distance moved is calculated as a total of all the light and all the dark intervals for each 
individual experiment, and then the average for all three experiments are calculated. For 
larvae swimming more that the DMSO control in the light period, the number is represented 
with green, those moving less than the DMSO in the light or dark period are represented with 
a red number. Black numbers indicate that that value equals that of the DSMO control 
larvae, indicating a complete reversal of the PTZ induced light/dark response.  
  
3.2.5 PTZ increase the expression of c-fos 
It has been demonstrated previously that seizure-like behaviour is accompanied by an 
increase in expression levels of cfos in neurons (S. C. Baraban et al. 2005; 
Singewald, Salchner, and Sharp 2003). The cfos gene can thus act as a useful marker 
for elevated levels of neuronal activity following seizure, which has previously been 
demonstrated in larval zebrafish subjected to 15mM of PTZ (S. C. Baraban et al. 
2005; Baxendale et al. 2012). To test whether the reversal of the PTZ-induced VMR 
response influenced cfos-expression, RNA was extracted from larvae at the end of a 
PTZ experiment and quantitative PCR was used to analyse expression levels of cfos. 
The gene expression levels of cfos were increased in larvae treated with both 5 mM 
PTZ and 15mM PTZ (Figure 3.2.8). This corresponds to what has previously been 
reported (S. C. Baraban et al. 2005; Ellis, Seibert, and Soanes 2012). To test if 
alfaxalone had any effect on cfos expression, RNA was extracted from larvae at the 
end of a VMR-assay. Larvae treated with a combination of alfaxalone and PTZ 





Moreover, larvae treated with alfaxalone alone, also showed a slight increase in c-fos 
expression, compared to that of DMSO treated fish (Figure 3.2.8).   
 
Figure 3.2.8: Preliminary quantitative PCR analysis of cfos expression in 
zebrafish larvae.  
A: Expression of cfos increases in zebrafish larvae treated with increasing levels of PTZ. 
RNA was extracted from 12 larvae in each group. B: larvae treated with alfaxalone and PTZ 







Work by Afrikanova and others has demonstrated that the use of a zebrafish assay in 
screening compounds with anti-convulsant effects has been a valid model to use. 
These studies all reported the use of 15 – 20 mM PTZ and a locomotor assay 
performed under constant darkness (Afrikanova et al. 2013; S. C. Baraban et al. 
2005). We have found that there are some disadvantages of this method, as the use of 
15mM PTZ leads to a robust seizure activity, ultimately resulting in the loss of 
posture and hereby a decreased swimming activity. Another issue is the use of a 
tracking protocol performed under constant darkness as the majority of AEDs used 
today possess sedative effects, and the natural swimming behaviour of zebrafish 
larvae under tracked during constant darkness, is an initial period of high activity, 
followed by a steady decrease in activity (MacPhail et al. 2009; Padilla et al. 2011). 
Thus analysing potentially sedative compounds under constant darkness can lead to 
the identification of false positive compounds. In this chapter I have demonstrated 
the use of a different assay to study AEDs, by using a lower PTZ concentration, 
combined with an alternative locomotor assay, thereby allowing us to distinguish 
between AEDs with a general sedating effect and compounds with a specific PTZ-
relating activity. Using this technique, we have determined that the majority of 
compounds tested were not effective in reversing the PTZ-induced phenotype, but 






3.3.1 Low concentration of PTZ leads to distinct behavioural 
phenotype in zebrafish larvae 
 
The concentrations of PTZ used in this study to induce a behavioural change in the 
larvae are lower than concentrations used in other epileptic studies previously 
performed in zebrafish (Afrikanova et al. 2013; S. C. Baraban et al. 2005; Hortopan, 
Dinday, and Baraban 2010). The high levels of PTZ, 15mM - 20mM, employed in 
zebrafish studies by others, induce a strong convulsive phenotype. Zebrafish treated 
with 15mM of PTZ go through a series of behavioural stages, termed I, II and III, as 
part of the seizure activity (Baraban et al., 2005). The culmination of the increased 
swimming activity in larvae treated with 15mM PTZ is a whole-body clonus-like 
convulsions, closely resembling that of PTZ-induced seizures reported in rodents 
(Erhardt et al. 1995). The fish lose posture, and spend a lot of time on the side, only 
moving slightly in bursts (S. C. Baraban et al. 2005), resulting in an overall decrease 
in swimming activity. The increase in swimming activity caused by the high 
concentration of PTZ (15-20 mM) in the dark is the main quantified output from 
these assays (S. C. Baraban et al. 2005; Berghmans et al. 2007; Vermoesen et al. 
2011). The zebrafish assay described in this chapter uses a lower concentration of 
PTZ and quantifies the change in larval behaviour by observing the reversed 
response to changes in the light-dark cycles. Using short-duration cycles of light and 
dark conditions, it was shown that zebrafish larval activity increased during dark 
phases and dropped during light phases, as it has been reported previously (MacPhail 





study. As reported previously, the highest concentration (15mM) showed a high 
increase in swimming activity in the beginning of the assay, which declined over 
time, most likely due the onset of clonus-like seizures, causing the fish to lose 
posture and inhibiting their swimming (S. C. Baraban et al. 2005). Interestingly, the 
5mM concentration of PTZ induced a complete reversal of the ordinary dark/light 
behaviour observed in 5 dpf old larvae. This could suggest that 5mM PTZ causes a 
sub-threshold inhibition of GABA-signalling, which when challenged with a stressor, 
e.g. a sudden burst of light, triggers swimming activity (Figure 3.2.1). In a non-
human primate model of photosensitivity and seizure, it has been shown that baboons 
with naturally occurring photosensitive seizures, have very low GABA levels (Lloyd 
et al. 1986). These baboons have recurrent seizures, which can be triggered by 
sudden light flashes.  
 
3.3.2 Poor effect of compounds with previously reported anti-epileptic 
function on the light/dark phenotype 
 
The ability of fourteen compounds to normalise the PTZ-induced phenotype in 
response to alternating periods of light and dark conditions was assessed. Only three 
of the compounds tested in this assay proved to be able to normalise the altered 
light/dark response, caused by low levels of PTZ treatment. However, the 
normalisation was partly masked by a sedating effect of the compounds. Rodent 





the most effective AEDs to inhibit PTZ-evoked seizures (Löscher 2011), and this has 
been shown previously in zebrafish larval PTZ models (Afrikanova et al. 2013; S. C. 
Baraban et al. 2005; Berghmans et al. 2007). PTZ-models in zebrafish larvae have 
shown that larvae treated with valproate, diazepam and ethosuximide protect against 
PTZ-induced seizures, both in the locomotor assay and in reducing the aberrant 
electrical discharges, normally associated with PTZ induced seizures (Afrikanova et 
al. 2013). Diazepam is a known benzodiazepine compound used in the clinic as an 
anti-convulsant, anxiolytic, sedative, and muscle relaxant. It exerts these effects 
through the modulation of the GABAA-receptor, and has a strong affinity for the α1 
and the α3 subunits, enhancing the association of GABA to the receptor, thereby 
enhancing the inhibitory neurotransmission caused by GABA activity (Olsen and 
Sieghart 2009).   The sedative effect of diazepam became evident in the VMR at 
0.3µM, which was visible as a reduced swimming activity in the light period (Figure 
3.2.4). These findings are consistent with previous reports, albeit the sedative effect 
of diazepam reported by others occurred at higher concentrations (Afrikanova et al. 
2013; Berghmans et al. 2007; Hortopan, Dinday, and Baraban 2010). An explanation 
for this could the different tracking conditions used when analysing the locomotor 
activity. When untreated larvae are tracked under constant darkness, they show an 
initial period of high activity, which quickly declines and become a low steady state 
swimming (MacPhail et al. 2009). In larvae treated with 15mM PTZ, a rapid increase 
in general locomotor activity is present, followed by a slow decline, due to the 
clonus-like convulsions induced over time (Afrikanova et al. 2013; S. C. Baraban et 





swimming behaviour of larvae under constant light conditions (MacPhail et al. 
2009). A possible interpretation of this lack of movement could be that the 
compound has a specific anti-convulsive effect, but the observed response is the 
result of a sedative effect by a particular compound. By challenging the larvae with 
constant changes in light conditions, a sedative effect will become more obvious. 
Ethosuximide also show a limited effect in the VMR-reversal, but from 
electrographic activity data, it has been shown that ethosuximide has low or no effect 
on reducing PTZ induced electrical discharges (Afrikanova et al. 2013; S. C. Baraban 
et al. 2005). A suggested effect of Ethosuximide is through the  increase in GABA-
synthesis and release (Greenhill et al. 2012), which could be attributed to the partial 
rescue of the PTZ-induced phenotype in this assay. However this increase in GABA 
signalling could ultimately cause sedation as well.  
Valproate is a broad-spectrum anti-epileptic drug, thought to function through a 
GABA related mechanism. Valproate inhibits the breakdown of GABA thereby 
increasing the availability of the inhibitory neurotransmitter, which is likely to be the 
mechanism of action resulting in the effect in the current PTZ assay (Owens and 
Nemeroff 2003). Only three of the tested compounds, namely diazepam, 
allopregnanolone and alfaxalone, demonstrated an ability to neutralize the PTZ-
induced change in behaviour. This does not correlate with earlier work using a higher 
PTZ concentration, where the majority of standard AEDs were able to suppress PTZ-
induced excessive movements in larval zebrafish (Berghmans et al. 2007). The assay 
used to screen the AEDs in this study found the majority of the AEDs to be sedative 





effect is consistent with what Afrikanova and colleagues reported (2013), and is a 
known side effect of many of the classic AEDs (Afrikanova et al. 2013; Cavanna et 
al. 2010). A reason for the discrepancy between the data presented in this study and 
that of Berghmans and colleagues is the incubation time of AEDs. Berghmans and 
colleagues applied the AEDs for 24 hours, whereas this study only incubated the 
larvae for 1 hour with the AEDs. (Berghmans et al. 2007). The bioavailability of the 
compounds must be assumed different after 24 hours of incubation, compared to an 
incubation time of one hour, and the sedative effect could be more pronounced after 
longer exposure times, which could explain the discrepancy between the Berghmans 
study and others, the present one included (Afrikanova et al. 2013; Berghmans et al. 
2007). 
 
3.3.3 Neuroactive steroids are effective against PTZ-induced behavioural 
changes  
Amongst the therapeutics able to neutralize the PTZ-induced phenotype in this study, 
the most pronounced effects were seen by treatment with two neuroactive steroids, 
alfaxalone and allopregnanolone. Neurosteroids are metabolites of steroid hormones 
known to regulate neural activity. Allopregnanolone is a neurosteroid synthesized 
from cholesterol in the brain, and it has an important functional association to 
anxiety disorders and depression. A reduction of allopregnanolone levels has been 
shown to correlate negatively with depression, anxiety and post-partum depression 
(Brot et al. 1997; Schüle, Nothdurfter, and Rupprecht 2014). Allopregnanolone and 





GABAA-receptor.  They bind to a specific motif between α and β-subunits of the α1, 
α3 and α4-subunit containing receptor (Chase Matthew and Doodipala Samba 2013). 
The binding increases the opening time of the receptor, allowing more Cl
-
 to pass 
through the channel, thereby creating a hyperpolarized membrane potential, 
decreasing the likelihood of another action potential to be fired (Akk et al. 2007; 
Twyman and Macdonald 1992). The GABAA receptors have several modulatory 
allosteric binding sites for benzodiazepines, general anaesthetics, barbiturates and 
neurosteroids (Korpi, Gründer, and Lüddens 2002). The mechanism underlying the 
effect of alfaxalone and allopregnanolone reported here is thus likely based on the 
ability of these compounds to modulate GABAA receptor-mediated transmission, 
working together to fine-tune GABA response, thereby reversing the  exaggerated 
response to light.  
 
3.3.4 Co-treatment with a neurosteroid abolishes the sedative effect of 
diazepam 
From mice, it has been shown that a combination of neurosteroids and 
benzodiazepines had a combined beneficial effect on epileptic symptoms (Gasior et 
al. 1997). In addition, there are also several rodent studies that have demonstrated a 
rationale for neuroactive steroids in the pharmacological management of seizure-
related disorders (Gasior et al. 1997; Kaminski, Livingood, and Rogawski 2004) and 
evidence suggests that circulating neurosteroids regulate seizure frequency and 
severity (Reddy and Jian 2010) .  Whilst monotherapy is normally the preferred goal 





consideration. Poly-drug therapy can be applied when the drug combination 
improves control of disease symptoms without increasing toxic manifestations of the 
pharmaceutical treatments. Ideally, such adjunct therapy permits side-effect profiles 
to be reduced through the lowering of individual drug dosages. From the experiments 
with the combined treatments, it appears that there is a good synergistic effect of 
diazepam and the neurosteroids, is such a way that lower concentration of both 
compounds can be used, and thereby avoid the sedative effect of both compounds, 
which is in an undesired effect in seizure treatment. In a previous study by Gasior et 
al. (1997), it was shown that inactive doses of neuroactive steroids markedly 
enhanced the anticonvulsant effects of diazepam against PTZ in mice without 
significantly increasing motor toxicity (Gasior et al. 1997). This is consistent with 
the data presented in this study, where both alfaxalone and allopregnanolone 
markedly enhanced the ability of diazepam to rescue the PTZ-induced phenotype. 
Interestingly, potentiation of the protective action of diazepam was not accompanied 
by an augmentation of the behavioural toxicity of diazepam. As a result, the 
therapeutic index of the drug combinations was markedly improved over that of 
diazepam itself. 
3.3.5 Other behavioural effects of PTZ  
In rodents and non-human primates several reports suggest that low level of PTZ can 
cause anxiety-like behaviours. This low level of GABAA antagonism have been 
reported to cause anxiety-like behaviours in the elevated plus maze and the open 





effect of the AEDs in this PTZ-assay could be due to the fact that the primary 
behavioural response seen in larvae treated with low-levels of PTZ and subjected to 
changes in the light and dark conditions are not a seizure related. From rodent and 
primate studies it has been shown that low levels of PTZ has been reported to cause 
anxiety in these models (Jung, Lal, and Gatch 2002). This could be a possible 
explanation for the lack of effect of the anti-convulsant compounds, and the highly 
specific effect of Diazepam and the two neurosteroids, which have all known 
anxiolytic properties.  
3.4  Conclusion 
Using the zebrafish larvae as a complementary model to screen small molecules has 
become increasingly popular. A number of publications describe the use of larvae as 
a model of epilepsy and screening potential AEDs. These publications have 
described the behaviour of zebrafish larvae treated with high levels of PTZ, and 
utilized the total distance moved during constant illumination as a measure of effect 
of different compounds. I found by modulating zebrafish behaviour with 5mM PTZ 
and challenging the larvae with changes in light conditions, a different behavioural 
response is detected. This alternative assay could potentially serve as an alternative 
in-vivo screening method to screen potential AEDs, thereby help to identify 
compounds with or without sedative effects. About 30 % of patients with epilepsy 
there is no treatment because they do not respond to the current possible treatments. 
There is a need for new assays to find new treatments for this group of patients. 





affected differently and hereby open the window for a different way of treating 





4 Modulating behaviour through cAMP 






Developing new treatment strategies for mental disorders is needed. No new 
treatments for anxiety disorders have been developed since the approval of selective 
serotonin reuptake inhibitors (SSRI). These were approved in 1987, and the efficacy 
of these compounds has not improved considerably since then (Cryan and Sweeney 
2011). Another class of compounds with anxiolytic effect are the benzodiazepines. 
Developed in the 1950’s this class of compounds targets the GABAA-receptor, 
leading to an increased inhibitory neuro-transmission, resulting in sedation, 
tolerance, drowsiness and dependence. Despite these side effects, the benzodiazepine 
compounds are still used to treat acute anxiety and panic attacks, due to the fast 
acting effect of these compounds (Argyropoulos and Nutt 1999).  
The need for discovering compounds targeting different pathways involved in 
regulating anxiety is evident. For this, the use of the zebrafish is promising. Several 
reports have demonstrated the translational value of the zebrafish model in anxiety 
research, both utilising the larvae (Richendrfer et al. 2012; Schnörr et al. 2012; 
Steenbergen, Richardson, and Champagne 2011b; Ellis, Seibert, and Soanes 2012) 
and adult animals (Levin, Bencan, and Cerutti 2007; Egan et al. 2009; Maximino et 
al. 2010).  
A pathway known to be involved in neuronal signalling pathways is the cAMP 
pathway (see 1.1.4.2). The regulation of cAMP signalling is controlled by the 





Indications for the importance of this pathway’s involvement in mental illness have 
come from both genetic and pharmacological studies.  
Millar et al showed that the PDE4B gene was completely disrupted by a chromosome 
translocation in two patients with psychosis (Millar et al. 2005, 1). PDE4B and 
PDE4D have also been shown to be interacting partners of the DISC1-gene 
(Disrupted in Schizophrenia 1), a schizophrenia susceptibility gene, underpinning the 
importance of PDE4-function in psychiatric illness (Bradshaw and Porteous 2012). 
Further evidence has been provided by studies done in knockout models in mice, 
where mice lacking   PDE4B- function show an anxiety-like behaviour (Zhang et al. 
2008), and PDE4D-knock out models  show antidepressant and anxiolytic-like 
behaviours (Zhang et al. 2002b; Schaefer et al. 2012). These data demonstrate both 
the importance and complexity of PDE4-signalling in regulation of cAMP, and its 
importance in regulating emotional behaviour. Treatment with phosphodiesterase 
inhibitors cause several effects indicating the importance of cAMP regulation in the 
brain. Rolipram is a phosphodiesterase 4 inhibitor, and is important for the 
hydrolysis of cAMP in the CNS and in the cells of the immune system.  Much 
evidence point to the fact, that Rolipram has a beneficial effect on neuronal survival 
(Kranz et al. 2014) and regeneration of axons following spinal cord injury (Nikulina 
2004). In rodents, Rolipram has been shown to improve cognitive performance when 
mice are tested in the Morris water maze, and moreover, treatment with 
phosphodiesterase inhibitors leads to increased cognitive effects (Akar et al. 2014). 





improve the survival of striatal neurons and increase neurogenesis in brain areas 
affected by Huntington’s Disease (Demarch et al. 2008)  
These findings suggest an important role for cAMP signalling and PDE4 activity in 
the CNS. The majority of these findings have been attributed to the activation of the 
transcription factor, cAMP Response Element Binding protein (CREB) (Demarch et 
al. 2007; Demarch et al. 2008; Wang et al. 2012; Nakagawa et al. 2002).  
How the mechanism of PDE4/cAMP signalling leads to anxiety-like behaviour is not 
clear. To elucidate how cAMP and PDE4 are involved in regulating behaviour, the 
zebrafish larvae could be a possible model organism, in the quest to identify the 
signalling pathways involved in anxiety, mediated through cAMP signalling.   
In zebrafish, Rolipram causes decreased habituation in the startle response (Best et 
al. 2008), and other compounds with PDE-inhibitor effect cause increased activity in 
adult zebrafish (Maximino, Lima, et al. 2011) and thigmotaxis in larvae (Schnörr et 
al. 2012).  
 
4.1.1 Measuring anxiety in zebrafish larvae 
Thigmotaxis, or wall-hugging, is one of the most reliable behavioural outputs when 
studying anxiety-related behaviour in rodents. Animals displaying anxiety-like 
behaviours tend to stay close to the wall or floor of an arena and this specific 
behaviour can be attenuated by treating with anxiolytic compounds, and enhanced by 
anxiogenic compounds (Reviewed in Steimer 2011). Zebrafish larvae display 





causing anxiety or stress (Richendrfer et al. 2012; Schnörr et al. 2012). In 2011, 
Schnörr and colleagues demonstrated how the treatment with compounds with 
anxiolytic or anxiogenic effects influenced the placement of 5 dpf old zebrafish in a 
multi-well plate (Schnörr et al. 2012). Caffeine, a compound known to cause anxiety 
in rodents (El Yacoubi et al. 2000), increased the time the larvae spend at the edge of 
the well, and this was enhanced further when the fish were challenged with a stress-
inducing stimuli, the onset of sudden darkness. This effect was attenuated by 
diazepam, an known anxiolytic compound (Schnörr et al. 2012). Richendrfer et al. 
reported an increase in thigmotatic behaviour in 7 dpf zebrafish larave treated with 
caffeine. Challenging the larvae using an computer-generated image of a red 
bouncing ball in one area of the well, further enhanced the thigmotatic behaviour 
(Richendrfer et al. 2012). The validation of the thigmotaxis as an anxiety-related 
behaviour, was further established by the fact that diazepam decreased the 
thigmotaxis, whereas fluoxetine, a selective serotonin re-uptake inhibitor with anti-
depressant effect, had no effect on thigmotatic behaviour (Richendrfer et al. 2012).  
The light dark test is another assay with translational value, that has been established 
for larval zebrafish. Using a tank consisting of one black and one white half, 
Steenbergen and colleagues demonstrated that 6 dpf old zebrafish larvae have a 
strong preference for the white compartment of the tank, and this preference is 
further enhanced when fish are treated with caffeine, wherease larvae treated with 
buspirone and diazepam, both known anxiolytics, have a increased exploratory 
behaviour in the dark comparement and a decreased latency to enter the dark 





4.1.2 Modulation of cAMP in zebrafish larvae cause thigmotaxis 
From a small molecule screen our lab identified Rolipram as causing an increased 
response to touch and hyper-contracted pigmentation pattern in 5 dpf old zebrafish 
(Richardson et al. 2008). Further work in our lab has also shown that Rolipram also 
cause thigmotaxis in an open-field assay in 3 and 5 dpf old larvae (N. Grant, Master 
thesis). The thigmotatic response is dependent on light conditions, as larvae kept in 
the dark do not show an increased thigmotaxis (N. Grant, Master thesis). These data 
suggests that Pde4-inhibition in zebrafish cause anxiety-like behaviours. However, 
the pathway involved in this behaviour is not yet clear. To further elucidate on this 
pathway, the zebrafish offers the unique potential to probe signalling pathways 








Figure 4.1.1: Cyclic AMP modulators cause thigmotaxis in zebrafish larvae.  
A: The placement of 3 dpf old larvae at the edge of an arena after Rolipram treatment, B: A 
schematic of the placement of A 3 dpf old zebrafish at the edge. C: Pictures from a petri dish 
assay, counting number of fish placed at the edge of the petri dish after drug exposure (Blue 
dots represents larvae counted as not displaying thigmotatic behaviour, whereas orange dots 
mark larvae counted as displaying thigmotatic behaviour). D: The distribution of embryos at 
the edge is increased in the light compared to the dark. E: Caffeine causes thigmotaxis in 
zebrafish embryos, which is enhanced when the fish are placed in the light (Data from K. 





4.1.2.1 MAPK signalling regulate thigmotaxis in zebrafish larvae 
To elucidate on the possible pathways involved in regulating the anxiety-like 
behaviour in zebrafish larvae caused by PDE4-inhibiton, Nicola Grant, a former 
master student in our lab performed a small molecule screen (N.Grant, Master 
Thesis, 2011). Using the thigmotaxis assay, a selection of kinase inhibitors were 
screened for compounds capable of restoring normal orientation in the thigmotaxis 
assay. Eighty kinase inhibitors (Screen-Well
TM
 Kinase Inhibitor Library, Enzo Life 
Sciences, UK), were screened on zebrafish larvae treated with 15µM of Rolipram, 
displaying the thigmotaxis behaviour. From this screen inhibitors targeting the 
MAPK pathway was indentified as disrupting the Rolipram-induced thigmotaxis (N. 
Grant, Master thesis, 2011). The most potent compound capable of reversing the 
thigmotatic behaviour was the MEK inhibitor, PD98059. Due to the potent effect of 
PD98059, another MEK inhibitor, PD0325901, was also tested. PD0325901 have 
been in clinical development for treating several types of cancers (Zhao and Adjei 
2014). Treatment with PD0325901 also abolished the Rolipram-inudced thigmotaxis 
in 3 and 5 dpf old zebrafish (N. Grant, Master thesis, 2011 & Lundegaard et al, 







Figure 4.1.2: MEK inhibition counteracts thigmotaxis induced by cAMP-
modulation in zebrafish larvae.  
A: A schematic showing the setup of the screen by Nicola Grant. B: The thigmotaxis assay, 
showing the data with the MEK inhibitor PD0325901. Orange dots represent larvae oriented 
correctly, e.g. perpendicular to the edge of the dish, and thereby counted as displaying 
thigmotatic behaviour. Blue dots represent larvae, which do not display thigmotaxis (Date 
from K. Anastasiaki 2011 Ph.D thesis and Lundegaard et al. 2015).  
 
4.1.2.1.1 The MAPK pathway 
The data from the small molecule screen done by our lab, clear suggest an important 
function of mitogen-activated protein kinase pathway in the mediation of anxiety-
like behaviour in zebrafish larvae (see Figure 4.1.2). The mitogen-activated protein 
kinase pathway is involved in the regulation of a myriad of cellular processes 
including cell proliferation, differentiation, gene regulation, development, and 
motility, among other functions (Stork and Schmitt 2002; Gerits et al. 2008). Signal 
transduction through this cascade can be mediated through the small G proteins, like 
the RAS-SOS-GRB2 complex. The activation of Ras results in the subsequent 





So far, four distinct MAPK cascades have been identified. These include ERK, JNK, 
p38 and BMK. Of these four, ERK has been described intensively (Rubinfeld and 
Seger 2005). The ERK cascade consists of three levels of subsequent serine/threonine 
protein kinases: a RAF (C-Raf, B-Raf and Raf-1), two MEK (MEK1/MEK2). Upon 
activation of RAS, the ERK cascade members are recruited by scaffold proteins and the 
RAF protein activates its downstream targets MEK1 and MEK2 by phosphorylation. 
This allows the activation of MEK1/2, and MEK1/2 in turn phosphorylates ERK1 and 
ERK2. Phosphorylated ERK can either translocate into the nucleus or directly 
phosphorylate other proteins in the cytoplasm (Figure 4.1.3). In the nucleus, ERK1/2 
mainly activates MSK1/2, another protein kinase, which can activate CREB1 and ELK1 






Figure 4.1.3: The RAF-MEK-ERK signalling cascade.  
Schematic representation of the RAF-MEK-ERK signalling pathway. Initial activation of the 
pathway is through ligand binding of the extracellular receptor. This leads to a dimerization 
of the receptor complex, causing the G-protein to become phosphorylated and activated. The 
disassociation of the α-subunit allows the cascade to progress through a series of 
phosphorylation events, ultimately resulting in a translocation of the activated kinase, ERK, 






4.1.2.1.2 Regulation of PDE4 isoforms by PKA and MAPK signalling  
The regulation of the transcription and activity of the PDE4 isoforms and the 
alternative spliced variants are subject to a complex regulation (Simon J. MacKenzie 
et al. 2002). Crucial for regulating this activity is the UCR regions. In the long-
formPDE4s, the phosphorylation of UCR1by PKA activates the long form PDE4s, 
thereby leading to the degradation of cAMP, ultimately leading to the inactivation of 
PKA signaling. However, the UCR2 negative regulate PDE4 through 
phosphorylation by ERK, but this inhibitory effect can be reversed by the 
subsequently phosphorylation of UCR1 by PKA (Lim, Pahlke, and Conti 1999; 
Simon J. MacKenzie et al. 2002). The UCR1 domain is absent in short and super-
short forms of PDE4 (see Figure 1.1.4 ), suggesting that PKA cannot activate these 
two splice forms of PDE4 (Simon J. MacKenzie et al. 2002). However, there has 
been a binding site for ERK identified on all the catalytic domains of PDE4 isoforms, 
expect for PDE4A (Baillie et al. 2000).  In addition to this complex phosphorylation 
pattern, the effects of PDE4 phosphorylation by ERK are different depending on 
isoform. Short isoforms are activated by ERK phosphorylation, whereas the long 
isoforms are strongly inhibited, and super-short isoforms are weakly inhibited by 
phosphorylation (S.J. MacKenzie et al. 2000). This elaborate phosphorylation pattern 
establish several layers of regulation of cAMP degradation and activation, and 
demonstrates the elaborate cross-talk taking place between the two signaling 






Figure 4.1.4: Schematic illustration of the cross talk between cAMP and RAF-MEK-
ERK signalling pathways. 
There are several points of cross talk between the MAPK and cAMP pathways. G-coupled 
receptor activation leads to increase in cAMP, which in turn stimulates EPAC or PKA. 
EPAC activation leads to phosphorylation of the small GTPase, RAP1. Rap1 activates 








4.2 Aim of chapter 
The aim of this chapter was to evaluate the effect of cAMP and MAPK cross talk in 
zebrafish larvae, and how this cross talk modulates behaviour.  
4.3 Results  
Our lab has previously identified Rolipram from a small molecule screen, as causing 
contracted melanocytes and a hyper-response to touch (Richardson et al. 2008), and 
additional work in the lab identified a thigmotaxis-behaviour in an open field assay 
in 3 and 5 dpf larvae (N. Grant, Master thesis). These findings promoted us to further 
study the behavioural effect of Rolipram in zebrafish larvae. The data presented in 
this chapter demonstrates how chemical modulation of cAMP levels control 
locomotor activity in zebrafish larvae. Specifically the inhibition of PDE4-enzymes 
leads to hyperactivity and prolonged movement. Rolipram treatment also enhanced 
cAMP levels in vivo and activated the MAPK pathway. This activity of the MAPK 
pathway could be reversed by treating larvae with a specific MEK-inhibitor, 
PD0325901, resulting in a reversal of hyperactivity and MAPK signalling.   
 
4.3.1 Rolipram increase the swimming activity of zebrafish larvae 
Hyperactivity has been associated with anxiety and stress in zebrafish larvae (Ellis, 





aversive conditions, like constant darkness, is known to attenuate such behaviours 
(MacPhail et al. 2009; Schnörr et al. 2012).  
Using Rolipram to activate cAMP signalling, our lab discovered that treatment with 
Rolipram caused thigmotaxis in 3 and 5 dpf old larvae (see Figure 4.1.1). This was 
further substantiated through the effects of other compounds known to modulate 
cAMP, like IBMX and Forskolin (Figure 4.1.1).  
Analysing the behaviour of zebrafish after Rolipram treatment showed that Rolipram 
significantly increases the swimming activity of 5 dpf old larvae. Forskolin, an 
activator of the adenylate cyclases, and 3-isobutyl-1-methylxanthine (IBMX), a non-
selective PDE inhibitor, were also capable of inducing hyperactivity of 5 dpf old 
larvae. Figure 4.3.1 show that modulation of cAMP causes a significant increase in 









Figure 4.3.1: Compounds modulating cAMP levels cause an increase in locomotor 
activity.  
Bar graph showing the total distance moved, tracked during constant darkness (A) or light 
(B) for 30 min. DMSO (n=48), Rolipram (n=48), Forskolin (n=48) and IBMX (n=48). Data 
analysed using One-way ANOVA, followed by Tukey’s post-test. Data plotted as mean +/-
SEM. P < 0.001 (***), p < 0.01 (**), p<0.05(*). 
 
4.3.2 Long-term effect of Rolipram treatment on swimming activity 
To determine if the Rolipram-induced hyperacitvity was due to a lack of habituation 
to the darkness and the small environment, I tested Rolipram on larvae under 
prolonged exposure to darkness (5 hours) and analysed the swimming activity for for 
the first 10 minutes of every hour, to test if the hyperactivity was sustained over time. 
Data was calcluated as total distance moved over time. Five dpf larvae were plated in 





Rolipram or the equivalent volume of DMSO as a control, and the plate was 
immediately placed in the  DanioVision observation chamber with the lights off. All 
the larvae were screened for developmental defects prior to testing. This was done to 
exclude unhealthy larvae from the assay before start. The initial swimming activity 
was recorded for the first 10 minutes, to determine the baseline activity of the larvae 
after drug addition and the disturbance of being moved from the light to the darkness 
of the chamber. After one hour the Rolipram treated group showed a significant 
increase in swimming activity, compared to that of the DMSO-treated larvae.  The 
DMSO-treated larvae showed a gradual decrease in activity over time, whereas the 
Rolipram treated group continued to display increased swimming activity compared 
to the DMSO-larvae, throughout the course of the experiment (Figure 4.3.2). These 
findings show that the hyperactivity caused by Rolipram treatment does not diminish 
over time, and the larvae do not adjust to their environment as seen in DMSO-treated 






Figure 4.3.2: Long term effect of Rolipram on swimming activity on 5 dpf old 
larvae 
Histograms showing the normalized data plotted from habituation experiment with 
Rolipram. Fish treated with DMSO (n=48) or Rolipram (n=48) were tracked under constant 
darkness for 5 hours. The distance travelled for the first 10 min of every hour were analysed. 
The data from individual wells were normalized and values are allocated to bins, and plotted 







4.3.3 PDE inhibitors cause an increase in locomotor activity 
Modulation of cAMP in 5 dpf old zebrafish larvae cause an increased thigmotaxis 
and hyperacitivty in the swimming assay. To further elucidate on the function of the 
role of PDEs in mediating hyperactivty, I did a blind screen on 10PDE inhibitors 
(See Table 4: 1). Using a dose curve approach, I tested all the compounds in a 
concentration range from 3nM to 3µM. I screened all the compounds three times in 
the swimming assay. The test was performed blindly, and four compounds were 
identified as causing an increase in actibity of 5 dpf old larvae. Three out of the four 
hits targeted the PDE4 family, suggesting that the specific inhibition of PDE4 is 
enough to induce hyperactivity in the zebrafish larvae. One other compound, a dual-
PDE-type inhibitor targeting both PDE2 and PDE10, also caused an increase in 






Figure 4.3.3: Graph 1 of 2: concentration response of phosphodiesterase inhibitors. 
Dose response of the PDE-inhibitors from Lundbeck. The data is total distance moved over 1 
hour, with 12 larvae per drug concentration. All experiments is repeated n=3. The data are 
analysed using One-Way ANOVA, followed by Bonferroni's post-test. P<0.05. * = 






Figure 4.3.4: Graph 2 of 2: concentration response of phosphodiesterase inhibitors  
Dose response of the PDE-inhibitors from Lundbeck. The data is total distance moved over 1 
hour, with 12 larvae per drug concentration. All experiments is repeated n=3. The data are 
analysed using One-Way ANOVA, followed by Bonferroni's post-test. P < 0.05. * = 







Figure 4.3.5: Summary of PDE inhibitors and their effect of swimming activity 
in 5 dpf larvae  
The swimming activity of larvae compared to that of DMSO control. The data shown is the 
dose causing the maximum increase in swimming activity, or the highest dose tested, for the 
compounds that show no effect on swimming activity. The data are plotted as the fraction of 




















PDE1 (458) Pfizer 
PDE1 (83nM) 
PDE4 (2.6µM) 
3nM – 3µM Not significant 
PDE2 (432) Neuro3D PDE2 (130nM) 3nM – 3µM Not significant 
PDE4 (439) Decode 
PDE4 
(77%@10µM) 
3nM – 10µM 3µM 
PDE4D (611) Decode 
PDE4 
(64%@10µM) 
3nM – 3µM 3µM 
PDE4 
(Rolipram) 
Sigma PDE4 (1.6µM) 3nM – 3µM 3µM 
PDE9 (498) Bayer PDE9 (140nM) 3nM – 3µM Not significant 
PDE10 (455) Lundbeck 
PDE2(4nM) 
PDE10 (4nM) 
3nM – 3µM Not significant 





3nM – 100µM 
Significant at 
10nM – 20µM 





3nM – 3µM Not significant 





3nM – 3µM  Not significant 
Table 4: 1: List of PDE inhibitors included in the PDE screen 
List of PDE inhibitors from Lundbeck A/S. I obtained 10 PDE inhibitors, targeting different 
PDEs. Included in the screen was Rolipram, synthesised at Lundbeck. The table lists the 
Lundbeck identification number (omitting F15), patenting company (except Rolipram), the 
concentration of compound needed to give 100 % inhibition of the listed isoforms of PDEs, 
the drug concentrations tested in the swimming assay and at what concentration a significant 






4.3.4 Inhibition of MEK impedes hyperactivity in PDE4 treated 
larvae 
To test if the hyperactivity could caused by Rolipram and other cAMP modulators 
could be due to an activation of the MAPK-pathway, 5 dpf old larvae were treated 
with a combination of Rolipram and the specific MEK1/2 inhibitor, PD0325901.  In 
the presence of 1.5µM PD0325901, the hyperactivity of Rolipram treated larvae was 
absent compared to those treated with Rolipram alone.   
From these experiments, it was clear that hyperactivity is also regulated through the 
MAPK pathway. Larvae treated with Rolipram and PD0325901 are not hyperactive. 
Data from these experiments also revealed another interesting cavioat. When the data 
was plotted as bar graphs, with mean distance moved +/- SEM, there was a large 
degree of intre-experimental variation. From a histogram plot of normalised data, it 
became clear, that in the group of larvae treated with Rolipram, there is a distinct 
group of larvae that swim significantly more than that of the DMSO-treated larvae 
(Figure 4.3.6) . This could indicate that there is a subset of larvae in the group, that 
respond much stronger to Rolipram (Figure 4.3.6 B). The Rolipram-induced 
hyperactivity was absent in larvae treated with both Rolipram and 1.5µM 







Figure 4.3.6: Rolipram induced hyperactivity can be reversed through MEK-
inhibition 
A: Movement plots from EthoVision XT9. B; Histograms plotted with the normalized data 
from a total of 7 experiments of behavioural analysis with Rolipram, PD0325901 and a 
combination of the two. Data are displayed as bins, which have been bootstrapped to 
determine the 95CI for the data. C: Bootstrapped means plotted with a 95% CI, showing a 
significant increase in swimming activity when larvae are treated with Rolipram. Note that 
when removing the group of larvae with very high swimming activity (B), the Rolipram still 
causes an significant increase in swimming activity, displayed by none-overlapping CI, and 





4.3.5 Increased cAMP levels in vivo following treatment with 
Rolipram  
Rolipram targets the PDE4-proteins, which are responsible for the hydrolysis of 
cAMP (S J MacKenzie and Houslay 2000). Inhibition of PDE4 leads to increased 
cAMP signaling in vivo, but to what extent this inhibition can been seen as a 
measurable effect in zebrafish larvae has not been shown. To determine if the effect 
of Rolipram and forskolin did result in increased cAMP in vivo, cAMP was extracted 
from 5 dpf old larvae and treated with the same treatment regime as previously 
described for the hyperactivity assays. Results show that there is a significant higher 
level of cAMP in larvae treated with Rolipram, and more pronounced increase after 







Figure 4.3.7: Increased cAMP levels in whole larvae treated with Rolipram and 
Forskolin. 
Data from ELISA assay measuring cAMP levels. Data are represented as ration of cAMP 
levels compared to DMSO-treated fish. Data analysed using One-Way ANOVA, followed by 
Turkey’s post-test. P<0.05. *= significant, ***= highly significant. Data from 15 larvae per 







4.3.5.1 MEK inhibition only cause decreased cAMP levels in 
forskolin treated larvae, but not in Rolipram-treated larvae 
To test if the reduced hyperactivity observed in larvae subsequently treated with 
PD0325901 correspond with a similar decrease in cAMP levels, cAMP levels were 
determined from combination-treated larvae. Interestingly, in larvae treated with the 
combination of Rolipram and PD0325901 there was no reduction in cAMP levels, 
but instead a small increase, although this was not significant (n=3). When adding 
PD0325901 til forskolin-treated larvae, there was a significant reduction in cAMP 
levels, compared to forskolin-only treated larvae.  
 
 
Figure 4.3.8: ELISA assay determining cAMP levels following combination treatment. 
5 dpf old zebrafish were treated with Rolipram +/-PD0325901 or Forskolin +/- PD0325901. 
Data are plotted as ratio of cAMP compared to DMSO control, which is 1. 15 fish per 
treatment group, experiment repeated 3 times. Data analysed with One-way ANOVA, 







4.3.6 Rolipram activates MAPK signalling 
As the inhibition of MEK can rescue the Rolipram-induced hyperactivity, but does 
not reverse the increased levels of cAMP, I tested whether the MAPK-pathway was 
activated by Rolipram treatment. A total of 15 five dpf old larvae were treated with 
Rolipram showed increased pERK levels, determined by Western blot analysis of 
whole larvae. The expression of pERK in larvae treated with the combination of 
Rolipram and PD0325901 showed very low levels of pERK, moreover confirming 
that the MEK-inhibiton has worked, in the larvae treated with PD0325901 alone 









Figure 4.3.9: Rolipram treatment increases pERK in whole embryos.  
A: Western blot analysis using anti-pERK (Green) (anti-phosphor p42/44, Cell Signalling 
Technology, 1:2000) and total ERK (red, anti-p42/44, Cell signalling Technology,1:1000). 
B: Quantification of protein levels; pERK levels normalized to the total ERK levels. 
Quantification was done using the LiCor Image Suite. Data analysed using One-Way 









The work presented in this chapter illustrates the use of zebrafish larvae to study the 
effect of PDE inhibition and cAMP manipulation on the swimming behaviour in 5 
dpf zebrafish larvae. The results in this chapter established that compounds 
increasing cAMP levels in zebrafish larvae also induce locomotor hyperactivity, 
specifically through PDE4 inhibition but not through the inhibition of other PDE 
proteins. This hyperactivity is reversible by treatment with the MEK-inhibitor, 
PD0325901, which also results in decreased pERK expression, but not cAMP levels 
in the larvae. This suggests a cross-talk between the cAMP and MAPK pathway in 
regulating behaviour in zebrafish larvae. In particular, the PDE4-family appears to be 
of importance for this link.   
4.4.1 Rolipram increases cAMP in zebrafish larvae 
Larvae treated with Rolipram and forskolin have increased levels of cAMP, which 
correlates with previous in vivo and in vitro studies (Andersen 2002; Lelkes et al. 
1998). Forskolin treatment increases activity of  adenylate cyclase, and thereby 
directly  stimulate cAMP-synthesis (Alewijnse et al. 1997), whereas Rolipram 
inhibits cAMP hydrolysis (Beavo, Francis, and Houslay 2006). (Miles D. Houslay, 
Baillie, and Maurice 2007). Increased cAMP levels are associated with improved 
cognition (Wiescholleck and Manahan-Vaughan 2012), mood regulation (Landgraf, 
McCarthy, and Welsh 2014), anti-depressive effects (Lelkes et al. 1998) and 





messenger in the nervous system. The data presented in this chapter shows that 
increased cAMP is involved in the modulation of hyperactivity and anxiety in 
zebrafish larvae.  
4.4.2 PDE4 inhibition causes hyperactivity in zebrafish larvae 
The phosphodiesterase 4 inhibitor, Rolipram, was developed as a mood stabilizer but 
was withdrawn due to adverse effects, like emesis in patients (Zhu, Mix, and 
Winblad 2001). It is still extensively used as a tool compound in research, due to its 
strong specificity for PDE4-enzymes (Cherry, Thompson, and Pho 2001; Dlaboga, 
Hajjhussein, and O’Donnell 2006; Y.-F. Li et al. 2009b). In rodent behavioural 
models, Rolipram causes antidepressant-like effects, with decreased immobility in 
the forced swim test and the tail suspension test . Furthermore, cognitive tests 
indicate that Rolipram improves spatial learning and cognition (Y.-F. Li et al. 
2009b). As Rolipram targets all four isoforms or PDE4-proteins, it has been difficult 
to determine the biological role of the different isoforms. The generation of knockout 
mouse models lacking specific PDE4-genes, has helped to elucidate on the roles of 
the different member of genes in the family. PDE4A and PDE4B-knockout mice 
display anxiogenic-like behaviours (R. T. Hansen, Conti, and Zhang 2014; Zhang et 
al. 2008), whereas PDE4D-knockout mice show an anti-depressant phenotype 
(Zhang et al. 2002b).  
My studies inducate , that in zebrafish larvae Rolipram cause behavioural phenotypes 
relating to an anxiogenic-like phenotype. The fact that PDE4 inhibition causes 





development Pde4a and Pde4b are more highly expressed or more important in 
regulating behaviour in zebrafish. This is further supported by the fact, that a subset 
of larvae show an  increased response to Rolipram, which could be attributed to 
differences in expression levels of different Pde4s. pde4b, resulting in a increased 
anxiogenic effect of Rolipram (Figure 4.3.6). The importance of pde4-function in 
mediating zebrafish larval behaviour was further supported by the data from the 11 
PDE-inhibitors, where it was demonstrated that inhibition of the Pde4 proteins 
caused  hyperactivity in zebrafish larvae. Of the 11 PDE-inhibitors tested, three 
specifically targeted the PDE4-family. One was Rolipram and one was a second pan-
PDE4 inhibitor. Interestingly, the 611-compound is designed to be a specific Pde4d-
inhibitor, as the structure is modelled on the small PDE4D-allosteric modulator 
described previously (Burgin et al. 2010). This compound also caused an increase in 
hyperactivity in zebrafish larvae. Further studies need to be performed to further 
substansiate these findings. However, from rodent models, it has been shown that 
pde4d-knockout mice have an anti-depressive behaviour, and are in-sensitive to the 
anti-depressive effects of Rolipram. This indicates, that Pde4d is important in the 
anti-depressant effects of Rolipram in zebrafish.   
A PDE2/10 inhibitor (#446) was identified in this screen to also have an effect on the 
swimming activity of zebrafish larvae, whereas other PDE2 and 10 inhibitors tested 
(compound #434 and #450) had no effect. Moreover, two compounds targeting either 
PDE2 (#432) or PDE10 (#455) had not effect on swimming activity. These data 
indicate that the effect observed in larvae treated with the #446 compound could be 





phosphodiesterase. They hydrolyse both cAMP and cGMP (Beavo, Francis, and 
Houslay 2006), and are highly expressed in the brain. It remains to be determined 
whether PDE2 and PDE10 are important for this behaviour in zebrafish, but it is 
noteworthy that all the PDE4-selective compounds in this screen significantly 
modulated hyperactivity in zebrafish larvae indicating that PDE4 is an important 
regulator of activity in zebrafish.  
 
4.4.3 Cyclic AMP and MAPK cross talk in zebrafish behaviour 
Treatment with PD0325901 reversed the hyperactivity in larvae treated with 
Rolipram. Increased cAMP activates PKA, and this in turn can activate the MAPK 
pathway through B-raf activation (Erhardt et al. 1995; Vogt Weisenhorn et al. 2001). 
B-raf depletion in juvenile mouse brains cause an anxiolytic behaviour, evident on 
the molecular level as decreased pERK levels (Wefers et al. 2012) whereas depletion 
during adulthood leads to depressive behaviour in adult mice (Wefers et al. 2012). 
The involvement of MAPK in depression has also been demonstrated by Einat and 
colleagues. They treated  mice with a MEK inhibitor, SL327, and subsequently tested  
their performance in the forced swim test, and found that mice treated with SL327 
showed an increase in total swim activity and decrease in total immobility time, 
indicative of a less depressive behaviour (Einat et al. 2003). To further substantiate 
these findings, they stained for pERK in brain slices from rats subjected to condioned 





area of the brain known to be involved in the regulation of fear and anxiety. (Einat et 
al. 2003). 
In the Rolipram-treated larvae, the PD0325901 treatment did not decrease the 
increase in cAMP levels, but it did reverse the hyperactivity of the larvae, and also 
the levels of pERK. It is known that pERK is involved in the regulation of PDE4-
activity (M D Houslay and Baillie 2003; Waltereit and Weller 2003). In cardiac 
muscle cells, a signalling complex consisting of the A-Kinase Anchoring Protein 
(AKAP), PKA and long-form PDE4D3. This complex recruits ERK5 to the signaling 
module, and phosphorylated ERK5 inactivates long-form PDE4D3, which leads to 
increaed cAMP levels. This in turn activates PKA, leading to a second 
phosphorylation of long-form PDE4D3 on a different residue, resulting in an 
activation of PDE4D3, and hence hydrolysis of cAMP (Reviewed in Jarnaess and 
Taskén 2007). This indicates that increased activity of MAPK in the larvae, are 
important in regulating the hyperactivity.  
In fear conditioned rats, pERK levels are increased ant they rats display an 
anxiogenic phenotype in the elevated plus maze (Ailing et al. 2008). Subsequent 
treatment of the fear-conditioned rats with a MEK inhibitor, PD09859, leads to an 
abolishment of the anxiogenic behavior, indicated by a higher degree of exploratory 
nature, the amount of time spent in the open arms and increased number of rearings. 
This  performance correlated with a decreased pERK expression, thus indicating the 
inhibition of the MAPK-pathway can lead to anxiolytic effects (Ailing et al. 2008). 





and thigmotaxis. By using the zebrafish as a model system, I have shown that the 
cross-talk between cAMP and MAPK modulates zebrafish hyperactivity.  
 
 
Figure 4.4.1: A novel therapeutic strategy: MEK inhibitors to treat cAMP-mediated 
anxiety. 
A: In control fish, PDE4 is a negative regulator of cAMP activity. This regulation is obtained 
through hydrolysis of the second messenger. B: In zebrafish, blocking PDE4 or activating 
AC with small molecules leads to increased cAMP in vivo. This cause an activation of the 
MAPK signalling pathway, leading to an anxiogenic response in zebrafish. C: The activation 
of the MAPK signalling pathway obtained through increase cAMP levels in vivo can be 
perturbed by blocking the MAPK-signalling pathway at different levels. Either through 
direct blockage of the receptor or by blocking the downstream signalling pathway using 
specific inhibitors, inhibiting ERK or MEK.  
 
4.4.4 Concluding remarks 
During this study I found that inhibitors of PDE4-activity play an important role in 
regulating anxiogenic-like behaviour in zebrafish larvae. Using small molecules in 
combination with automated tracking equipment, I have shown that zebrafish larvae 





anxiogenic-like behaviour is dependent on MAPK signalling, as cAMP modulators 
cause increase in pERK levels in 5 dpf old larvae, and subsequently treatment with a 
specific MEK inhibitor, PD0325901, leads to alleviation of this anxiogenic 
phenotype. These data suggests that by using the zebrafish embryo model, it is 
possible to elucidate on the cross-talk between cAMP and MAPK pathways in 






5 Modulation of behaviour in adult 






The use of adult zebrafish in behavioural research has expanded over the recent 
years. In particular the modulation of behaviour using known anxiolytic or 
anxiogenic compounds have been well described (Egan et al. 2009; Levin, Bencan, 
and Cerutti 2007; Bencan, Sledge, and Levin 2009; Maximino, da Silva, et al. 2011).  
Work in our lab (Figure 4.1.1) and others (Richendrfer et al. 2012; Schnörr et al. 
2012) have shown that modulation of the cAMP pathway can induce thigmotaxis is 
larvae zebrafish. Moreover, five day old zebrafish larvae treated with PDE4-
inhibitors show an increase in swimming activity both in the light and in the dark 
(see 4.4.2). I found that this hyperactivity can be reversed by treating the larvae with 
a specific MEK inhibitor, PD0325901. The nervous system of the larvae at 5 dpf is 
less complex than that of adults, and adult fish have a more elaborate and developed 
behavioural repertoire (R. E. Blaser, Chadwick, and McGinnis 2010; Collier and 
Echevarria 2013). To gain insight into how Rolipram affects adult zebrafish 
behaviour and the cross talk between cAMP and MAPK in regulating behaviour, 
adult behavioural assays were performed. The novel tank test and the shoaling assay 
have both been validated as means of studying anxiety and stress in adult zebrafish 
(Speedie and Gerlai 2008; Stewart et al. 2011), therefore these two assays were used.  
5.1.1 The shoaling assay 
Zebrafish are social animals, that live in groups, and have an innate shoaling 
behaviour, that develops with age (C Buske and Gerlai 2011).  The organization and 





predator (Speedie and Gerlai 2008), the addition of alarm pheromones to the water 
(Speedie and Gerlai 2008) and psychoactive drugs (Green et al. 2012).  
The shoaling assay has been suggested as a potential assay to model social 
withdrawal, aggression and depression. Modulation of glutamate signalling by 
treating fish with MK-801, a NMDA-receptor antagonist, disrupts the shoal in 
zebrafish. Fish treated with MK-801, a NMDA receptor antagonist, show an 
disruption in shoaling behaviour, displayed by a larger distance between individual 
subjects, which has been interpreted as a display of anti-social or depressive 
behaviour (Maaswinkel, Zhu, and Weng 2013). An alternative version of the 
shoaling assay is the group performance task (Gebauer et al. 2011). This assay 
measures both the shoal cohesion but also the placement in the tank. In this assay, 
buspirone causes the fish to explore the top of the tank, but with no effect on shoal 
cohesion (Gebauer et al. 2011).  
5.1.2 The novel tank assay 
The novel tank test is one of the most widely used behavioural tests when analysing 
adult zebrafish behaviour (Egan et al. 2009; Levin, Bencan, and Cerutti 2007; Rachel 
E. Blaser and Rosemberg 2012). Like rodents, when introduced into a novel 
environment, fish also show an initial lack of exploration. They tend to stay close to 
the walls and bottom of the tank, when they are initially introduced into the tank. The 
bottom dwelling behaviour is sometimes referred to as geotaxis. After a habituation 
period the fish become more exploratory and venture up into the top of the tank 





of time spend at the bottom of the tank, how long and how often, the fish is in the top 
zone of the tank, frequency of erratic movements and freezing behaviours. These 
parameters have all been shown to be modulated by treatment with either anxiolytic 
or anxiogenic compounds (Egan et al. 2009). Chronic treatment with fluoxetine, 
commonly known as Prozac ®, produces anxiolytic-like behaviours in adult 
zebrafish, when administered for two weeks. The fish showed a higher degree of 
exploration to the top zone of the novel tank and less erratic behaviours and freezing 
incidents. Furthermore, the level of whole body cortisol is significantly reduced in 
the fish. These data all suggests that the adult zebrafish model is suitable for studying 
anxiety-like behaviours.  
 
Figure 5.1.1: Schematic of the shoaling assay and the novel tank assay. 
A: A schematic representation of the shoaling assay/group behaviour task. B: Schematic 






5.2 Aim of chapter 
The aim of this chapter was to establish two assays to evaluate anxiety-like 
behaviours in adult zebrafish. After implementation, the behavioural assays will be 
used to evaluate the effect of PDE4-inhibition on adult zebrafish. 
 
5.3 Results 
5.3.1 Setting up the novel tank assay 
In the novel tank assay, I treated single fish separately with compound or vehicle for 
20 minutes prior to testing in the novel tank. After treatment the fish were carefully 
transferred to the novel tank and the behaviour was recorded from the side for 6 min 
(Figure 5.2.1). This amount of time has been shown by other to be sufficient to allow 
the fish to habituate to the novel tank and slowly begin exploring the top of the tank 
as well as the bottom (Egan et al. 2009). As the data from the larvae experiments (see 
4.3.1) indicate that Rolipram causes anxiety-like behaviour, e.g. thigmotaxis and 
hyper activity, I wanted to test the effect of Rolipram on adult fish in the novel tank 
test. Before testing Rolipram, a test routine for the novel tank test was first 
established using a compound with a known anxiolytic effect. This enabled me to 
distinguish between normal behaviour and anxiolytic behaviour of the fish in the 






Figure 5.3.1: Visualisation of the EthoVision output from a novel tank test.  
A: Traces of the swimming pattern of an adult fish tracked for 5 minutes in the novel 
tank test. The purple area is the bottom zone and the green is the top zone. B: 
Screenshot of the integrated tracking visualization of the i: swimming distance, ii: 
velocity, iii: zone placement and iv: movement status for a 4 second time interval.  
The purple bar is when the fish is active in the bottom zone and the green bar is the 
top zone of the tank.  
 
5.3.1.1 Buspirone causes an anxiolytic effect on zebrafish 
Buspirone is a specific serotonin 5-HT1a partial agonist, with known anxiolytic 
properties that has been shown to induce anxiolytic behaviour in zebrafish models in 





Previous reports have described several behavioural parameters as a measure of 
anxiety levels in adult fish tested in the novel tank test. These include time spent at 
the top of the tank, latency to enter the top zone, total distance moved, frequency of 
erratic behaviours and time spent immobile  (referred to as freezing) (Egan et al. 
2009; Rachel E. Blaser and Rosemberg 2012; Gebauer et al. 2011). The behaviour of 
adult fish treated with 0.001% DMSO, as a control, was compared to that of fish 
treated with 10µM buspirone, with a final DMSO content of 0.001%. The fish treated 
with 10µM buspirone for 20 minutes spend a significantly higher amount of time at 
the top of the tank, compared to untreated fish, and the latency to move into the top 
zone was significantly lower in the buspirone treated fish compared to untreated fish 
(Figure 5.3.2 A&B). Adult fish treated with 10µM of buspirone for 20 minutes 
showed a higher degree of top-zone entries in the novel tank test than fish treated 
with DMSO only, although this was not significant (Figure 5.3.2 C). There was no 
effect on the distance travelled between the two treatment groups, and although 
buspirone-treated fish showed a lower amount of erratic episodes, this was not 
significant. The same was true for the freezing behaviours (Figure 5.3.2 E&F). These 







Figure 5.3.2: Buspirone causes significant increases in time spend in the top of the novel 
tank.  
i: (A) Adult zebrafish treated with buspirone show an increase in the time spend at the top of 
the tank (p<0.01), and also a latency to enter the top of the tank (p<0.05) (B). There was no 
significant difference between the erratic movements (E) or the freezing behaviours (F) 
displayed by fish treated with buspirone. The experiment was repeated 2 times, with 5 fish 
per treatment group. All trials were 6 minutes in total, and the data was analysed using an 
unpaired t-test. ii: tracking plots and heat maps from the Actual Track software (Actual 





5.3.2 Rolipram and its effect on the behaviour of adult zebrafish 
Modulation of cAMP levels through PDE4 inhibition and adenylate cyclase 
activation has been shown to increase thigmotaxis and locomotor activity in 
zebrafish larvae (see Chapter 4). Larvae treated with caffeine, a weak PDE-inhibitor, 
has been shown by our lab ( Figure 4.1.1)  and others (Richendrfer et al. 2012) to 
display increased thigmotaxis in an open field test, and increased latency of larvae to 
enter the dark compartment in the light-dark test (Steenbergen, Richardson, and 
Champagne 2011b). Adult fish treated with caffeine display  increased erratic 
behaviours, freezing and latency to enter the top zone of the tank of the novel tank 
(Egan et al. 2009). To test if Rolipram treatment causes similar effects in adult fish, I 
treated adult zebrafish with Rolipram, and implemented two different behavioural 
assays, the novel tank test and the shoaling assay.  
5.3.2.1 Anxiogenic effect of Rolipram in the novel tank diving 
test 
Adult zebrafish were treated with 30µM of Rolipram for 20 min and transferred to a 
novel tank. The activity and movement pattern of the fish was recorded from the side 
in a 6 minute trial (Egan et al. 2009). Movies were subsequently analysed using 
EthoVision XT9 (Noldus Information Technology, The Netherlands). Zebrafish 
treated with 30µM Rolipram showed a significant increase in the time spend at the 
bottom of the tank (p=0.05, n=5), and also a significantly higher number of erratic 





treated fish or the velocity, indicating that the overall locomotor activity was not 
affected in fish treated with Rolipram (Figure 5.3.3). 
 
 
Figure 5.3.3: Behavioural analysis of the Rolipram effect on adult zebrafish.  
A: Bar graph showing the behavioural data from a novel tank test. Rolipram increase time 
spend in the bottom zone. Zebrafish showed behaviours previously reported to be related 
with anxiety. A significant increase in time spend at the bottom of the tank (p<0.05) and the 
frequency of erratic behaviours (p<0.05) were observed in fish treated with Rolipram. 
Groups of 5 fish were treated with DMSO or Rolipram, 2 experimental repeats. B: Birds nest 
and heat maps of representative experiment of one fish treated with 0.001% DMSO (top) and 







5.3.3 Inhibiting MEK activity does not cause anxiolytic behaviour in 
adult fish 
The effect of buspirone on adult zebrafish is very pronounced, causing the fish to 
spend more time at the top of the tank and less time performing erratic movements 
and freezing bouts (Figure 5.3.2). The MAPK pathway has been implicated in 
anxiety and depression in rodents (Coyner et al. 2014; Wefers et al. 2012). In larval 
zebrafish our lab has shown that treatment with a MEK-inhibitor alleviates 
thigmotaxis (Figure 4.1.1) and hyper activity (Figure 4.3.6). Thus inhibiting MEK 
causes an anxiolytic effect. To test if inhibiting MEK in adult fish causes an 
anxiolytic response in the novel tank test, I treated adult fish with 3µM PD0325901 
and analysed their response to introducing them into a novel environment in the 
novel tank assay. The treatment with PD0325901 did not result in a significant 
difference in anxiolytic behaviours compared to that of DMSO-treated fish (Figure 
5.3.4). There was no observed difference in the time spend in the top zone of the 
tank, latency to enter or erratic behaviours. The freezing behaviour is the one 
parameter with a clear difference. However, the freezing behaviour was only 
displayed by one DMSO-treated fish, thereby skewing the data (Figure 5.3.2). 
Therefore it appears that inhibition of MEK does not cause an effect of behaviour on 







Figure 5.3.4 PD0325901 treatment does not cause an anxiolytic phenotype in the novel 
tank. 
Adult zebrafish treated with 3µM PD0325901 for 20 min prior to testing the in the novel 
tank assay. The only behavioural parameter with a distinct difference between the two 
treatments was the frequency of freezing episodes. Only one adult fish (DMSO treated) 
showed a freezing period (7 seconds). None of the other fish had any freezing episodes (5 






5.3.3.1 Rolipram causes bottom dwelling in groups of adult fish 
When fish treated with Rolipram are transferred to a novel tank, they display 
anxiety-like behaviours (Figure 5.3.3), thus treatment with Rolipram cause a stress or 
anxiety-like response in both larvae and adult zebrafish. To further establish the 
effect of Rolipram in adult zebrafish, I used a second behavioural assay, the shoaling 
assay. Shoaling is an innate behaviour in adult fish, and this behaviour has been 
demonstrated as another parameter that is modulated in zebrafish in response to 
anxiety and fear in adult fish (Green et al. 2012; Christine Buske and Gerlai 2011). 
The response to alarm pheromones or the presence of a predator leads to a change in 
the placement in the tank, causing the fish to spend more time at the bottom of the 
tank, and in a tighter shoal (C Buske and Gerlai 2011; Green et al. 2012). As 
PD0325901 can reverse the Rolipram induced hyperactivity, suggesting the 
importance of MAPK signalling in mediating the anxiety-like response in zebrafish 
larvae, I wanted to test if this regulating was conserved in adult zebrafish. I therefore 
tested if a potential phenotype can be reversed by co-treating the adult fish Rolipram 
and PD0325901.  
The fish were incubated in a 1.5L tank with either DMSO, 30µM Rolipram, 3µM 
PD0325901or 30µM Rolipram + 3µM PD0325901 for 20 minutes.  After incubation 
the fish were filmed for 5 minutes from above, to measure shoaling density, and from 
the side to evaluate the placement in the tank. I found that fish treated with Rolipram 
spend significantly higher percentage of their time at the bottom of the tank, with 





dwelling was not observed in the fish with DMSO or PD0325901 alone and thus 
similar to the findings from the novel tank assay. When the fish were treated with a 
combination of Rolipram and PD0325901, the bottom dwelling was significantly 
different from the Rolipram only fish, suggesting that the importance of MAPK 
signalling in regulating anxiety-like behaviours due to PDE4 inhibition is conserved 
in adult zebrafish. Interestingly, there was no effect on the shoal cohesion between 







Figure 5.3.5: Placement in tank in the shoaling assay after Rolipram and PD0325901 
treatment.  
A: Bar graphs showing the percentage of time spend in the top or bottom of the shoaling 
tank, 5 fish per group. Data are presented as mean +/- SEM (experimental replicates n= 5 per 
treatment group). Data were analysed a Two-Way ANOVA followed by a Bonferroni’s 
posthoc test. Rolipram treated fish spend significantly more time at the bottom of the tank 
(p<0.001) and this is reversed by co-treatment with 3µM PD0325901 (p<0.01). There was no 
effect of PD0325901 alone (p>0.05).  B) Representative tracking plots of the swimming 
pattern of a group of 5 adult zebrafish from each of the 4 treatment regimes. C: Activity heat 
maps corresponding to the relative time the fish spent in the areas of the tank during the 5 
min trial. The heat maps are 2D Kernel Density Estimates, with a custom colour map to 





5.3.4 Increased whole-body cortisol levels in adult zebrafish in 
response to Rolipram treatment 
The endocrine response to stress and anxiety in mammals are regulated by the HPA 
axis. In humans and zebrafish the stress hormone released during anxiety and stress 
is cortisol, and increased whole body levels of this hormone during stress or anxiety 
in adult zebrafish have been demonstrated previously (Barcellos et al. 2007; Egan et 
al. 2009). To determine if fish treated with Rolipram have increased cortisol levels, 
groups of five fish from a shoaling assay were snap frozen, and cortisol was 
extracted, using a modified version of a previously described method (Cachat et al. 
2010; Ramsay et al. 2006) and cortisol levels were determined using an enzyme 
immunoassay kit (Salimetrics Europe Ltd, UK). Fish treated with Rolipram had a 
significantly higher level of cortisol (mean=6.749, SEM +/- 1.106) compared to fish 








Figure 5.3.6: Increased cortisol levels in adult zebrafish treated with 30µM Rolipram.  
Cortisol levels in fish treated with 30µM Rolipram or 0.001% DMSO (20 minutes) was 
measured. A significantly higher level of cortisol was detected in fish treated with Rolipram 
(Students t-test; p=0.0113). The experiment was repeated 3 times in total, with 5 fish in each 
treatment group per experiment.   
 
5.3.5 Genetic modulation of Pde4d activity  
The next series of experiments were to examine whether phenotypes observed 
through pharmacological modulation of Pde4-activity are recapitulated in a genetic 
model of pde4d-loss of function. From the Zebrafish Mutation Project (The Sanger 
institute, Cambridge, UK) we obtained a zebrafish mutant line with a nonsense point 
mutation (A to T) located at the beginning of the PDEase domain of the Pde4d-gene 
in the zebrafish. The nonsense mutation causes the conversion of a lysine residue to a 
Stop codon, with the predicted result being a loss-of-function. From rodent studies 





decrease in immobile periods in the forced swim test and the tail suspension test, two 
tests commonly used to assess depression-like phenotypes in rodents (Zhang et al. 
2002a). To determine if any of the phenotypes caused by Rolipram in the adult fish 
was recapitulated in the Pde4d-mutants I did a novel tank assay and a shoaling assay 
on adult Pde4d-/- and their wild-type siblings.   
 
Figure 5.3.7: The PDE4D gene in humans and zebrafish 
A: A schematic representation of the zebrafish transcript, pde4d-001, and the point of 
mutation in the pde4d-/- fish from the Sanger Institute. B: The overlap between the exon-
homology between zebrafish and human PDE4D. The exons are aligned according to 
homology. The exons are coloured with different colours for the ease of comparison, with 
alternating exons in alternating dark and light colour. The dark and light blue are the 
zebrafish gene structure and the dark and light purple are the human gene structure. C: 
Sequence alignment between zebrafish and human cDNA sequences of PDE4D. The red 
lines represent sequence identity, blue lines mismatching sequences. There is an overall 90.5 






5.3.5.1 Pde4d-loss of function cause an decrease in shoaling 
behaviour 
Heterozygous pde4d-mutants from the Sanger institute were outcrossed and the 
progeny were genotyped. Heterozygous mutants were kept and in-crossed, progeny 
were genotyped and wild-type, heterozygous and homozygous mutants were raised 
in the facility. The siblings were out-crossed and progeny were genotyped. This was 
repeated until a F4 generation of wild-type, heterozygous and homozygous siblings 
were obtained. These fish were used for testing in the behavioural assays. To test for 
shoaling differences in the mutants compared to wild-type siblings, the behaviour of 
the fish were recorded from the side and the top, in the shoaling assay. The behaviour 
of the fish were analysed using Actual Track (Actual analytics Ltd, UK). The data 
analysis showed that pde4d-/- have a decreased shoaling behaviour, evident as a 
larger distance between individual fish in the group compared to that of wild-type 
siblings (Figure 5.3.8). There was also a significant difference between the time 
spend at the top of the tank, compared to that of the wild-type-siblings. The latency 








Figure 5.3.8 Adult pde4d-/- zebrafish have a decreased shoaling behaviour. 
Bar graphs depicting the data from a shoaling assay from groups of 4 fish (n=4 per 
genotype). The fish were tracked in the shoaling assay, and data was analysed in using an 
independent-samples t-test to determine if there was a significant difference in the 
behaviours in the shoaling assay. A&B display data analysed from the side and C-E display 
data from the top. Groups of 4 fish were tracked and a total of 16 fish were analysed from 






5.3.5.2 A specific pde4d-inhibitor partly recapitulates the 
phenotype of the pde4d-mutants 
From the PDE-inhibitor screen on larval zebrafish I identified a PDE4D-inhibitor 
that caused a significant increase in swimming activity of the zebrafish larvae. This 
inhibitor is designed as a specific PDE4D-inhibitor, originally published by Burgin 
and colleagues in 2010 (Burgin et al. 2010). This small allosteric inhibitor binds to 
the catalytic site of PDE4D-protein, thereby inhibiting its binding to cAMP. To test if 
the behavioural phenotype of observed in the pde4d-mutants is recapitulated by the 
PDE4D-specific inhibitor, I did a shoaling assay using groups of 4 fish, treated with 
3µM of the PDE4D inhibitor (#611) or 0.001% DMSO. After 20 minutes of 
incubation, the behaviour of the fish was recorded from the side and top. The fish 
treated with the PDE4D-inhibitor showed a significant decrease in shoal cohesion, 
compared to that of DMSO treated fish, and also a significant increase in velocity 
(Figure 5.3.9) 
 
Figure 5.3.9: F152611 increases the shoaling distance in wild-type fish. 
Bar graphs showing the data from the shoaling assay with adult fish treated with 3µM 
F152611. A) F152611 significantly increases the distance between the fish in the shoal 
(p<0.0001), and also cause an increase in velocity of the fish (B) (p=0.001). There was no 







5.4.1 Validation of the novel tank assay using a known anxiolytic 
compound 
The use of adult zebrafish in behavioural research has been developed during the last 
decade (Robert Gerlai, Fernandes, and Pereira 2009; Kalueff, Stewart, and Gerlai 
2014; R. E. Blaser, Chadwick, and McGinnis 2010; Egan et al. 2009; Green et al. 
2012). Using the natural behaviours of zebrafish to study the effect of compounds 
with known function have aided in the development of the zebrafish as a useful 
model in neurobiology research (Egan et al. 2009; Stewart et al. 2011). Using a 5-
HT1a-recepter agonist, buspirone (Buspar®), a novel tank assay was established in 
the lab. Fish treated with buspirone displayed a behavioural phenotype indicating a 
less anxious state, visible as more time spend at the top of the tank, less erratic 
behaviours, decreased latency to enter the top area of the tank. These data 
corresponds to what others have reported on the use of buspirone in the novel tank 
(Bencan, Sledge, and Levin 2009; Egan et al. 2009). During the setup of this assay 
several challenges arose. When setting up assays to study the behaviour of adult fish, 
there are several considerations to make. In the novel tank assay I have used a tank 
that is identical in shape to the home tank the test fish are housed in in the fish room. 
Initially a larger, rectangular tank was tested, but fish introduced into this tank 
displayed a high degree of freezing and no ventures into the top of the tank (data not 
shown). This indicates that the fish have a heightened anxiety level, making the 
analysis of the behaviour in the novel tank difficult. Therefore, I used a trapezoid 





housed in. Also, the stocking density of the fish has an important impact on the 
anxiety and stress levels of the fish (Ramsay et al. 2006), and thus fish for 
behavioural assays were housed at a maximum stocking density of 4 fish per litre of 
water. A minimum level of handling is also recommended, as handling and netting 
also increase the stress levels in the fish, further adding to the bias of results (Ramsay 
et al. 2009), and prior to testing, fish are moved in their home tank to the testing 
room, and allowed to acclimatise for a minimum of two hours before the testing is 
done, also to minimize stress and anxiety.  
5.4.1.1 Challenges when using automated behavioural analysis 
The ease of capturing and analysing behavioural data in zebrafish has increased with 
the availability of tracking software for automated behavioural analysis. The ability 
to load a large amount of captured behavioural recordings into the software and 
allowing the software to run the analysis overnight is very useful and time-saving. 
However, it is very important to look through the captured data after data analysis 
has been completed, as mistakes in the tracking occur. The result of these mistakes 
can be miscalculations of animal behaviour, due to loss of subject recognition by the 
software. A way to validate the tracking can be done by using the Integrated 
Visualization-function available in EthoVision XT9 and later versions. This function 
allows the researcher to scan through the acquired data, and thereby detecting any 
time points where the software lost contact with the subject (Figure 5.4.1).  
Although the use of automated tracking software is very practical and makes the 





in different areas of the tank and the distance they move, fast and high-throughput, 
some behaviours are still difficult analyse using automated setups. The quantification 
of erratic behaviours and freezing behaviours is determined by manual 
quantification, done by the researcher. This is time consuming and labours, making 
the novel tank test difficult to use in a high-throughput screen setting.   
 
Figure 5.4.1: Screenshot depicting the errors in tracking occurring in 
EthoVision XT9 
The data output from the integrated visualization function showing the tracked data of one 
fish from a shoaling assay. The tracking window displays a 4 sec time window of tracking. 
The visualization can be followed in real time while the data is analysed. A: The velocity of 
the subject is tracked throughout the trial. Notice the break in tracking (red line) which 
indicates that the software lost track of the fish for a short while. B: Distance moved in the 
entire arena. The same part of the trial is missing, due to loss of signal or bad detection 
settings. C show the placement in the novel tank, purple is the total arena and green the top 






5.4.2 Rolipram increase bottom dwelling and erratic behaviours in 
the novel tank test 
Previous reports on the effect of Rolipram in animal models have indicated that 
Rolipram causes an anxiolytic and anti-depressant-like phenotype (Y.-F. Li et al. 
2009b; Silvestre, Fernández, and Palacios 1999). However, other reports have 
reported the effect of Rolipram to be anxiogenic (Heaslip and Evans 1995), and data 
from our lab indicates that Rolipram causes anxiety-like behaviour in zebrafish 
larvae. Rolipram administered to adult fish cause an increase in behaviours 
previously shown to be associated with anxiety, namely erratic behaviours and less 
time spend at the top of the tank (Figure 5.3.3) (Rachel E. Blaser and Rosemberg 
2012; Egan et al. 2009; Levin, Bencan, and Cerutti 2007). These behaviours are 
similar to the behavioural effects of caffeine, another cAMP modulator. Caffeine 
induce erratic behaviours and the time spend at the bottom of the tank, which is a 
behaviour that is thought to be in parallel to thigmotaxis in rodents (Egan et al. 
2009). Caffeine is a weak PDE-inhibitor, and treatment with caffeine cause an 
increase in cAMP levels. Similar effects have been shown  in Rolipram treated 
animals (Zhang et al. 2005). Thus the increased cAMP levels through PDE-inhibition 
can potentially be responsible for the behavioural phenotypes displayed by fish 
treated with Rolipram. Rolipram 





5.4.2.1 Rolipram cause bottom dwelling in the shoaling assay, 
but has no effect on shoal cohesion  
As the phenotype of Rolipram treatment corresponds to an anxiety-like behaviour of 
adult zebrafish in the novel tank test, I sought to further characterise the response of 
adult fish to Rolipram treatment. The shoaling behaviour of adult fish have 
previously proven to be sensitive to modulation with alarm pheromone, 
hallucinogenic compounds (Green et al. 2012) and anxiolytic compounds (Gebauer 
et al. 2011). Fish treated with Rolipram display a significant increase in the time 
spend at the bottom of the tank during the group-behaviour  assay (Figure 5.3.5) and 
in the novel tank test (Figure 5.3.3), and also an increase in whole body cortisol 
levels (Figure 5.3.6).  Bottom dwelling is thought to be a thigmotaxis-like behaviour 
(Bencan, Sledge, and Levin 2009), and has been reported to be increased in fish 
subjected to chronic unpredictable stress (Piato et al. 2011). Interestingly fish that 
has been subjected to unpredicted chronic stress, show an increase in bottom 
dwelling, without an effect on the shoal cohesion (Piato et al. 2011). Subjecting fish 
to treatment with alarm pheromone leads to an increase in shoal cohesion, causing 
the fish to swim closer together (Speedie and Gerlai 2008). This is suggested to be an 
anti-predatory response, functioning as a protection against predators (Miller and 
Gerlai 2007). Alarm pheromone does not cause the fish to spend more time at the 
bottom of the tank when they are in a shoal (Speedie and Gerlai 2008), but does 
increase bottom dwelling in the novel tank test (Egan et al. 2009). This suggests that 





immediate threat, like the presence of a predator, can be distinguished from the 
response caused by chronic stress or being challenged by placement in a novel 
environment. Rolipram had no effect on the shoal cohesion in adult zebrafish, 
indicating that the behavioural output in Rolipram-treated fish is caused by a 
signalling pathway not related to the alarm pheromone response. However, this needs 
to be examined in more detail, preferably making use of available mutant lines.  
5.4.2.2 MEK inhibition reverse the Rolipram-induced phenotype 
In the larval assays we have shown that the Rolipram-induced changes in behaviour 
can be reversed by inhibiting the MAPK-signalling pathway through MEK-inhibition 
(see Chapter 4). Groups of adult fish treated with Rolipram, show an increased 
bottom dwelling, which can be reversed by inhibiting MEK signalling (Figure 5.3.5). 
Increased cAMP signalling can activate the MAPK signalling through PKA and ERK 
phosphorylation. From rodent studies it is known, that rats that have been subjected 
to fear conditioning display increased anxiety in the elevated plus maze. This 
increased anxiety is correlated with an increase in pERK expression in the prefrontal 
cortex (Ailing et al. 2008). Treating these fear conditioned rats with the MEK 
inhibitor PD98059 significantly improved the performance of the rats in the elevated 
plus maze, and down-regulated the pERK expression in vivo (Ailing et al. 2008). 
Furthermore, rodent studies have shown that as mice subjected to conditioned fear 
show an increased expression of pERK in the amygdala. Mice that have been 
genetically selected as low or high anxiety-like behaviour, are selected and bred for 3 





Immunohistochemistry showed that mice initially selected as having a high anxiety 
state showed a significant increase in pERK expressing cells in the amygdala of these 
mice, indicating the MAPK signalling is activated in anxiety (Coyner et al. 2014).  
Thus, as Rolipram activates the MAPK pathway, the increased thigmotaxis, 
hyperactivity and bottom dwelling is reversible by treatment with the PD0325901. 
This suggests that also in zebrafish, the MAPK pathway play an important role in 
regulating anxiety-like behaviour.  
5.4.2.3 Genetic disruption of Pde4d-activity cause disruption in 
shoal cohesion and less bottom dwelling in zebrafish 
Rodent studies using knock-out models of specific PDE4-genes have helped in the 
understanding of the diverse functions of the different genes in regulating behaviour 
(R. T. Hansen, Conti, and Zhang 2014; Zhang et al. 2008; Zhang et al. 2002a). Mice 
lacking PDE4A and PDE4B display anxiogenic like behaviours in the elevated plus 
maze and the open-field test (R. T. Hansen, Conti, and Zhang 2014; Zhang et al. 
2008).  Mice lacking PDE4D show decreased immobility time in the forced swim 
test (FST) and the tail suspension tests (TST). These behaviours are reminiscent of 
an anti-depressive effect, and treatment with classic anti-depressants, like fluoxetine 
(Prozac®), decrease the immobility time in these tests (Zhang et al. 2002a). 
Rolipram has previously been reported to induce anti-depressant effects in animal 
models (Reviewed in Zhu et al., 2001), but treatment with Rolipram did not enhance 
the anti-depressant-like behaviour in the PDE4D-/- mice, tested in the FST and TST. 





TST following treatment with Rolipram. This suggests that the anti-depressant effect 
of Rolipram is mediated through PDE4D-function. In zebrafish, Rolipram induced 
anxiogenic-like effects, and when treating Pde4d-/- adults with Rolipram, they still 
appear to spend more time at the bottom of the tank (preliminary data, data not 
shown). This suggests, that the bottom-dwelling in zebrafish, is not dependent on 
Pde4d-function.   
Genetic loss of Pde4d-function in adult zebrafish causes the fish to spend more time 
at the top of the tank in shoaling assay, recorded from the side (Figure 5.3.8). 
Moreover, they display decreased shoal cohesion, causing them to swim further apart 
(Figure 5.3.8). These findings suggest that loss of Pde4d function in zebrafish does 
not cause anxiety, instead it appears that the fish are less anxious, spending more 
time at the top of the tank, and this is reminiscent with effects seen in fish treated 
with known anxiolytic compounds, like fluoxetine (Bencan, Sledge, and Levin 2009) 
and buspirone (Figure 5.3.2). However, these phenotypes have also been indicated to 
be reminiscent of a disruption of social behaviour, which has been demonstrated in 
fish treated with MK-801, a NMDA-receptor antagonist, used to model autism and 
schizophrenic-like behaviour in animal models, and have shown to disrupt shoal 
cohesion in adult zebrafish (Maaswinkel, Zhu, and Weng 2013).  
Interestingly, a PDE4D-compound identified in the PDE-screen, F152611, which has 
been designed as an allosteric modulator of PDE4D (Burgin et al. 2010), also 
disrupted the shoal cohesion when WT fish were treated with the compound. 





surprising, as when tested in the larvae assay, F152611 caused an increase in 
swimming activity, indicating that the effect on zebrafish larvae were the same as the 
effect seen in Rolipram treated larvae. This suggests that this compound might have 
another function than that of Rolipram in adult zebrafish but not in larvae. Further 
studies are needed to fully understand the function of Pde4d-function in zebrafish.  
 
5.4.3 Concluding remarks 
In zebrafish Rolipram caused an anxiety-like behaviour which is further supported by 
the increase in cortisol levels in fish treated with Rolipram. In the adult zebrafish, the 
cross-talk between cAMP and MAPK signalling in regulating behaviour is 
conserved, as the behavioural effects of Rolipram in the shoaling assay could be 
counteracted by inhibiting the MAPK-signalling pathway, through MEK-inhibition.  
The anxiogenic effect of Rolipram in zebrafish could be speculated to be through 
Pde4a and Pde4b inhibition, as PDE4A and PDE4B-/- mice shown anxiogenic 
behaviour. To further support this is the fact that the pde4d-/- zebrafish did not 
recapitulate the behavioural phenotype of Rolipram in the shoaling assay or the novel 
tank assay. Instead, genetic loss of pde4d-function leads to phenotypes resembling an 
anti-depressant phenotype or antisocial phenotype. The PDE4D-inhibitor did 
recapitulate the decreased shoaling observed in pde4d-/- fish, but interestingly the 
effect on the placement in the tank resembled that of Rolipram treated fish. This 





or the genetic loss of pde4d during development cause a neurodevelopment defect, 














6.1 Final comments 
Some of the major challenges in drug discovery today are the low number of new 
drugs that are approved and made available to patients. This is especially bad for 
treatments for psychiatric illnesses.  A reason for this is due the high research costs 
needed to develop new drugs from the beginning until the drug reach the market. 
These research costs and the loss of revenue as patents expire faster today than 20 
years ago, has a major impact on the risks big pharmaceutical companies are willing 
to take when venturing into new drug developments (Garnier 2008).  
This is a major challenge, as the number of people suffering from mental disorders is 
increasing, making new and effective treatments more needed than ever. One way to 
bring down costs of drug development and to get a head start on it, is to do drug 
repurposing (Fishman and Porter 2005). Drug repurposing is the use of existing 
drugs for new targets. When undertaking clinical trials the target and predicted 
effects of the drug needs to be stated prior to the trial, which often leads to failure of 
the drug, due to side effects, e.g. behavioural effects or toxic effects (Chong and 
Sullivan 2007).  
The use of rodents in drug screens is slow, expensive and laborious. For this the 
zebrafish offers an excellent compromise between ―system complexity and practical 
simplicity‖ (R. Gerlai 2003).   
Therefore, the need for an alternative screen model in drug discovery is needed. In 





for their effect on behavior. Using a well-known pro-convulsant drug, PTZ, I show 
that in this project I have employed the zebrafish in small molecule screens to 
modulate the behaviour of larvae and adult fish. In this project I have made use of the 
zebrafish larvae as a model organism to test compounds with known effect on 
behaviour. Using two different types of behavioural larval assays, the light/dark 
response and the swimming activity assay, I have shown that, mainly through the 
cAMP and MAPK pathway.  
I first studied the effect of compounds that could induce a clear behavioural 
response, which would be possible to modulate chemically. I used the PTZ model, as 
this model had been described previously as a an epilepsy model in zebrafish larvae 
(S. C. Baraban et al. 2005). This model served as an excellent model to do a 
phenotypic small molecule screen for compounds reversing that potential effect of 
PTZ. From the initial studies I found an unexpected effect of PTZ, which at the time, 
was unreported. Using low levels of PTZ, and alternating light/dark cycles, I found 
that 5 dpf old larvae display a complete reversal of activity in response to changes in 
light or darkness. To identify compounds capable of reversing this effect, I screened 
14 compounds with known anti-epileptic or GABAA binding affinity. I showed that 
by combining a diazepam with a neurosteroid, potentiated the effect of diazepam, 
and increased the concentration needed to reverse the PTZ induced phenotype. 
Secondly, I established that compounds known to elevate cAMP levels causes 
hyperactivity in zebrafish larvae. In particularly the inhibition of PDE4-isoforms 





the zebrafish larvae model could serve as a model of choice in phenotypic drug 
screens.  
Furthermore, the involvement of cAMP and MAPK cross-talk in mediating 
behaviour in zebrafish, suggests that this approach would be useful in small molecule 
screens for drug-repurposing approaches. Screening known compounds for their 
potential to reverse behaviours induced by cAMP increase, could potentially lead to 
the identification of compounds modulating pathways important for regulating 
behaviour, not previously known.  
Lastly, I demonstrated that chemical and genetic modulation of PDE4 activity in 
adult fish affected behaviour. I showed that in adult fish, Rolipram caused an 
anxiety-like phenotype in the novel tank assay and in the shoaling assay. That the 
effect was anxiogenic-like was further confirmed by the increased levels of cortisol 
detected in adult fish treated with Rolipram.  
The behaviour of Rolipram-treated fish differs from the observed behavioural 
phenotype of a pde4d-/- adult zebrafish. Both in the shoaling and the novel assay do 
the fish lacking pde4d-activity behave differently than the Rolipram-treated fish. In 
contrast to a bottom seeking behaviour, these fish spend more time exploring the 
tank, both in a group and as an individual fish. From rodent studies, there is an 
overlap between the behaviours of Rolipram treated mice and mice lacking PDE4D. 
Both Rolipram treated mice and PDE4d-/- mice show increased performance in 
memory tests and also a decrease in immobility in the forced swim test and the tail 





to enhance the performance of the PDE4d-/- mice, but do so in the PDE4D+/+ mice, 
indicating the anti-depressant and cognitive enhancing effects of Rolipram could be 
medicated through PDE4-inhibition. Pde4d-/- fish treated with Rolipram show an 
increased bottom seeking behaviour, suggesting that this effect of Rolipram in 






6.2 Further directions 
6.2.1 Identify specific site of MAPK activation in zebrafish brains 
So far the data I have suggest that cAMP elevations increase pERK expression, and 
this increased activity of pERK lead to anxiety-like behaviours in zebrafish. This 
suggests that involvement of the amygdala. The amygdala is important in the 
regulation of fear and anxiety in rodents, and studies have shown that fear 
conditioned anxiety leads to an up-regulation of pERK in the amygdala and the 
medial prefrontal cortex (Ailing et al. 2008). Treatment with a specific MEK 
inhibitor reverses this effect, both behavioural and biochemically.   
It would therefore be interesting to see what areas of the central nervous system 
show up-regulation of pERK after PDE4-inhibition. This will aid in the elucidation 
in understanding the regulation of anxiety in zebrafish.  
Also a detailed gene expression profile of the different isoforms of PDE4 could aid 
in our understanding of how cAMP and PDE4-isoforms help regulate behaviour in 
zebrafish. From the Rolipram experiments on larvae, there are some indications that 
a subset of larvae respond with higher hyperactivity than the rest. Testing the 
expression level of Pde4a, Pde4b and Pde4d in larvae identified as strong responders 
to Rolipram treatment could perhaps help to elucidate the reason for this high activity 





6.2.2 Translational value of the Rolipram assay in adult zebrafish 
Rolipram has been shown to cause antidepressant and cognitive enhancing effects in 
rodents (Akar et al. 2014; Y.-F. Li et al. 2009b). In the zebrafish, Rolipram and 
PDE4 inhibitors cause anxiety-like effects, suggesting a different mechanism of 
action in mice and zebrafish. However, most of the studies done on rodents use a 
chronic treatment regime of Rolipram, and not an acute. Therefore, we tried to dose 
mice with Rolipram for 1 hour, and then test them in the open field test for 10 
minutes. This time has been described as being the most effective when evaluating 
anxiolytic or anxiogenic behaviours, as mice might habituate to the environment if 
tracked for longer. Mice were dosed and allowed to rest for 1 hour after dosing.  
From the preliminary data, it appears that the mice treated with Rolipram show an 
anxiety-like behaviour, with less exploration time in the centre of the arena, and 
more time spend at the edge of the arena, a thigmotatic behaviour, and more periods 
of freezing. To test if this behaviour was dependent on MAPK signaling, we dosed 
the mice with two different doses of MEK inhibitor for 1 hour after Rolipram dosing. 
Mice treated with Rolipram and PD0325901 showed a higher degree of exploration 
in the center of the arena and less periods of immobility. The data was not 
statistically significant, but did show a trend. These preliminary data suggests that 
acute treatment with Rolipram might cause anxiety-like behaviour in mice, and this 
can be reversed by inhibiting MAPK signalling. More work is needed, though, to 







Figure 6.2.1: Data from the open field test on Rolipram and PD0325901 treated mice.  
A: Quantified data from open field trials. The number of entries into the centre of the arena 
are calculated (n=12 mice), B: The total distance moved (n=12) and C: the time spend in the 
centre of the arena. D: Mice were tracked using the EthoVision XT9.5 software. The traces 
in figure D show the movement pattern of 1 mouse in the open field arena during an entire 
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8.1 Chemical structures and synthesis methods of for the 
PDE inhibitors from Lundbeck A/S 
 
Compound 1 = F152458, PDE1 inhibitor 
 
MW 275.35, IC50: 30nM (PDE1B), 140nM (PDE1C)  
Compound 1 was synthesized as described in  ―Small-molecule phosphodiesterase 
probes: discovery of potent and selective CNS-penetrable quinazoline inhibitors of 
PDE1―. John M. Humphrey, Eddie Yang,a Christopher W. am Ende, Eric P. Arnold, 
Jenna L. Head, Stephen Jenkinson, Lorraine A. Lebel, Spiros Liras, Jayvardhan 
Pandit, Brian Samas, Felix Vajdos, Samuel P. Simons, Artem Evdokimov, Mahmoud 






Compound 2 = F152432 
 
MW: 399.442, IC50 PDE2: 130 nM 
Compound 2 (ND7001) was synthesized as described in ―Preparation of 
benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors‖, 
Abarghaz, Mustafa; Biondi, Stefano; Duranton, Jerome; Limanton, Emmanuelle; 











Compound 3 was synthesized as described in ―biaryl PDE4 inhibitors for treating 
pulmonary and cardiovascular disorders‖, Singh Jasbir; Gurney Mark; Burgin Alex; 














Compound 4 = F152611, PDE4D-inhibitor 
 
MW 409.41 
Compound 4 was synthesized as described in ―biaryl PDE4 inhibitors for treating 
pulmonary and cardiovascular disorders‖, Singh Jasbir; Gurney Mark; Burgin Alex; 











Compound 5 = F152497 = Rolipram, PDE4 inhibitor 
 
MW: 275.40, IC50 PDE4: 1600 nM 











MW: 356.73, IC50 PDE9 = 55nM 
Compound 6 (Bay 73-6691) has been described in ―Characterization of the First 
Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line‖, Frank 
Wunder, Adrian Tersteegen, Annegret Rebmann, Christina Erb, Thomas Fahrig, 






Compound 7 : F152455, PDE10 (+2?) inhibitor 
 
MW: 332.41, IC50 PDE10: 15 nM  
Compound 7 was synthesized as described in ―NOVEL PHENYLIMIDAZOLE 
DERIVATIVES AS PDE10A ENZYME INHIBITORS‖, Andreas Ritzen, Jan 
Kehler, Morten Langgard, Jacob Nielsen, John Paul Kilburn, Mohamed M. Farah, 
patent application US 2010/0016303Al). 
The compound has further been described in the: M. Jørgensen, J. Kehler, M. 
Langgaard, N. Svenstrup, L. Tagmose ‖Selective inhibitors of PDE2, PDE9, and 
PDE10: modulators of activity of the central nervous system‖ , Annual Reports in 
Medicinal Chemistry 2013, 48, 37 and at the 243
rd
 ACS Meeting in San Diego, 
March 25-29 2012 (―4-Phenyl imidazoles: A novel class of phosphodiesterase 10A 
(PDE10A) inhibitors as a potential new generation of antipsychotics‖,  Jan Kehler, 
Andreas Ritzén, Mauro Marigo, Ask Püschl, John Paul Kilburn, Morten Langgård, 
Christoffer Bundgaard, Mads Kreilgård, Claus Tornby Christoffersen, Lise Tøttrup 
Brennum, Anders B. Lassen, Björn Steiniger-Brach, Jacob Nielsen; oral presentation 






Compound 8 = F152446, PDE2 + 10 dual inhibitor 
MW: 338.80, IC50 5.5nM (PDE2), 0.85nM (PDE10) 
Synthesis of AF40315: 
 
 
Compound 8 (4-Bromo-2-methoxy-6-nitro-phenylamine) was synthesized as 
follows: 2-Methoxy-6-nitro-phenylamine (34.5 g, 205 mmol) and NaOAc (27.9 g, 
341 mmol) were dissolved in acetic acid (300 mL) at ambient temperature. A 
solution of bromine (10.6 mL, 205 mmol) in acetic acid (25 mL) was added drop-
wise over 15 minutes. After 10 minutes the mixture was cooled on an ice/water bath 
to precipitate a solid that was washed with heptanes and dried to afford the title 
compound (35.8 g, 71%). 
 
    
7-Bromo-2-chloro-5-methoxy-3-methyl-quinoxaline. 4-Bromo-2-methoxy-6-nitro-








































and THF (200 mL). 5% Pt/C (4.0 g) was added, and the mixture was treated with 
hydrogen gas (2 bar) at ambient temperature for 2 hours. The catalyst was filtered 
off, and the volatiles were removed in vacuo to afford 5-bromo-3-methoxy-benzene-
1,2-diamine in quantitative yield. This material was dissolved in methanol (750 mL) 
and treated with 2-oxo-propanoic acid methyl ester (7.80 mL, 86.3 mmol) at ambient 
temperature overnight. The crude solid was filtered off and the filtrate was partially 
concentrated in vacuo (to allow the dark brown/black mother liquer to be discarded 
before obtaining a second crop of solid). The combined solids were dried to afford 
18.5 g of a mixture of 7-bromo-5-methoxy-3-methyl-1H-quinoxalin-2-one and 6-
bromo-8-methoxy-3-methyl-1H-quinoxalin-2-one as a beige solid. This material was 
refluxed in phosphoryl chloride (200 mL) for 1 hour. The volatiles were removed in 
vacuo. The residue was quenched with ice/water and extracted into Et2O/DCM. The 
organic layer was washed with sat. aq NaHCO3 and subsequently with brine before it 
was dried over MgSO4 and filtered. The filtrate coated onto Celite by co-
concentration in vacuo prior to chromatographic pufication (eluent: heptanes  
EtOAc). After repeated chromatography, 7-bromo-3-chloro-5-methoxy-2-methyl-
quinoxaline (17.5 g, 74%) and 7-bromo-2-chloro-5-methoxy-3-methyl-quinoxaline 


















(5-Methoxy-3,7-dimethyl-quinoxalin-2-yl)-hydrazine. Hydrazine monohydrate 
(4.5 mL, 92 mmol) was added to suspension of 2-chloro-5-methoxy-3,7-dimethyl-
quinoxaline (1.58 g, 7.10 mmol) in ethanol (120 mL). The resulting suspension was 
refluxed for 15 h. The crude mixture was concentrated in vacuo to approximately 
half its original volume before toluene (70 mL) was added and the mixture was 




A mixture of (5-methoxy-3,7-dimethyl-quinoxalin-2-yl)-hydrazine (300 mg, 1.37 
mmol) and 2-chlorobenzaldehyde (203 mg, 1.44 mmol) was suspended in THF (11 
mL) in a MW vial. The vial was capped, and the overhead space was flushed with 
argon before the mixture was heated at 100 °C for 25 minutes under MW conditions. 
After cooling to ambient temperature, iodobenzene diacetate (593 mg, 1.84 mmol) 
was added. The mixture was subjected to MW irradiation at 100 °C for 40 min. The 
volatiles were removed in vacuo. The residue was purified by chromatography 















1) THF MW, 100 °C, 25 min
2) PhI(OAc)2, MW, 100 °C, 40 min







H NMR (500 MHz, CDCl3):  7.72-7.51 (m, 4H), 6.84 (s, 1H), 6.58 (s, 1H), 4.08 (s, 
3H), 3.21 (s, 3H), 2.27 (s, 3H).  
LC/MS:, retention time 0.63 min, UV-purity 99%, ELS-purity 100%, mass observed 
339.1 g/mol. Analytical LC/MS data was obtained on a Waters Aquity UPLC-MS 
consisting of Waters Aquity including column mamager, binary solvent manager, 
sample organizer, PDA detector (operating at 254 nM), ELS detector, and TQ-MS 
equipped with APPI-source operating in positive ion mode. LC-conditions: The column 
was Acquity UPLC BEH C18 1.7µm ; 2.1x50mm operating at 60°C with 1.2 ml/min of 
a binary gradient consisting of water + 0.05 % trifluoroacetic acid (A) and acetonitrile + 
5% water + 0.05 % trifluoroacetic acid. Gradient: 0.00 min 10 % B; 1.00 min 100 % B; 






Compound 9 = F152434, PDE2+10 dual inhibitor 
 
MW: 308.76, IC50 3.5nM (PDE2), 40nM (PDE10) 
Compound 9 (1-(2-chlorophenyl)-4,8-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline) 
was synthesized as described in M. Jørgensen, A.T. Bruun, L.K. Rasmussen, M. 
Larsen PCT Int. Appl. (2013), WO 2013034755 (Example Ij1). Below is 
characterization data for Compound 9:  
1
H NMR (600 MHz, CDCl3) δ 7.91 (d, J = 8.2 Hz, 1H), 7.70 – 7.65 (m, 1H), 7.65 – 
7.61 (m, 2H), 7.53 (ddd, J = 7.5, 5.4, 3.4 Hz, 1H), 7.35 (ddd, J = 8.3, 1.7, 0.5 Hz, 
1H), 6.95 (d, J = 0.5 Hz, 1H), 3.04 (s, 3H), 2.25 (s, 3H). 
LC/MS:, retention time 1.56 min, UV-purity 98.1%, ELS-purity 100%, mass 
observed 309.0 g/mol. Analytical LC/MS data was obtained on a Sciex API150EX 
instrument equipped with APPI-source operating in positive ion mode. The HPLC 
consisted of a Shimaduzu LC10-Advp LC pump, SPD-M20A PDA detector 
(operating at 254 nM), and SCL-10A system controller. The autosampler was a 
Gilson 215, column oven was a Jones Chromatography 7990R, and ELS detector 
was a Sedere Sedex 85. LC conditions: the column was a Waters Symmetry C-18 4.6 










consisting of water + 0.05% trifluoroacetic acid (A) and methanol + 0.05% 
trifluoroacetic acid (B); gradient: 0.01 min 17% B, 0.27 min 28% B, 0.53 min 39% 
B, 0.8 min 50%B, 1.07 min 59% B, 1.34 min 68% B, 1.6 min 78% B, 1.87 min 86% 
B, 2.14 min 93% B, 2.38 min 100% B, 2.4 min 17% B, 2.8 min 7% B; total run time 
2.8 min. 
 
